<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     f10k2020_enzobiocheminc.htm     <description>      ANNUAL REPORT      <text>       <title>       </title>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0; margin-bottom: 0; width: 100%">        <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <b>         UNITED STATES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <b>         SECURITIES AND EXCHANGE COMMISSION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <b>         Washington, DC 20549        </b>       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <b>         FORM 10-K        </b>       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        <u>         (Mark one)        </u>       </p>       <p style="font: 6pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">        ☒        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THESECURITIES EXCHANGE ACT OF 1934        </font>       </p>       <p style="font: 6pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        For the fiscal year ended July 31, 2020       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        or       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">        ☐        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OFTHE SECURITIES EXCHANGE ACT OF 1934        </font>       </p>       <p style="font: 6pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        For the transition period from ______________ to ______________       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Commission File Number 001-09974       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="padding-bottom: 1.5pt; width: 25%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 50%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt">            <b>             ENZO    BIOCHEM, INC.            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; width: 25%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Exact name of registrant as specified in its charter)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: black 1.5pt solid; text-align: center; width: 45%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            New    York           </font>          </td>          <td style="text-align: center; width: 10%">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; text-align: center; width: 45%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13-2866202           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (State or other jurisdiction    of           </font>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (I.R.S. Employer           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-size: 10pt">            incorporation or organization)           </font>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Identification No.)           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            527 Madison Ave.           </font>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            New    York, New York           </font>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10022           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Address of principal    executive offices)           </font>          </td>          <td>           <font style="font-size: 10pt">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Zip Code)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 25%">          </td>          <td style="width: 50%; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (212) 583-0100           </font>          </td>          <td style="width: 25%">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Registrant’s telephone number, including area code)           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <b>         Securities registered pursuant to Section12(b) of the Act:        </b>       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: Black 1.5pt solid; width: 27%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Title    of Each Class           </font>          </td>          <td style="padding-bottom: 1.5pt; width: 2%; text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 26%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Trading    Symbol           </font>          </td>          <td style="padding-bottom: 1.5pt; width: 2%; text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 43%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Name    of Each Exchange on Which Registered           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common Stock, $.01    par value           </font>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ENZ           </font>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The New York Stock    Exchange           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark if the registrant is a well-known seasonedissuer, as defined in Rule 405 of the Securities Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.3pt; text-indent: -8.65pt">        <font style="font-family: Times New Roman, Times, Serif">         Yes        </font>        ☐        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        ☒       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark if the registrant is not required tofile reports pursuant to Section 13 or Section 15(d) of the Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.3pt; text-indent: -8.65pt">        <font style="font-family: Times New Roman, Times, Serif">         Yes        </font>        ☐        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        ☒       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark whether the registranthas submitted electronically every Interactive Data File required to be submittedand posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrantwas required to submit and post such files).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.3pt; text-indent: -8.65pt">        <font style="font-family: Times New Roman, Times, Serif">         Yes        </font>        ☒        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        ☐       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant (1) has filedall reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (orfor such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.3pt; text-indent: -8.65pt">        <font style="font-family: Times New Roman, Times, Serif">         Yes        </font>        ☒        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        ☐       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant is a large acceleratedfiler, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitionsof “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act.       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 20%">           <font style="font-size: 10pt">            Large accelerated filer            <font style="font-family: Times New Roman, Times, Serif">             ☐            </font>           </font>          </td>          <td style="width: 18%">           <font style="font-size: 10pt">            Accelerated filer            <font style="font-family: Times New Roman, Times, Serif">             ☐            </font>           </font>          </td>          <td style="width: 18%">           <font style="font-size: 10pt">            Non-accelerated filer            <font style="font-family: Times New Roman, Times, Serif">             ☒            </font>           </font>          </td>          <td style="width: 22%">           <font style="font-size: 10pt">            Smaller reporting company ☒           </font>          </td>          <td style="width: 22%">           <font style="font-size: 10pt">            Emerging company growth            <font style="font-family: Times New Roman, Times, Serif">             ☐            </font>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If an emerging growth company, indicate by check mark if theregistrant has elected not to use the extended transition period for complying with any new or revised financial accounting standardsprovided pursuant to Section 13(a) of the Exchange Act. ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-size: 5pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant has filed a reporton and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting underSection 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued itsaudit report. ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-size: 5pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act of 1934). Yes        </font>        ☐        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        ☒       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The aggregate market value of the registrant’s votingstock held by non-affiliates of the registrant was approximately $110,441,000 as of January 31, 2020.       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The number of shares of the Company’s common stock, $.01par value, outstanding at October 12, 2020 was 47,895,050.       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        DOCUMENTS INCORPORATED BY REFERENCE       </p>       <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Portions of the definitive Proxy Statement to be delivered toshareholders in connection with the Annual Meeting of Shareholders to be held on or about January 4, 2021 are incorporated by referenceinto Part III of this annual report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0; margin-bottom: 0; width: 100%">        <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         TABLEOF CONTENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="padding-bottom: 1.5pt; width: 7%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 87%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Description            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; width: 2%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 4%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Page            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#a_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Part I             </b>            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 1.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Business            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           1          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 1A.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Risk Factors            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            24           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 1B.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Unresolved Staff Comments            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            38           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 2.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Properties            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            38           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 3.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Legal Proceedings            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            38           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 4.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Mine Safety Disclosures            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            39           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <a href="#a_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Part II             </b>            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 5.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            33           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 6.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_010">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Selected Financial Data            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            41           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 7.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_011">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Management’s Discussion and Analysis of Financial Condition and Results of Operations            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            42           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 7A.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_012">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Quantitative and Qualitative Disclosures About Market Risk            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            53           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 8.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_013">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Financial Statements and Supplementary Data            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            53           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 9.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_014">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Changes in and Disagreements with Accountants on Accounting and Financial Disclosure            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            53           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 9A.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_015">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Controls and Procedures            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            53           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 9B.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_016">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Other Information            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            54           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#a_017">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Part III             </b>            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 10.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_018">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Directors, Executive Officers and Corporate Governance            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 11.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_019">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Executive Compensation            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 12.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_020">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 13.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_021">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certain Relationships and Related Transactions, and Director Independence            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 14.           </font>          </td>          <td style="vertical-align: top">           <a href="#a_022">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Principal Accountant Fees and Services            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#a_023">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Part IV             </b>            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#a_024">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 15.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#a_024">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Exhibits and Financial Statement Schedules            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <a href="#fin_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             List of Consolidated Financial Statements and Financial Statements Schedule            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-1           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <a href="#fin_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Report of Independent Registered Public Accounting Firm            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-2           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <a href="#fin_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Balance Sheets            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-3           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <a href="#fin_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Operations            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-4           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <a href="#fin_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Comprehensive Income (loss)            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-5           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <a href="#fin_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Stockholders’ Equity            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-6           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <a href="#fin_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Cash Flows            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-7           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <a href="#fin_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Notes to Consolidated Financial Statements            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-8           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <a href="#fin_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Schedule II - Valuation Accounts and Qualifying Accounts            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            S-1           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->         i         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">        <b>         <a name="a_001">         </a>         PART I        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="a_002">        </a>        Item 1.        <u>         Business        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo Biochem, Inc. (the “Company” “we”,“our” or “Enzo”) is an integrated diagnostics, clinical lab, and life sciences company focused on deliveringand applying advanced technology capabilities to produce affordable reliable products and services that enable our customers tomeet their clinical needs. Through a connection with the market, we provide advanced biotechnology solutions to the global communityas affordable and flexible quality products and services. We develop, manufacture and sell our proprietary technology solutionsand platforms to clinical laboratories, specialty clinics, researchers and physicians globally. Enzo’s structure and businessstrategy represent the culmination of years of extensive planning and work.  The Company has the unique ability to offerlow cost, high performance products and services for diagnostic testing, which ideally positions us to capitalize onthe reimbursement pressures facing diagnostic labs. Our pioneering work in genomic analysis coupled with our extensive patent estateand enabling platforms have positioned the Company to continue to play an important role in the rapidly growing molecular medicinemarketplaces.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo develops low cost diagnostic platform products and relatedservices. Our platform development includes automation-compatible reagent systems and associated products for sample collectionand processing through analysis. We develop affordable products and services to improve healthcare, one of the greatest challengestoday. Enzo combines over 40 years of expertise in technology development with assay development capabilities and diagnostic testingservices to create high performance, cost-effective, and open assay solutions. The ability to combine these assets in one companyis unique. With our strong intellectual property portfolio integrated with assay development know-how, production, distribution,validation and services capabilities, we have enabled sustainable products and services for a market that is facing increasingpressure in costs and reimbursement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo technology solutions and platforms and unique operationalstructure are designed to reduce overall healthcare costs for both government and private insurers. Our proprietary technologyplatforms reduces our customers’ need for multiple, specialized instruments, and offer a variety of high throughput capabilitiestogether with a demonstrated high level of accuracy and reproducibility. Our genetic test panels are focused on large and growingmarkets primarily in the areas of personalized medicine, women’s health, infectious diseases and genetic disorders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For example, our GENFLEX ™ platform is a high-throughput,automated, and scalable instrument for processing molecular diagnostics tests within a clinical production setting. While initiallyfocused on COVID-19 and Women’s Health assays, it can lead to the development of an entire line of molecular products thatcan allow laboratories to offer a complete menu of services for this $7 billion plus growing market at a cost that allows themto enjoy an acceptable margin. These products include testing sample collection, molecular, and antibody tests, as well as instrumentation,all on a global basis. Our solutions provide tools to physicians, clinicians and other healthcare providers to improve detection,treatment and monitoring of a broad spectrum of diseases and conditions. In addition, reduced patient to physician office visitstranslates into lower healthcare processing costs and greater patient services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In the course of our research and development activities, wehave built a substantial portfolio of intellectual property assets, comprised of 475 issued patents worldwide and over 63 pendingpatent applications, along with extensive enabling technologies and platforms.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Operating Segments        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are comprised of three interconnected operating segmentswhich have evolved out of our core competencies involving the use of nucleic acids as informational molecules and the use of compoundsfor immune modulation and which have been augmented by previous acquisitions of a number of related companies. Information concerningsales by geographic area and business segments for the years ended July 31, 2020, 2019 and 2018 is located in Note 17 in the Notesto Consolidated Financial Statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Below are brief descriptions of each of our operating segments:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <u>          Enzo Clinical Lab         </u>        </b>        is a clinical reference laboratoryproviding a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. TheCompany believes having a Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified and College of AmericanPathologists (“CAP”) accredited medical laboratory located in New York provides us the opportunity to more rapidlyintroduce cutting edge products and services to the clinical marketplace. Enzo Clinical Labs offers an extensive menu of molecularand other clinical laboratory tests and procedures used in patient care by physicians to establish or support a diagnosis, monitortreatment or medication, and search for an otherwise undiagnosed condition. Our laboratory is equipped with state-of-the-art communicationand connectivity solutions enabling the rapid transmission, analysis and interpretation of generated data. We operate a full serviceclinical laboratory in Farmingdale, New York, a network of over 30 patient service centers throughout New York, New Jersey andConnecticut, two free standing “STAT” or rapid response laboratories in New York City and Connecticut, an in-houselogistics department, and an information technology department. Under our license in New York State, we are able to offer testingservices to clinical laboratories and physicians nationwide.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         1         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <u>          Enzo Life Sciences         </u>        </b>        manufactures, develops andmarkets products and tools for clinical research, drug development and bioscience research customers worldwide. Underpinned bybroad technological capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic informationby laboratories around the world. Information regarding our technologies can be found in the “Core Technologies” section.We are internationally recognized and acknowledged as a leader in the development, manufacturing validation and commercializationof numerous products serving not only the clinical research market, but also the life sciences markets in the fields of cellularanalysis and drug discovery, among others. Our operations are supported by global operations allowing for the efficient marketingand delivery of our products around the world.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <u>          Enzo Therapeutics         </u>        </b>        is a biopharmaceutical venturethat has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, manyof which are derived from the pioneering work of Enzo Life Sciences. Enzo Therapeutics has focused its efforts on developing treatmentregimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects.This focus has generated a clinical and preclinical pipeline, as well as more than 100 patents and patent applications.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s primary sources of revenue have historicallybeen from the clinical laboratory services provided to the healthcare community and product revenues, royalty and licensing ofEnzo Life Sciences’ products utilized by customers worldwide. The following table summarizes the sources of revenues forthe fiscal years ended July 31, 2020, 2019 and 2018 (in thousands except percentages):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; border-bottom: Black 1.5pt solid">           Fiscal year ended July 31,          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 28%; text-align: left">           Clinical laboratory services          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           47,964          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           63          </td>          <td style="width: 1%; text-align: left">           %          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           51,115          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           63          </td>          <td style="width: 1%; text-align: left">           %          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           71,077          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           70          </td>          <td style="width: 1%; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Product revenues          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           26,561          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           35          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           30,055          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           37          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           29,224          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           29          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           Grant and royalty income          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,496          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           712          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 4pt">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           76,021          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           81,170          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           101,013          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Markets        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Clinical diagnostics        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The U.S. clinical diagnostics market has been reported by industrysources to be greater than $25 billion per year nationally and over $60 billion worldwide. It is comprised of a broad range oftests based on clinical chemistry, microbiology, immunoassays, genomics, proteomics, gene expression profiling, blood banking,and cancer screening assays through histology as well as newer bodily fluid based approaches.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Many of these tests employ traditional technologies such ascell culture technologies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Immunoassays are based on the use of antibody biomarkers directedagainst a specific target or antigen to detect that antigen in a patient sample. Cell culturing techniques involve the growth,isolation and visual detection of the presence of a microorganism and often its susceptibility to FDA approved drugs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There are several drawbacks to these more traditional technologies.Immunoassays do not allow for early detection of diseases because they require minimum levels of antigens to be produced by themicroorganism in order to be identified. These levels vary by microorganism, and the delay involved could be several days or severalmonths, as seen in HIV/AIDS. Cell cultures are slow, labor intensive and not amenable to all microorganisms. For example, gonorrheaand chlamydia are difficult to culture.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Molecular diagnostics have many advantages over traditionaltechnologies. Since gene-based diagnostics focus on the identification of diseases at the molecular level, they can identify thepresence of the disease at its earliest stage of manifestation in the body. These tests provide results more rapidly, are applicableto a broad spectrum of microorganisms and can easily be automated in a multiplex platform.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Several advances in technology are accelerating the adoptionof gene-based diagnostics in clinical laboratories. These advances include high throughput automated formats that minimize laborcosts, non-radioactive probes and reagents that are safe to handle, and amplification technologies that improve the sensitivityof such diagnostics.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 4; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        According to industry sources, the market for molecular diagnostictools, assays and other products is currently more than $7 billion per year, and is acknowledged as one of the fastest growingsegments in the in-vitro diagnostics industry, growing at more than twice the rate of traditional diagnostics. Contributing tothis growth are, among other factors:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the increasing number of diagnostic tests being developed from discoveries in genomic research;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            advances in formats and other technologies that automate and accelerate gene-based diagnostic testing;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            growing emphasis by the healthcare industry on early diagnosis and treatment of disease and;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            application of gene-based diagnostics as tools to match therapies to specific patient genetics, commonly referred to as pharmacogenomics or companion diagnostics.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Diagnostic Products        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There is a large and growing global demand by biomedical andpharmaceutical companies for research and diagnostic tools that both facilitate and accelerate the generation of biological information.This demand can be met by gene and protein target-based diagnostics for which a variety of formats and tools have been developedthat enable researchers to study biological pathways. These tools can identify mutations in gene sequences and variations in geneexpression levels that can lead to disease, or they can quantify biomarkers that provide insight into disease and potential therapeuticsolutions. These techniques use instruments such as DNA sequencing and genotyping equipment, microarrays, fluorescent microscopes,high content screening platforms, flow cytometers and plate readers. Common among these instruments is the need for reagents thatallow the identification, quantification and characterization of interactions of specific genes or nucleic acid sequences, proteins,cells, and other cellular structures and organelles.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe this market will continue to grow as a result of:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            long term commitment to research spending by academic, government and private organizations to determine the function and clinical relevance of the gene sequences and proteins that have been identified by genomics research,           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            development of commercial applications based on information derived from this research and,           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            on-going advancements in tools that accelerate these research and development activities.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Therapeutics        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe our core technologies have broad diagnostic and therapeuticapplications. We have focused our efforts on discovering how best to treat pathologies associated with growth or metabolic controland immune-mediated diseases, including autoimmune diseases and cancers. Although the causes of disorders such as Crohn’sdisease, autoimmune uveitis and non-alcoholic steatohepatitis (NASH) remain unknown, various features suggest immune system involvementin their pathogenesis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We continue to test technologies we believe can serve as enablingplatforms for developing medicines that genetically target and inhibit viral functions, as well as medicines that regulate theimmune response. In addition to such therapeutic products, we continue to capitalize on our nucleic acid labeling, target and signalamplification, and detection technologies and intellectual property to develop diagnostic and monitoring tests for various diseases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe our expertise in developing and securing approvalsof novel platform technologies will enable us to shorten the development time and capture meaningful market share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Strategy        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our strategy is focused on offering quality and affordable testingsolutions to high volume market segments where reimbursement pressures have caused challenges for our customers within these segments.Our customers need cost of goods savings. To achieve this, we have taken common workflows and applied Enzo’s innovative technicalexpertise to each platform part in order to achieve integrative cost effective solutions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our objective is to develop and manufacture high value, affordableand reliable diagnostic products and services using our proprietary technologies to allow our customers to meet their clinicalneeds. Our proprietary technology platforms, if successful, will alter the existing business models and improve economics acrossthe healthcare industry. Our strong intellectual property estate provides freedom to operate and compete in a rapidly growing moleculardiagnostic healthcare marketplace.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 5; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe our expertise in developing and marketing proprietarytechnology platforms uniquely positions Enzo to provide products and services that will change the fundamental relationship betweenmolecular diagnostic companies and clinical laboratories. Our technology platforms will provide economic and market optionalityto use Enzo’s products and services for margin improvement. As such, clinical laboratories will be able to enter and competein markets that until now have been out of reach due to poor economic standing caused by high costs of reagents and equipment rentalarrangements from molecular diagnostic companies coupled with lower reimbursement from governmental payers and commercial healthcareinsurers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our objective allows clinical laboratories to purchase low costreagents and kits to be run on open system platforms already in use in their labs, or to use Enzo as a low cost reference laboratory.Enzo’s integrated business model not only provides benefits to clinical laboratories, but also to insurance providers whowill benefit from more clinical laboratories being able to compete for testing services with national laboratories.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition to selling these highly effective and compatibleplatforms and their assays, we are positioning ourselves as a reference lab for independent labs nationwide primarily by offeringlower cost reference services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our commitment to utilizing our proprietary technologies todevelop clinically relevant diagnostics, while helping to relieve the cost pressures that independent laboratories are bearingis core to our strategy.  It underscores the progress we are achieving in our strategy of utilizing Enzo’s integratedstructure to produce diagnostic products and services relevant to today’s dynamic and challenging healthcare marketplace.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        By developing a broad technology base, we are positioned fora robust flow of products and services that will provide medically relevant, cost effective solutions easily adaptable to the workflowof the clinical laboratory, and its ability to do so is based on several factors, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -22.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            The Company’s integrated structure that enables it to internallydevelop and advance products seamlessly from innovation through validation and commercialization.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -22.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            The unique ability to deliver high performance, easily adaptable productsand services that are also cost effective for independent labs as well as Enzo’s own clinical lab in a steadily decliningreimbursement environment           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.75pt; text-indent: -11.25pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Ample finances with which to execute and follow through on the Company’sintegrated strategy.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Increase investment in research and development &amp;product development         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are increasing our research and development efforts to developnew leading edge solutions in the rapidly growing molecular diagnostic marketplace, as well as in the important segments of AnatomicalPathology, Cytology and Immunohistochemistry.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our development activities are directed to each step ofthe clinical testing process, from sample collection and processing through analysis. Our goal is to manufacture thecomponents required for each step in the diagnostic process for integration into an open platform.  Enzo’s systemsolutions will enable clinical laboratories to more effectively participate in the diagnostics market where decliningreimbursements and rigid costs from suppliers currently prevail.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Current technology platforms under development include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            AMPIPROBE® Genetic Amplification Platform – easily adaptable,affordable, real time DNA amplification and detection           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            FLOWSCRIPT® Gene Expression Platform – enhanced flow cytometryfor single cell analysis           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            POLYVIEW PLUS® Enhanced Immunohistochemistry – optimizedreagents for clear, consistent immunohistochemistry and in situ hybridization results moving Pathology to the next generation           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Enhanced Immunoassays – pushing sensitivity to expand immunoassayapplications           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo’s proprietary platforms and the related assays developedcan provide more sensitive diagnostic information at lower costs than many other currently marketed tests. The Company designsits products to be able to work with lower specimen volume which not only allows the laboratories to run more tests from of a singleclinical specimen, but also may reduce the need for patients to submit additional samples, thus reducing unnecessary physicianvisits.  The Company’s newly approved assays are the forerunners of a comprehensive line of diagnostic solutions underdevelopment by Enzo to address the critical needs of clinical laboratories that are often locked into closed-system contracts withmolecular diagnostics suppliers which, with ever-declining reimbursements, reduce or even eliminate operating margins.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 6; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          New Molecular Diagnostic platform         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo has developed and validated a new molecular diagnosticsplatform, GENFLEX™ Molecular System, which, unlike current closed system platforms, has an open access feature, flexibilityand compatibility with a full clinical workflow. It is believed to be uniquely characterized as an automated, clinically compatible,open platform that operates with multiple reagents and sample types allowing for cost savings and Laboratory Developed Tests (LDTs),while remaining comparable with FDA-approved products. It has been optimized to fully address existing clinical work flows whilealso providing the flexibility to develop and incorporate new work flows. The clinical diagnostic industry is challenged by decliningreimbursements and high reagent costs associated with “closed systems” diagnostic platforms that prohibit the use ofthird-party reagents. The new Enzo “open system” molecular diagnostic platform is compatible with existing sample collectiondevices. It runs on a standardized, simplified sample processing (fluid handling and nucleic acid isolation) and amplification/detectionworkflow, and was designed to provide high performance and adaptable solutions to existing lab workflow, while addressing the criticalneed for lower cost solutions. The platform is compatible with a sample input capacity up to 1 ml of whole blood, serum, plasma,urine, gynecological and non-gynecological specimens, and offers high throughput, 96-well plate molecular testing in less thanfour hours run time. At full capacity, the platform can process as many as three 96-well plates (268 samples total) in about eighthours for most of the company’s tests. Using our proven AMPIPROBE® technology, Enzo has developed multi-target viralload assays and multi-target DNA-based women’s health assays optimized for the new automated, open system platform, and iscurrently in the process of developing a screening assay for oncogenic forms of HPV. The platform has current compatibility withmore than sixteen (16) Enzo-developed clinical tests in the areas of sexual health (STIs), women’s health, virology, upperrespiratory infections, plus others, with a built-in capacity to run new or esoteric laboratory developed tests.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Continue to commercialize new platforms for moleculardiagnostics via multiple channels         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have developed several enabling platform technologies thatmay have utility in the development of a new generation of molecular diagnostic products designed to meet the needs of the currentclinical marketplace. Our lead solution is the AMPIPROBE® platform, which is our proprietary target amplification and detectiontechnology that has been shown to require substantially less starting material than conventional methods such as polymerase chainreaction (PCR) based products. With the GENFLEX™ platform it may be possible to increase the number of analytes that canbe assayed from a single clinical specimen, which in turn may reduce the need for physicians to recall patients to obtain additionalclinical material for testing. In addition by increasing the number of analytes tested in a single clinical preparation, the GENFLEX™platform may be able to produce diagnostic tests at a significantly lower cost than conventional assays. Moreover, the need forless starting material may also lead to diagnostic tests with improved sensitivity, thus allowing detection of certain analytespresent in minute quantities that are below the limit of detection of conventional assays. With several GENFLEX™ assays alreadydeveloped and validated, we continue to invest in the development of a consistent pipeline of additional assays.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The FLOWSCRIPT® Gene Expression platform is another uniquetechnology translation offering additional alternatives to common molecular assays. We have already introduced the first productusing our FLOWSCRIPT® platform technology for the identification of gene expression in clinical samples specifically detectionof mRNA from Human papillomavirus (HPV) oncogenes E6 and E7. Overexpression of these HPV oncogenes promotes the growth of malignantcells, leading to the development of cervical cancer. The FLOWSCRIPT® technology platform is a proprietary, flow cytometry-basedmolecular detection system for the multiplex analysis of cell function and identity that was developed by cross-functional teamsat Enzo. The HPV E6/E7 assay is the first product to utilize this novel platform. Analysis is performed on a small volume of aliquid cytology specimen and can thus be easily incorporated as a reflex test measure following abnormal Pap smear results. Theassay, and the platform on which it is based, allows for the simultaneous analysis of several different genes expressed in everycell in a given sample. In this manner, it is possible to produce clinically relevant data at the single cell level. Unlike otherassays that study mRNA expression, FLOWSCRIPT® assays are performed using a homogeneous system that eliminates washing stepsthat can reduce fluctuation of results. Additionally, the assay’s use of an external control improves run-to-run consistency.As a result, both hands on time and the number of steps are reduced, allowing for improved economics. In data presented at a 2015pathology conference in Italy, Enzo’s assay was shown to produce reliable and consistent results near the limit of assaydetection. Furthermore, Enzo anticipates using this platform for a multitude of applications such as study of other cancers andthe evaluation of an individual’s immune state as well as products targeted to the drug development market, among others.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The FLOWSCRIPT® platform is used to help guide providers in assessing the risk of progression to cervical cancer and whethercolposcopy or follow-up screening should be the preferred course of action. This assay demonstrates Enzo’s commitment toutilizing our proprietary technology and bringing forward clinically relevant diagnostics that can inform patient and physiciandecision-making with potential to reduce spending associated with advanced stage disease. Moreover, it is indicative of how wellwe are executing our strategy of utilizing our integrated structure to produce products that are relevant to today’s evolvinghealthcare marketplace.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 7; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Expand platform development to other important, but financiallystressed, diagnostic areas         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo’s POLYVIEW PLUS® Enhanced Immunohistochemistryplatform offers solutions within the area of Anatomical Pathology through optimized assays for clear, consistent immunohistochemistryand in situ hybridization results moving Pathology to the next generation. This platform has been used in conjunction with validatedbiomarkers for detecting cancers and their progression especially in the areas of women’s health.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Maximize our resources by collaborating with others intherapeutics research and commercialization activities         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We enter into research collaborations with leading academicand other research centers to augment our core expertise on specific programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our clinical trial of OPTIQUEL® is a direct result of aresearch collaboration; we acquired the rights and intellectual property to this candidate drug and technology intended for usein the treatment of autoimmune uveitis. Working with scientists and physicians in the United States and abroad, Enzo continueddrug development to the stage of a clinical trial.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have research and clinical collaborations with other institutionsincluding Hadassah University Medical Center in Jerusalem, Israel relating to our immune regulation technology. Through collaborationssuch as these and other licensing agreements we continue to develop novel therapeutics for the stimulation and enhancement of boneformation and glucose control, among others. Products emanating from this technology could provide potential therapy for bone disorders,including bone loss, bone fractures, periodontitis, diabetes and other indications. There can be no assurance that any of thesecollaborative projects will be successful.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Similarly, we may seek to fully exploit the commercial valueof our technology by partnering with for-profit enterprises in specific areas in order to act on opportunities that can be accretiveto our efforts in accelerating our development program.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Exploit our marketing and distribution infrastructure         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo Life Sciences maintains relationships with academic andcommercial groups worldwide in sourcing and commercializing high value reagents developed by leading researchers. We have alsodeveloped a sales and marketing infrastructure to directly service our end users such as clinical laboratories, researchers andpharmaceutical companies, while simultaneously positioning the Company for targeted product line expansion. Our global sales, marketing,manufacturing, product development and distribution infrastructure is integrated and consolidated as a single global business.Enzo Life Sciences operates, under its own name, worldwide through wholly owned subsidiaries (in USA, Switzerland, Benelux, Germany,and the UK), a branch office in France and a network of third party distributors in most other significant markets worldwide. Ourcomprehensive product portfolio allows us to deliver integrated solutions to basic researchers, drug developers and clinical researchersaround the globe. Our research allows us to provide solutions in all key research areas including: Genomics, Cell Biology, BiomarkerDetection, and in a multitude of applied research markets including: Bioprocess, Personal Care, Cancer Research, and Neuroscienceto name a few.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Expand and protect our intellectual property estate         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Since our inception, we have followed a strategy of creatinga broadly encompassing patent position in the life sciences and therapeutics areas. We have made obtaining patent protection acentral strategic policy, both with respect to our proprietary platform technologies and products, as well as broadly in the areasof our research activities. During fiscal 2020, we were issued 55 patents and expanded our patent estate in the area of nucleotides,amplification, labeling and detection, among others.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Product Development and Pipeline        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo is committed to delivering a robust line of products andservices that will provide medically relevant, cost effective solutions that are easily adaptable to the workflow of clinical laboratories. The Company’s integrated Life Sciences-Clinical Labs structure continues to be instrumental in its ability to seamlesslydevelop and advance products from innovation and manufacturing in our life sciences group to validation and commercialization throughour clinical laboratory.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s development pipeline includes an extensiveline of assays for detection of numerous women’s health infectious agents, particularly sexual health infections (STIs) aswell as for the identification of other pathogens.  The Company is also developing a proprietary line of products designedto aid pathologists in differentiating the characteristics of various tumors from biopsy specimens.  The Company’s molecularproducts and services are targeted at a market currently estimated to be in excess of $7 billion annually.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 8; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Since 2015 we have had 10 submissions andapprovals on lab developed tests (LDTs) from the New York State Department of Health for clinical analysis based on Enzo’sproprietary technology platforms, and one Emergency Use Authorization (EUA) by the FDA. The comprehensive program includes 16 analytesand multiple specimen source and collection devices.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have received approval of AMPIPROBE® HCV Assay for thequantitative detection of Hepatitis C and AMPIPROBE® HBV Assay for the quantitative detection of Hepatitis B. These assaysare based on the proprietary nucleic acid amplification and detection technology platform which was the first in a line of productsto be developed at Enzo to address the critical needs of the molecular diagnostics market and serves as validation of Enzo’sunique business strategy and structure. We were granted final approval of AMPIPROBE® Candidiasis Assay. This multiplex assayis designed to identify the presence of five of the most common species of Candida from a single vaginal swab. Industry estimatesput the number of tests performed for the identification of Candida at over 10 million per year in the US alone. It is also estimatedthat over 70% of women will develop a Candida infection during their reproductive lifetime. While an independent assay, it willalso serve as a component of a comprehensive women’s health panel. We were granted final approval for three additional women’shealth related molecular diagnostic tests for use with the Company’s versatile and economic AMPIPROBE® platform. Approvalwas given for a real-time PCR-based method for qualitative detection of        <i>         Neisseria gonorrhea        </i>        ,        <i>         Chlamydia trachomatis        </i>        and        <i>         Trichomonas vaginalis        </i>        in vaginal swab specimens. The Company’s AMPIPROBE®-based pipeline includes an extensiveline of assays for identification of additional women’s health infectious diseases as well as for the quantification ofviral load in serum or plasma specimens. This proprietary technology platform is the foundation of our ever-increasing line ofmedically relevant, cost-effective and easily adaptable solutions for clinical laboratories. We were granted conditional approvalof another women’s health infectious disease diagnostic panel, which when combined with the Company’s previously approvedpanels, makes for one of the most comprehensive, efficient  and affordable diagnostic products and services on the markettoday.  A variety of infections, including sexually transmitted ones, are detected from a single vaginal swab collectionvia the Company’s proprietary, versatile and cost-effective AMPIPROBE® platform. In July 2019, we announced the NewYork State Health Department approval for AmpiProbe Neisseria gonorrhea (NG) and Chlamydia trachomatis (CT) DNA tests with oral(pharyngeal) and rectal specimens. This expands the Company’s menu allowing Enzo to provide one of the most comprehensivepanels for STI testing for not only women but also men, who represent a rapidly growing segment for such testing. These assaysare an important addition to Enzo’s expanding line of women’s health products, while also helping to solidify Enzo’sposition as a leading full service women’s health lab.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In July 2020 we received Emergency Use Authorization (EUA) fromFDA for our proprietary product for the detection of Coronavirus SARS-CoV-2. The EUA enables other laboratories to use this productwith three diverse platforms without requiring further validation. These platforms include our proprietary GENFLEX™ automatedhigh-throughput platform, Qiagen’s QIAsymphony® SP lower-throughput platform and Enzo’s manual workflow. The AMPIPROBE®SARS-Cov-2 Test System includes three components: sample collection, AMPIXTRACT™ SARS-CoV-2 Extraction Kit for sample processing,and the AMPIPROBE® SARS-CoV-2 Assay Kit for detection and analysis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In February 2020 we received New York State approval for ourCT/NG/TV tests using liquid-based cytology sample collection on our proprietary GENFLEX™ platform. GENFLEX™ is a commerciallyavailable sample-to-result molecular diagnostic platform that includes sample collection, sample processing, amplification anddetection. The GENFLEX™ open system delivers high-throughput, high capacity, workflow efficiency and flexibility at a muchgreater level of affordability than existing systems. The platform will provide a cost-effective, comprehensive menu of moleculardiagnostic products and services and highlights our continued ability to deliver high performance, open, flexible, adaptable andcost-effective products, devices and services. Compared favorably to all other proprietary platforms dominating the diagnostictesting market, our GENFLEX™ platform offers 30-50% cost-savings over current closed systems and addresses the $450 millionannualized global CT/NG/TV diagnostic market as well as the $1.3 billion Women’s health market. Extensions of the GENFLEX™platform, which we are currently developing, could eventually address the entire $7 billion molecular diagnostic market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In January 2018, we validated p16, a marker used extensivelyas a key diagnostic and prognostic biomarker of several cancers. Enzo’s validated p16 provides clear detection of tissueabnormalities in the field of cancer diagnostics, including cervical cancer’s progression. Additional compounds validatedinclude in-situ HPV probes and antibody markers such as CD138, Ki-67, p53, Vimentin, and prostate cancer markers. P16 complementsour POLYVIEW® immunochemistry detection. With current mounting cost and reimbursement pressures, Enzo’s new p16 testprovides a highly cost-effective alternative. Other p16 tests on the market have of late become unaffordable as a result of increasingreagent costs outweighing average reimbursements. When p16 is used in combination with Enzo’s POLYVIEW® detection system’sreduction of false-positives, the economics are substantially enhanced. This and other similar compounds comprise a $200 millionmarket.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 9; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In 2016, we were granted conditional approval of PLAQPRO™Lp-PLA        <sub>         2        </sub>        Assay. This is a biochemical activity assay designed to identify lipoprotein-associated phospholipase A2, amarker associated with the potential for coronary heart disease. The PLAQPRO™ Lp- PLA        <sub>         2        </sub>        Assay can be useful aspart of a cardiac testing panel for individuals at intermediate or high risk for developing coronary heart disease. Early identificationof increased risk of developing coronary heart disease offers the opportunity to adjust patient lifestyles or utilize medical interventionsto reduce risk. The assay was developed using the Company’s strong expertise in assay development, antibody production, smallmolecule chemistry, and detection technology. This cardiac assay delivers improved consistency and is designed to work on openplatform clinical analysis instruments. Enzo continues to support open platform configurations as one of the several factors thatcontribute value and cost effectiveness, which is vital to today’s clinical labs which are being confronted by shrinkingreimbursements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Products in the Company’s development pipeline includean extensive line of assays for detection of numerous women’s health infectious agents as well as for use in the identificationof pathogens for other markets.  The Company also reported that it expects to roll-out a line of products designed to aidpathologists in distinguishing the characteristics of various tumors from biopsy specimens using technology developed by Enzo scientists.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo is committed to delivering a robust line of products andservices that will provide medically relevant, cost effective solutions that are easily adaptable to the workflow of clinical laboratories. The Company’s integrated Life Science and Clinical Lab structure continues to be instrumental in its ability to seamlesslydevelop and advance products from innovation and manufacturing in our life sciences group and validation and commercializationthrough our clinical laboratory. Our product development activity and pipeline include the following products:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: bottom; width: 24%; border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Product/Technology           </font>          </td>          <td style="vertical-align: top; width: 1%">          </td>          <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 20%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected Availability (1)           </font>          </td>          <td style="vertical-align: top; width: 1%; text-align: center">          </td>          <td style="vertical-align: top; width: 54%; border-bottom: black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            Platform           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            FLU Panel 1/AMPIPROBE            <sup>             ®            </sup>            REAL-TIME AMPLIFICATION AND DETECTION           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q4 2020           </font>          </td>          <td style="text-align: center">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            GENFLEX™ Molecular System           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SARS-CoV-2 IgM ELISA Kit           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q4 2020           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ELISA           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Absorbance 96 Plate Reader           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q4 2020           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Instrument           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Vitamin D ELISA           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q4 2020           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ELISA           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SARS-CoV-2 Antigen Detection           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q1 2021           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ELISA &amp; Lateral Flow           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HPV High Risk Screen/ AMPIPROBE            <sup>             ®            </sup>            REAL-TIME AMPLIFICATION AND DETECTION           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q1 2021           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            AGENFLEX™ Molecular System           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            RNA ISH           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q2 2021           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             IN SITU            </i>            HYBRIDIZATION RNA DETECTION           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HIV Viral Load/AMPIPROBE            <sup>             ®            </sup>            REAL-TIME AMPLIFICATION AND DETECTION           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q2 2021           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            GENFLEX™ Molecular System           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HSV/VZV/AMPIPROBE            <sup>             ®            </sup>            REAL-TIME AMPLIFICATION AND DETECTION           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q2 2021           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            GENFLEX™ Molecular System           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Group Strep B/AMPIPROBE            <sup>             ®            </sup>            REAL-TIME AMPLIFICATION AND DETECTION           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Q2 2021           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            GENFLEX™ Molecular System           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; font-size: 11pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="font-size: 11pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Represents the calendar period.  There can be no assurances these products can be successfully developed within these timeframes or available on these dates, if at all.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Core Technologies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have developed a portfolio of proprietary technologies witha variety of research, diagnostic and therapeutic applications.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Gene analysis technology        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        All gene-based testing is premised on the knowledge that DNAforms a double helix comprised of two complementary strands that match and bind to each other. If a complementary piece of DNA(a probe) is introduced into a sample containing its matching DNA, it will bind to, or hybridize, to form a double helix with thatDNA. Gene-based testing is carried out by:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            amplification of the target DNA sequence (a process that is essential for the detection of very small amounts of nucleic acid);           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            labeling the probe with a marker that generates a detectable signal upon hybridization;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            addition of the probe to the sample containing the DNA; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            binding or hybridization of the probe to the target DNA sequence, if present, to generate a detectable signal.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have developed AMPIPROBE® as a broad technology basefor the labeling, detection, amplification and analysis of nucleic acids which is supported by our significant proprietary positionin these fields. This and other proprietary technologies are the building blocks of our GENFLEX™ Molecular System and othermolecular diagnostics platforms.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 10; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Amplification        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In the early stages of infection, a pathogen may be presentin very small amounts and consequently may be difficult to detect. Using DNA amplification, samples can be treated to cause apathogen’s DNA to be replicated, or amplified, to detectable levels. We have developed a proprietary amplification processfor multicopy production of nucleic acids, as well as proprietary techniques for amplifying the signals of our probes to furtherimprove sensitivity. Our amplification technologies are particularly useful for the early detection of very small amounts of targetDNA. We have also developed isothermal amplification procedures that can be performed at constant temperatures; unlike polymerasechain reaction (PCR) the most commonly used method of target nucleic acid amplification. These platform technologies could thuspotentially lead to assays with advantages over PCR-based tests which require expensive heating and cooling systems or specializedheat-resistant enzymes. Moreover, our AMPIPROBE® Nucleic Acid Amplification Platform, because of the reduced amount of startingmaterial needed for analysis, may lead to a next-generation of molecular diagnostics that can impart higher sensitivity at a lowercost than currently available assays.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Flow Cytometry        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have developed and launched our first product using our proprietaryFLOWSCRIPT® platform using flow cytometry to analyze messenger RNA (mRNA) transcript expression in individual cells in a mixedcell population. By studying whether a gene or a set of genes is turned on or off, it is possible to obtain clinically relevantinformation at the single cell level. Our first product, the FLOWSCRIPT® HPV E6/E7 Assay, examines the levels of E6/E7 mRNAtranscripts from multiple high risk types which account for over 95% of cervical cancers. We are planning to develop and introduceother products based on this platform technology in the future for applications such as immune-mediated disorders, metabolic disorderpatient monitoring, and other cancers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Non-Radioactive Labeling and Detection        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Traditionally, nucleic acid probes were labeled with radioactiveisotopes. However, radioactively labeled probes have a number of shortcomings; they are unstable and consequently have a limitedshelf life and they are potentially hazardous, resulting in restrictive licensing requirements and safety precautions for preparation,use and disposal. Finally, radioactive components are expensive. Our technologies permit gene analysis without the problems associatedwith radioactively labeled probes and are adaptable to a wide variety of formats.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Formats        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There are various processes, or formats, for performing probe-basedtests. In certain formats, the probe is introduced to a target sample affixed to a solid matrix; in others, the probe is combinedwith the sample in solution (homogeneous assay). Solid matrix assays include:        <i>         in situ        </i>        assays in which the probe reactiontakes place directly on a microscope slide; dot blot assays in which the target DNA is fixed to a membrane; and microplate andmicroarray assays in which the DNA is fixed on a solid surface, and the reaction can be quantified by instrumentation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Therapeutic Platform Development         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Cell Signaling Pathway        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The sphingosine pathway is a cell signaling pathway that hasbeen implicated in tumor cell growth and pathological inflammation. The enzyme Sphingosine kinase 1 is a critical enzyme in thispathway that acts by phosphorylating the cellular lipid Sphingosine to Sphingosine 1-Phosphate (S1P), an important biological mediatorof tumor cell proliferation and drug resistance in various cancers, and of immune function. The compound SK1-I is Enzo’sproprietary small molecule inhibitor of Sphingosine kinase 1, which the Company is currently developing for the treatment of hepatocellularcarcinoma (HCC), the most common form of liver cancer. SK1-I has shown activity against HCC in both        <i>         in vitro        </i>        cell cultureexperiments and in an        <i>         in vivo        </i>        xenotransplantation animal model of human HCC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The compound SK1-I and related compounds, as well as their usein oncology and other therapeutic areas, are covered by a family of issued U.S. patents co-owned by Enzo and Virginia CommonwealthUniversity (VCU) and exclusively licensed by VCU to Enzo. Foreign patent family members have also issued or been allowed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Wnt Cell Signaling Pathway        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        One area of Enzo’s therapeutic platform development isrelated to the development of pharmaceutical agents that affect protein-protein interactions. Over the past several years, ourscientists and collaborators have unlocked the secrets of a major cell signaling pathway, thus producing a means to modify biologicalactivity in a number of physiological systems.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 11; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Further investigation into the design and control of this systemhas allowed our scientists and their collaborators to determine the structure of key regulatory proteins and to identify activesites that can then become targets for Enzo’s proprietary technology generating system. Our technology is capable of generatingactive compounds that range from orally delivered small molecules to peptides, oligonucleotides and antibodies. We have performedpioneering work on the structure and function of lipoprotein receptor-related protein (LRP) and its ligands, developed a screeningtechnology to identify active compounds, and synthesized proprietary molecules capable of producing biological effects in cell-basedsystems and animal models of disease.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Through this work, we have identified both small molecules andpeptides capable of reversing sclerostin-mediated inhibition of Wnt signaling. Preclinical animal studies with several of thecandidate small molecules produced the following results: significant increases in total and femoral bone density through new boneformation; significant reduction in alveolar bone loss; and significant reduction in bone resorption       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Oral Immune Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We continue to explore a novel therapeutic approach based onimmune regulation. Our immune regulation technology seeks to control an individual’s immune response to a specific antigenin the body. An antigen is a substance that the body perceives as foreign and, consequently, against which the body mounts an immuneresponse. This platform technology is being developed as a means to manage Crohn’s disease.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There can be no assurance that we will be able to secure patentsor that these programs will be successful. The potential therapies we are developing could be used, if successful for the treatmentof a variety of diseases, including osteoporosis, osteonecrosis and other bone pathologies, diabetes, autoimmune uveitis and inflammatorybowel disease, including Crohn’s disease and ulcerative colitis, among others.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Clinical Laboratory Services        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We operate a regional clinical laboratory that offers extensivediagnostic services to New York, New Jersey and Connecticut medical communities. As part of our ongoing strategic growth plan wehave recently expanded service to Connecticut and other New England states. Our clinical laboratory testing is utilized by physiciansas an essential element in the delivery of healthcare services. Physicians use laboratory tests to assist in the detection, diagnosis,evaluation, monitoring and treatment of diseases and other medical conditions. Clinical laboratory testing is generally categorizedas clinical testing or anatomic pathology testing. Clinical testing is performed on body fluids, such as blood and urine. Anatomicalpathology testing is performed on tissues and other samples, such as human cells. Many clinical laboratory tests are consideredroutine and can be performed by most commercial clinical laboratories.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Tests that are not routine and that require more sophisticatedequipment and highly skilled personnel are considered esoteric tests and may be performed less frequently than routine tests.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We offer a comprehensive and broad range of routine esoteric,and molecular diagnostic clinical laboratory tests or procedures. These tests are frequently used in general patient care by physiciansto establish or support a diagnosis, to monitor treatment or medication levels, or to search for an otherwise undiagnosed condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our full service clinical laboratory in Farmingdale, New Yorkcontains an infrastructure that includes comprehensive information technology applications, logistics, client services and billingdepartments. We have a network of over thirty strategically located patient service centers and a full service phlebotomy department.Patient service centers collect from patients the specimens as requested by physicians. We also operate two fully equipped STATlaboratories in New York City and Connecticut. A “STAT” lab has the ability to perform certain routine tests quicklyand report results to the physician immediately.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Patient specimens are delivered to our laboratory facilitiesprimarily by our logistics department accompanied by a test requisition form. These forms, which are completed by the orderingphysician, indicate the tests to be performed and demographic patient information and in most instances are transmitted to us viaEnzoDirect, our proprietary computer-based ordering and results delivery system. Once the information is entered into the laboratorycomputer system the tests are performed on the corresponding laboratory testing instrumentation and the results are uploaded primarilythrough an interface from the laboratory testing instrumentation or in some instances, manually entered into the laboratory computersystem. Most routine testing is completed by early the next morning, and test results are reported to the ordering physician. Thesetest results are either reported electronically via EnzoDirect to a physician office Electronic Medical Records (EMR) system ordelivered by our logistics department directly to the ordering physicians’ offices. Physicians who request that they be calledwith a particular result are accordingly notified by our customer service personnel.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 12; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For fiscal years ended July 31, 2020, 2019 and 2018, respectively,approximately 65%, 63% and 70% of the Company’s revenues were derived from the Clinical Laboratory Services segment. Revenues,net of contractual adjustment, from direct billings under the Federal Medicare program during the years ended July 31, 2020, 2019and 2018 were approximately 23%, 21% and 16%, respectively, of the clinical laboratory services segment’s total revenue.The contractual adjustment is an estimate that reduces gross revenue, based on gross billing rates, to amounts expected to be approvedand reimbursed. We estimate contractual adjustment based on significant assumptions and judgments, such as the interpretation ofpayer reimbursement policies which bears the risk of change. The estimation process is based on the experience of amounts approvedas reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. Otherthan the Medicare program, revenues from UnitedHealthcare and Oxford Health Plan represented approximately 24%, 36% and 39%, respectively,of the Clinical Laboratory Services segment’s net revenue for the fiscal year ended July 31, 2020, 2019 and 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At July 31, 2020 and 2019, approximately 68% and 63%, respectively,of the Company’s net accounts receivable was derived from its clinical laboratory business. The Company believes that theconcentration of credit risk with respect to the Clinical Labs accounts receivable is mitigated by the diversity of its third partypayers that insure individuals. To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently,believes that its accounts receivable credit risk exposure, with respect to these payers, is limited. While the Company also hasreceivables due from the Federal Medicare program, the Company does not believe that these receivables represent a credit risksince the Medicare program is funded by the federal government and payment is primarily dependent on our submitting the appropriatedocumentation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Gross billings are based on a standard fee schedule we set forself-payers, all third party payers, including Medicare, health maintenance organizations (“HMO’s) and managed careproviders and expanding institutional relationships with direct billing. We adjust the contractual adjustment estimate quarterly,based on our evaluation of current and historical settlement experience with payers, industry reimbursement trends, and other relevantfactors. The other relevant factors that affect our contractual adjustment include the monthly and quarterly review of: 1) currentgross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements, and 3) the growth ofin-network provider arrangements and managed care plans specific to our Company. The clinical laboratory industry is characterizedby a significant amount of uncollectible accounts receivable related to the inability to receive accurate and timely billing informationin order to forward it on to the third party payers for reimbursement, and the inaccurate information received from the coveredindividual patients for unreimbursed unpaid amounts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Billing for laboratory services is complicated. Depending onthe billing arrangement and applicable law, we must bill various payers, such as patients, insurance companies and the FederalMedicare Program, all of which have different requirements. In both New York and New Jersey, the law prohibits the Company frombilling the ordering physician. Compliance with applicable laws and regulations, as well as internal compliance policies and proceduresadd further complexity to the billing process. We depend on the ordering physician to provide timely, accurate billing demographicand diagnostic coding information to us. Additional factors complicating the billing process include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            pricing differences between our standard gross fee schedules and the reimbursement rates of the payers;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disputes with payers as to which party is responsible for payment;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disparity in coverage and information requirements among various payers; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            differences in medical policies established by various payers.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We incur significant additional costs as a result of our participationin Medicare, as billing and reimbursement for clinical laboratory testing is subject to considerable and complex and stringentfederal and state regulations including those relating to coverage, billing and reimbursements. Future changes in regulationscould further complicate our billing and increase our billing expenses. These additional costs include those related to: (1) complexityadded to our billing processes and changes to our reimbursements; (2) training and education of our employees and customers; (3)compliance and legal costs; and (4) costs related to, among other factors, medical necessity denials and advance beneficiary notices.The Centers for Medicare &amp; Medicaid Services or CMS establishes procedures and continuously evaluates and implements changesin the reimbursement process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The established Medicare reimbursement rate for clinical laboratoryservices has been reduced by the Federal government in a number of instances over the past several years. In March 2010, U.S. federallegislation was enacted to reform healthcare. The legislation provided for reductions in the Medicare clinical laboratory fee scheduleof 1.9% for five years beginning in 2010 and also included a productivity adjustment which reduces the Consumer Price Index (“CPI”)market basket update beginning in 2011.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Diagnostic Products        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are a manufacturer of labeling and detection technologiesfrom DNA to whole cell analysis. Enzo’s products are backed by innovative technology platforms and a deep patent portfolio. With over 40 years of experience, Enzo continues to provide integrated solutions for drug development, pipeline basic research,drug discovery, quality control in drug development and diagnostics. Enzo Life Sciences offers a broad range of high-quality productsto advance research including proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits.  Enzo operatesin a highly competitive and price-sensitive marketplace and is repositioning itself by narrowing its product mix to concentrateon improved profitability, while also adding staff who are more experienced in operations. We have become a specialized assay supplieras part of our integrated strategic plan to deliver highly efficient, cost-effective assays for our own use and to sell to independentlabs. With direct sales operations in the US, Switzerland, Germany, UK, France, and Benelux, Enzo Life Sciences also supportsits products through a global network of dedicated distributors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 13; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        With a passion for genomics, Enzo was the first to develop productsfor non-radioactive labeling of nucleic acids. This technique was instrumental in the development of today’s genomic analysismarket. Our pioneering research in genetic modification medicine was the first to recognize that nucleic acids could be used astherapeutics. Our innovations in the detection of nucleic acids in solutions and solid matrices led to the development of technologyplatforms such as hybrid capture, as well as fluorescent and chromogenic        <i>         in situ        </i>        hybridization. Enzo remains at the forefrontof target amplification technologies critical in the detection of infectious agents, cancer markers, and genotyping. Our work inthe genomic space has resulted in technologies in gene expression and immune system regulation, which opened the door for the well-knownmolecular diagnostics assays used today.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The products we produce and supply include small molecules,proteins, antibodies, peptides, probes, immunoassays, biochemical assays and custom services. Our comprehensive portfolio of highquality reagents and kits in key research areas are sold to scientific experts in the following fields:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in; width: 35%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Bioprocess           </font>          </td>          <td style="width: 5%">          </td>          <td style="width: 60%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Immunology/Inflammation/Innate Immunity           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Cancer           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Metabolism           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Cell Death/Autophagy           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Pathology           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Cell cycle           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●            <i>             In situ            </i>            Hybridization           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Drug discovery           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Microarray Labeling           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Epigenetics           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Neuroscience           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     FISH           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Oxidative Stress           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Genomics           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Proteostasis           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     HPV           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Signal Transduction           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     ImmunoHistochemistry           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Stem Cell           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Viral signaling and detection           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Stress Proteins           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●     Toxicology           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We maintain the technology and products from acquired brandsincluding Alexis, Biomol International, Assay Designs, and Stressgen. Enzo strategically uses these brands to complete our productportfolio, allowing us to offer complete solutions to researchers in all fields. These brands are complementary to our core expertisein genomics and molecular biology. The Company intends to maintain the rights to the acquired brands which have long product histories.The Company believes the emphasis on the Enzo Life Sciences brand will result in stronger and clearer brand awareness and allowthe Company to execute the sale of higher value products and promote more products into the drug development, clinical researchand diagnostic markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Axxora.com -“The Reagents Marketplace”, Thousandsof Reagents, One Marketplace         </i>        </b>        Axxora.com is a proven distribution platform for original manufacturers of innovative researchreagents. An increasing number of researchers use our unique marketplace to connect with over 40 specialty manufacturers and gainaccess to over 100,000 products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Research and Development        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our principal research and development efforts are directedtoward developing innovative new clinical research and diagnostic platforms, and selective expansion of our research product lines,given our manufacturing and distribution capability. We have developed our core research expertise in the life sciences field asa result of over 40 years of dedicated focus in this area. We conduct our research and other product development efforts throughinternal research and collaborative relationships.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In the fiscal years ended July 31, 2020, 2019 and 2018, theCompany incurred costs of approximately $4.4 million, $3.2 million and $3.2 million, respectively, for research and developmentactivities. Starting in fiscal 2018, the Company’s research and development program was refocused to areas that had greateropportunity in molecular diagnostics and immunology chemistry to maximize revenues.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Internal Research Programs        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our professional staff, including 33 with post graduate degrees,performs our internal research and development activities. Our product development programs incorporate various scientific areasof expertise, including recombinant DNA, monoclonal antibody development, enzymology, microbiology, biochemistry, molecular biology,organic chemistry, immunology, flow cytometry and fermentation. In addition, we continuously review in-licensing opportunitiesin connection with new technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 14; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         External Research Collaborations        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have and continue to explore collaborative relationshipswith prominent companies and leading-edge research institutions in order to maximize the application of our technology in areaswhere we believe such relationship will benefit the development of our technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Sales and Marketing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our sales and marketing strategy is to sell our life sciencesproducts through: (i) direct sales to end-users under the Enzo Life Sciences name, with direct recognition to our acquired brands(ii) direct sales to end users under the Axxora electronic market place name (iii) supply agreements with manufacturers and (iv)distributors in major geographic markets. We operate with an understanding of local markets and a well-functioning distributionnetwork system across the globe. Scientists around the world who recognize the brands (Alexis, Assay Designs, Biomol, Enzo andStressgen) now receive products directly from Enzo Life Sciences where we are recognized for innovative high quality products,supported directly by our qualified technical staff. We sell the same products through our Axxora electronic market place whichis also the source for life science research reagents from over 40 original manufacturers. Our direct marketing and sales networkincludes fully-owned subsidiaries (USA, Switzerland, Germany, Benelux, and UK), a branch office in France and a network of thirdparty distributors in most other significant markets worldwide.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For Clinical Laboratory Services, we focus our sales effortson obtaining and retaining profitable accounts. We market these services to a broad range of ordering physicians in the metro NewYork, New Jersey and Connecticut regions through our direct sales force who are supported by client service and patient servicerepresentatives. We monitor and where appropriate, change the service levels and terminate ordering physician accounts that arenot profitable. We are focusing our efforts to attract and retain clients who participate with the providers with whom we haveregional contracts and are consistently looking to add higher value molecular and esoteric testing, both internally developed andwith partners, to our menu to assist sales in new account penetration as well as to improve our level of service to existing clients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Distribution Arrangements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We also distribute our life science products internationallythrough a network of distributors. Through these arrangements, we are able to leverage the established marketing and distributioninfrastructure of these companies in certain market places.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Competition        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We compete with other life science and biotechnology companies,as well as pharmaceutical, chemical and other companies. Competition in our industry is intense. Many of these companies are performingresearch targeting the same technologies, applications and markets. Many of these competitors are significantly larger than weare and have more resources. The primary competitive factors in our industry are the ability to create scientifically advancedtechnology, offer innovative products at the forefront of technological development to targeted market segments, successfully developand commercialize products on a timely basis, establish and maintain intellectual property rights and attract and retain a breadthand depth of human resources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our clinical laboratory services business competes with numerousnational, regional, and local entities, some of which are larger than we are and have greater financial resources than we do. Ourlaboratory competes primarily on the basis of the quality and specialized nature of its testing, reporting and information services,its reputation in the medical community, its reliability and speed in performing diagnostic tests, and its ability to employ qualifiedlaboratory personnel.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Intellectual Property        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We consider our intellectual property program to be a key assetand a major strategic component to the execution of our business strategy. A broad portfolio of issued patents and pending patentapplications supports our core technology platforms. Our policy is to seek patent protection for our core technology platforms,as well as for ancillary technologies that support these platforms and provide a competitive advantage.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In June 2020, we announced the issuance of a patent entitledSphingosine Pathway Modulating Compounds for the Treatment of Cancers. This patent is directed to methods for treating hepatocellularcarcinoma (HCC), the most common human liver cancer, using our proprietary compound SK1-I.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 15; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In May 2020, we announced the issuance of a U.S. Patent entitledSulfonated Sclerostin, Antibodies, Epitopes and Methods for Identification and Use Therefor. The patent is directed to methodsfor producing monoclonal antibodies against specific regions of human Sclerostin, a protein that is a negative regulator of bonegrowth. Inhibition of Sclerostin using monoclonal antibodies can be used to promote bone growth for the treatment of osteoporosis.This patent is a member of a broader U.S. and international patent family that includes issued patents and pending patent applicationsdirected to antibodies and their use in inhibiting Sclerostin as well as small synthetic peptides and their use in inhibiting Sclerostinin the treatment of bone disorders such as osteoporosis       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In April 2020, we announced the issuance of a U.S. patent entitledSphingosine Kinase Type 1 Inhibitors and Uses Thereof. This patent is directed to methods for inhibiting the enzyme Sphingosinekinase 1 in patients using the company’s proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors. Based onthe results obtained in the lupus model and prior work demonstrating the anti-inflammatory activity of SK1-I in animal models ofother immune disorders and on isolated human blood cells, the company is exploring avenues for the development of SK1-I as a potentialtreatment for COVID-19.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In August 2019 we announced the issuance of a U.S. patent entitledNucleic Acid Probes for In Situ Hybridization. This patent is related to a new probe technology developed by Enzo and transformativemethods of testing using the probes, which allow for significantly more cost effective, simple and scalable processes. These newprobes can be used to detect clinically relevant genomic targets with high-sensitivity in cell samples and biopsy tissue obtainedfrom patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At the end of fiscal 2020 we owned or licensed 475 patents relatingto products, methods and procedures resulting from our internal or sponsored research projects. There can be no assurance thatpatents will be issued on pending applications or that any issued patents will not be challenged (see Item 3, Legal Proceedings),or that they will have commercial benefit. We do not intend to rely on patent protection as the sole basis for protecting our proprietarytechnology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We also rely on our trade secrets and continuing technologicalinnovation. We require each of our employees to sign a confidentiality agreement that prohibits the employee from disclosing anyconfidential information about us, including our technology or trade secrets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our intellectual property portfolio can be divided into patentsthat provide claims in three primary categories, as described below:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Nucleic Acid Chemistry        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We currently have broad patent coverage in the area of nucleicacid chemistry. We have done extensive work on the labeling of nucleic acids for the purpose of generating a signal that datesback over twenty years. Enzo has multiple issued patents covering the modification of nucleic acids at their sugar and phosphatesites. The claims contained in these patents cover products that incorporate a signaling moiety into a nucleic acid attached toa sugar or phosphate for the purpose of nucleic acid detection or quantification, including sequencing and real time nucleic acidamplification. Enzo also has patents directed to proprietary dyes that may be used to label the sugar, base or phosphate positionsof nucleic acids.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Signal Delivery        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We also have a long history of innovation in the area of analytedetection using non-radioactive signaling entities. At the signaling entity itself, there are several Enzo patents that cover theformation of this structure. A patent which was allowed in 2006 covers the attachment of signaling molecules through the phosphatemoiety of a nucleic acid, which is how the signal-generating enzyme is bound.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Nucleic Acid Analysis Format        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We also have patents with issued claims covering the use ofarrays of single-stranded nucleic acids fixed or immobilized in hybridizable form to a non-porous solid support. These patentscover any product that uses arrays of nucleic acids for molecular analysis. In some instances, we may enter into royalty agreementswith collaborating research parties in consideration for the commercial use by us of the developments of their joint research.In other instances the collaborating party might obtain a patent, but we receive the license to use the patented subject matter.In such cases, we will seek to secure exclusive licenses. In other instances, we might have an obligation to pay royalties to orreach a royalty arrangement with a third party in consideration of our use of developments of such third party.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         REGULATION AFFECTING OUR BUSINESSES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Clinical Laboratory Services        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The clinical laboratory industry is subject to significant federaland state regulation, including inspections and audits by governmental agencies. Governmental authorities may impose fines, criminalpenalties or take other actions to enforce laws and regulations, including, but not limited to, revocation of a clinical laboratory’scertificate and/or license to operate a clinical laboratory. Changes in regulation may also increase the cost of performing clinicallaboratory tests, increase administrative requirements, and/or decrease the amount of reimbursement. Our clinical laboratory andwhere applicable patient service centers (PSCs) are licensed and accredited as required by law.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 16; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        CLIA (the Clinical Laboratory Improvement Amendments of 1988and its implementing regulations) regulates virtually all clinical laboratories in the United States. Among other things, CLIArequires non-exempt clinical laboratories to earn certification from the federal government and comply with various operational,personnel and quality requirements intended to ensure that their clinical laboratory testing services are accurate, reliable andtimely. CLIA does not pre-empt state laws that are more stringent than federal laws. As such, certain clinical laboratories mustalso meet state specific standards, including inspection, proficiency testing, and personnel requirements. Clinical laboratorycertificates, permits, or licenses are also required by various state and local laws, including certain jurisdictions that requirean out-of-state clinical laboratory to obtain a license/permit if they accept specimens from the state. Enzo has obtained licensesor permits in the states of New York, New Jersey, California, Pennsylvania, Maryland, and Rhode Island. Enzo also operates a clinicallaboratory in the state of Connecticut.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        CLIA assigns testing services into one of three categories onthe basis of complexity (waived, moderate complexity and high complexity) and establishes varying requirements depending upon thecomplexity category of the tests performed. A laboratory that performs high complexity testing must meet more stringent requirementsthan a laboratory that performs only moderate complexity testing, while those that perform only waived testing may apply for acertificate of waiver that if granted, would exempt the laboratory from most CLIA requirements. Our laboratory in Farmingdale,NY is certified to perform high complexity testing. In general, regulations promulgated by the United States Department of Healthand Human Services (“HHS”) require clinical laboratories that perform high or moderate complexity testing to implementsystems that ensure the accurate performance and reporting of test results, establish quality control and quality assurance systems,ensure that personnel meet specified standards, conduct proficiency testing by approved agencies, and undergo biennial inspections,among other requirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Clinical laboratories also are subject to state regulation.CLIA provides that a state may adopt different or more stringent regulations than Federal law, and permits states to apply forexemption from CLIA if HHS determines that the state’s laboratory laws are equivalent to, or more stringent than CLIA. TheState of New York’s clinical laboratory regulations contain provisions that are more stringent than Federal law, and NewYork has received an exemption from CLIA. Therefore, as long as New York maintains a licensure program that is CLIA-exempt, laboratoriesin New York may comply with CLIA requirements by establishing that they meet requirements for clinical laboratories under New Yorklaw. Enzo’s two New York laboratories are licensed in New York State and have ongoing programs that ensure that their operationsare in compliance with all applicable regulatory requirements, including the requirement to obtain approval to perform certainanalyte-specific testing or other methodologies which are not reviewed by FDA as laboratory-developed tests (LDTs).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Sanctions for non-compliance with applicable regulations mayinclude, but are not limited to, suspension, revocation, or limitation of a laboratory’s CLIA certificate and/or state license,as well as fines and criminal penalties. The loss of, or adverse action against, a certificate or license, the imposition of fines,penalties or other sanctions, or future changes in Federal, state or local laboratory laws and regulations (or in the interpretationof current laws and regulations) could have a material adverse effect on our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Billing and reimbursement for clinical laboratory testing aresubject to complex federal and state laws, rules and regulations, the violation of which may include, but is not necessarily limitedto: (1) exclusion from participation in federal health care programs (including Medicare and Medicaid); (2) asset forfeitures;(3) civil monetary penalties; (4) criminal fines and penalties; and (5) the loss of licenses, certificates and/or authorizationsnecessary to operate some or all of a clinical laboratory’s business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The health care industry has been undergoing significant changebecause third-party payers, such as Medicare, Medicaid, health maintenance organizations and commercial insurers, have increasedtheir efforts to control the cost, utilization and delivery of health care services. To address the problem of increasing healthcare costs, legislation has been proposed or enacted at both the Federal and state levels to regulate health care delivery in general,and clinical laboratories in particular. Additional health care reform efforts are likely to be proposed in the future. In particular,we believe that reductions in reimbursement for Medicare services will continue to be implemented from time to time. Reductionsin the reimbursement rates of other third-party payers, commercial insurers and health maintenance organizations are likely tooccur as well. We cannot predict the effect that current and future health care reform measures, if enacted, would have on ourbusiness, and there can be no assurance that such reforms, if so enacted, would not have a material adverse effect on our businessand operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Containment of health care costs, including reimbursement forclinical laboratory services, has been a focus of on-going governmental activity. In general, clinical laboratories must bill Medicaredirectly for the services provided to Medicare beneficiaries and may only collect the amounts permitted under the Medicare ClinicalLaboratory Fee Schedule. Under the Patient Protection and Affordable Care Act, expansion in the pool of covered lives may expandthe market for clinical diagnostic testing while at the same time, various policies aimed at reducing costs or bundling care mayreduce the rates paid for such services; the net impact of these factors on the market for our services is not clear . In April2014, Congress passed the Protecting Access to Medicare Act of 2014 (PAMA), which included substantial changes to the way in whichclinical laboratory services will be paid under Medicare. Beginning in 2018, Medicare payments for clinical laboratory servicesare paid based upon the volume-weighted median of private payer rates as reported by certain clinical laboratories across the US,replacing the previous system which was based upon fee schedules derived from historical charges for tests from the mid 1980’s.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 17; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Since Enzo’s clinical laboratory receives more than 50%of its total Medicare revenue from the Part B Clinical Laboratory Fee Schedule (CLFS) and the Physician Fee Schedule and receivesmore than $12,500 in Medicare CLFS revenues per year, we are considered an “applicable laboratory”, and as such, arerequired to report private payer rate information to CMS. Enzo initially reported data from the first two quarters of CY 2016 duringQ1 2017, and this information was used (along with data from other relevant laboratories) to calculate Medicare reimbursement ratesfor CY 2018-2022. The current reporting cycle requires us to report private payer rates for fee reimbursements for the period January1, 2019 to June 30, 2019 to CMS during Q1 2022. This combined data (and data from other laboratories) will be aggregated and utilizedagain as the basis for the 2023-2025 Medicare CLFS that is expected to be finalized in November 2022.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Future changes in federal, state and local regulations (or inthe interpretation of current regulations) affecting governmental reimbursement for clinical laboratory testing may have a materialadverse effect on our business. We cannot predict, however, whether and what type of legislation will be enacted into law. In addition,(1) reimbursement denials by third party payers, commercial insurers and health maintenance organizations, (2) reductions or delaysin the establishment of reimbursement rates, (3) carrier limitations on the insurance coverage of the Company’s servicesand (4) the use of the Company as a service provider may have a negative effect on the Company’s future revenues. Duringour fiscal 2016 and 2017, Medicare reimbursement rates remained constant with 2015 levels. However, PAMA-based cuts in Medicarereimbursement for certain services impacted fiscal 2018 results beginning in January 2018. PAMA cuts were implemented in calendaryear 2019 for certain services, which also impacted our financial results for our fiscal 2020 and 2019. Additional cuts are mandatedin calendar year 2020 and are expected to negatively impact our fiscal 2021 results. The impact of subsequent adjustments to Medicarerates are unclear at this time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Anti-Fraud and Abuse Laws        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Existing Federal and state laws also regulate certain aspectsof the relationship among healthcare providers, including clinical laboratories, and their referral sources (i.e., physicians,hospitals, other laboratories, etc.). One of these laws, known as the federal “Anti-Kickback Statute,” contains broadprohibitions against knowingly and willfully offering, paying, soliciting (i.e., asking for) or receiving remuneration (i.e., anythingof value) in any form (e.g., cash, gifts, certain discounts, cross-referrals between parties, etc.), either directly or indirectly,to induce or in return for the referral of an individual for the furnishing of or arranging for the furnishing of any item or servicefor which payment may be made in whole or in part by a federal health care program. or the purchasing, leasing, ordering, or arrangingfor or recommending purchasing, leasing, or ordering of any good, facility, item or service for which payment may be made in wholeor in part by a federal health care program.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Violation of the Anti-Kickback Statute may result in, amongother things, a criminal conviction, significant monetary penalties and exclusion from federal health care programs (includingMedicare and Medicaid). Any person or entity involved in a prohibited transaction is potentially subject to criminal and civilpenalties. A laboratory that claims payment for business generated by the Anti-Kickback Statute may also be subject to prosecutionfor violating a separate civil statute, the federal False Claims Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Federal substance abuse legislation enacted in October 2018(Eliminating Kickbacks in Recovery Act of 2018 or EKRA) contains an all-payer anti-kickback provision that is, by its terms, applicableto laboratories. We are attempting to clarify the application of that legislation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The federal False Claims Act is also a broad statute that thegovernment often utilizes to combat fraud and abuse in the health care environment. Among other things, the statute is violatedby any person who knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval; knowinglymakes, uses, or causes to be made or used, a false record or statement material to a false or fraudulent claim; conspires to committhe above (or other specified) violations; or knowingly makes, uses, or causes to be made or used, a false record or statementmaterial to an obligation to pay or transmit money or property to the government, or knowingly conceals or knowingly and improperlyavoids or decreases an obligation to pay or transmit money or property to the government. The federal False Claims Act also providesthat private parties may bring an action on behalf of (and in the name of) the United States to prosecute a federal False ClaimsAct violation. These private parties (known as “qui tam relators”) may share in a percentage of the proceeds that resultfrom a federal False Claims Act action or settlement. A person or entity found to have violated the federal False Claims Act maybe held liable for a per claim civil penalty. For penalties assessed after June 19, 2020, whose associated violations occurredafter November 2, 2015, the penalties range from $11,665 to $23,331 for each false claim, plus three times the amount of damagessustained by the government. The minimum and maximum per claim penalty amounts are subject to annual increases for inflation. Aperson violating the federal False Claims Act is also liable for the costs of the civil action brought to recover any such penaltyor damages. Other consequences may also result from a violation of the federal False Claims Act or similar state laws. For example,New York has also adopted its own false claims act statute, which closely mirrors its federal counterpart.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Another federal law, commonly known as the “Stark”law, prohibits physicians who have (or whose immediate family member has) a financial relationship with an entity that furnishesMedicare-covered “designated health services,” which includes clinical laboratory services (including anatomic pathologyand clinical chemistry services), from referring Medicare beneficiaries to that entity for “designated health services”unless a specific exception applies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 18; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition, laboratories may not bill federal health care programs,or any other payer, for services furnished pursuant to a prohibited referral. Violation of the Stark law may result not only indenial of payment for the underlying testing services, but also the imposition of civil monetary penalties and, potentially, FalseClaims Act liability. The Stark law also prohibits state receipt of federal Medicaid matching funds for services furnished pursuantto a prohibited referral. This provision of the Stark law has not been implemented by regulations, but some courts have held thatthe submission of claims to Medicaid that would be prohibited as self referrals under the Stark law for Medicare could implicatethe federal False Claims Act. Many states, including New York have adopted laws that are similar to the federal Stark law, whichcontain similar prohibitions and penalties and apply regardless of payer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Various federal and state laws, including the Stark law andNew York State laws, may also apply in ways that impose restrictions on the supplies and other items that laboratories may provideto their clients without charge. For example, in the case of the Stark law, laboratories may provide clients with items, devicesor supplies that are used solely to collect, transport or store specimens for the laboratory or to communicate results or testswithout implicating the law, but not surgical items, devices or supplies.. The Company has implemented procedures to ensure compliancewith these laws and restrictions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In 1997, the Department of Health and Human Services, Officeof the Inspector General (OIG) released a model compliance plan for the clinical laboratory industry and in 1998 released a voluntarycompliance program guidance for laboratories. One key aspect of the OIG guidance was an emphasis on the responsibility of laboratoriesto notify physicians that Medicare covers only medically necessary services. The OIG guidance on notices focuses on chemistry tests,especially routine tests, rather than on anatomic pathology services or the non-automated tests, which make up the majority ofthe Company’s business measured in terms of net revenues. Nevertheless, the notice could potentially affect physicians’test ordering habits more broadly. The Company is unable to predict whether, or to what extent, notices have impacted, or may impact,utilization of the Company’s services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The federal health care reform legislation adopted in March,2010, known as the Patient Protection and Affordable Care Act, contains provisions requiring providers to establish complianceprograms as a condition of enrollment in Medicare, Medicaid and the State Children’s Health Insurance Program. Implementingregulations and guidance for clinical laboratories has not yet been issued yet by the Centers for Medicare and Medicaid Services.In addition, New York State has adopted mandatory compliance program requirements for certain specified providers, including thosewho directly or indirectly bill or collect more than $500,000 annually in Medicaid payments, and entities licensed under certainarticles of the Public Health Law and Mental Hygiene Law, respectively. The Company has adopted its own Corporate Compliance Programbased upon the OIG model program guidance and in accordance with New York State’s requirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s compliance program focuses on, among otherthings, establishing clear compliance standards; auditing and monitoring of the Company’s billing and coding practices; trainingpersonnel on compliance standards, policies and procedures; preventing and detecting fraud, waste and abuse, enforcing a policyof non-retaliation and non-intimidation for good faith participation in the compliance program; and establishing good faith reportingof actual or suspected compliance violations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company seeks to structure its arrangements with physiciansand other customers in compliance with federal and state Anti-Kickback laws, Stark laws, False Claims Acts, and other applicablelaws, rules and regulations, and to keep current on developments concerning their application to the Company, including consultationwith legal counsel. However, the Company is unable to predict how such laws and regulations will be interpreted and applied inthe future, and thus no assurances can be given that its arrangements or processes will not become subject to scrutiny by a governmentalagency.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Standards for Electronic Healthcare Transactions and Privacy,Security and Breach Notification Requirements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Health Insurance Portability and Accountability Act of 1996,as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH Act”) (together,“HIPAA”), included “administrative simplification” provisions designed to standardize common electronictransactions in health care and to protect the security and privacy of health information. Congress’ purpose in promulgatingHIPAA was to increase the efficiency of health care transactions while, at the same time, protecting the confidentiality of patientinformation. HIPAA’s implementing regulations set forth standards for conducting certain electronic transactions, as wellas privacy, security and breach notification requirements applicable to certain health information. As part of its standards forelectronic transactions, HIPAA requires the use of a National Provider Identifier in electronic health care transactions. The NationalProvider Identifier is an identifier that replaced all other identifiers that are currently used or healthcare transactions (e.g.,UPIN, Medicaid provider numbers, identifiers assigned by commercial insurers). The regulations promulgated under HIPAA have verybroad applicability, including by specifically applying to health care providers that engage in certain standard electronic transactions,which may include physicians and clinical. Such health care providers, together with health plans and health care clearinghousesare subject to HIPAA as “Covered Entities”. HIPAA also applies to the “Business Associates” of CoveredEntities, which are generally individuals or entities that create, receive, maintain, transmit, use, or disclose protected healthinformation in performing certain functions or services for or on behalf of Covered Entities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 19; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The electronic transaction standards regulations created guidelinesfor certain common health care transactions. With certain exceptions, these standards require that, when we conduct certain transactionselectronically with another health care provider, health care clearinghouse or health plan, we must comply with the standards setforth in the regulations. The regulations established standard data content and format requirements for submitting electronic claimsand other administrative health transactions. Health care providers and health plans are required to use standard formats whentransmitting claims, referrals, authorizations, and certain other transactions electronically. The Company believes it is in compliancewith these standards. However, to the extent the Company engages in electronic standards that do not comply with applicable standardsunder HIPAA, payments to the Company may be delayed or denied.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Adhering to the privacy, security and breach notification requirementsunder HIPAA requires an extensive compliance infrastructure. We are required to maintain numerous policies and procedures in orderto comply with these requirements. Furthermore, we need to continuously ensure that there are mechanisms in place to safeguardthe privacy of PHI that is transmitted or maintained in any format (e.g. oral, written, or electronic). Failure to comply withthese requirements can result in criminal and civil penalties. In addition, to comply with the HIPAA security regulations in particular,we must ensure the confidentiality, integrity and availability of all electronic PHI (“EPHI”) that we create, receive,maintain, or transmit. We have some flexibility to fashion our own security measures to accomplish these goals. The security regulationsstrongly emphasize that we must periodically conduct an accurate and thorough assessment of the potential risks and vulnerabilitiesto the confidentiality, integrity and availability of our EPHI and then document our response to the various security regulationson the basis of that assessment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The privacy, security and breach notification regulations underHIPAA were last modified in 2013 as a result of final regulations published pursuant to the HITECH Act (“Omnibus Rule”).The HITECH Act requires, among other things, that Covered Entity health care providers, which may include laboratories, notifypatients of breaches of unsecured PHI, enter into business associate agreements with their business associates that meet certainrequirements, and take other steps to comply with the privacy, security, and breach notification requirements of the HITECH Act,which include making necessary revisions to many of their existing privacy policies and procedures. In addition, the HITECH Actmakes Business Associates directly liable to the Federal government for compliance with certain aspects of the privacy, securityand breach notification regulations. In addition, as implemented in the Omnibus Rule, a downstream subcontractor of a BusinessAssociate that creates, receives, maintains, or transmits PHI on behalf of the Business Associate is also itself considered a BusinessAssociate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Covered Entities and Business Associates are subject to potentiallysignificant civil and criminal penalties for violating HIPAA. Under the Omnibus Rule, health care providers, such as laboratories,that are subject to HIPAA as a Covered Entity are also vicariously liable for violations of HIPAA based on acts or omissions oftheir agents, including Business Associates, when the agent is acting within the scope of the agency. Complying with the electronictransaction, privacy, security and breach notification rules requires significant effort and expense for virtually all entitiesthat conduct health care transactions electronically and handle PHI.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We may also be subject to state laws that are not pre-emptedby HIPAA to the extent the state law is more stringent than HIPAA, provides individuals with greater rights with respect to theirprotected health information, or are broader in scope than HIPAA. Every U.S. state has also enacted its own breach notificationlaw that requires regulated entities to report certain data breaches to affected individuals, state regulators, and other parties.Failure to comply with applicable state privacy, security or breach notification laws may result in civil or criminal liability,private causes of action by individuals, administrative actions brought by state regulators, or other consequences that may adverselyimpact our business or reputation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Medical Regulated Waste        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are subject to licensing and regulation under federal, stateand local laws relating to the handling and disposal of medical specimens, infectious and hazardous waste, as well as to the safetyand health of laboratory employees. All our laboratories are required to operate in accordance with applicable federal and statelaws and regulations relating to biohazard disposal of all facilities specimens. We use outside vendors to dispose of such specimens.Although we believe that we comply in all respects with such federal, state and local laws, our failure to comply with those lawscould subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Occupational Safety        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition to its comprehensive regulation of safety in theworkplace, the U.S. Federal Occupational Safety and Health Administration (“OSHA”) has established extensive requirementsrelating to workplace safety for health care employers, including clinical laboratories, whose workers may be exposed to blood-bornepathogens such as HIV and the hepatitis B virus. These regulations, among other things, require work practice controls, protectiveclothing and equipment, training, medical follow-up, vaccinations and other measures designed to minimize exposure to, and transmissionof, blood-borne pathogens. The Federal Drug Enforcement Administration regulates the use of controlled substances in testing fordrugs of abuse. We are also subject to OSHA’s requirement that employers using hazardous chemicals communicate the propertiesand hazards presented by those chemicals to their employees. We believe that we are in compliance with these OSHA requirements.Our failure to comply with those regulations and requirements could subject us to tort liability, civil fines, criminal penaltiesand/or other enforcement actions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 20; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         18         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Other Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our business is and will continue to be subject to regulationunder various state and federal environmental, safety and health laws, including the Occupational Safety and Health Act, the ResourceConservation and Recovery Act, and the Atomic Energy Act or their state law analogs. These and other laws govern our use, handlingand disposal of various biological, chemical and radioactive substances used in our operations and wastes generated by our operations.We are required to possess licenses under, or are otherwise subject to federal and state regulations pertaining to, the handlingand disposal of medical specimens, infectious and hazardous waste and radioactive materials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that we are in compliance with applicable environmental,safety and health laws in the United States and internationally and that our continual compliance with these laws will not havea material adverse effect on our business. All of our laboratories are operated in accordance with applicable federal and statelaws and regulations relating to hazardous substances and wastes, and we use qualified third-party vendors to dispose of biologicalspecimens and other hazardous wastes. Although we believe that we comply in all respects with such federal, state and local laws,our failure to comply with those laws could subject us to denial of the right to conduct business, civil fines, criminal penaltiesand/or other enforcement actions. Environmental contamination resulting from spills or disposal of hazardous substances generatedby our operations, even if caused by a third-party contractor or occurring at a remote location could result in material liability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Regulation of Diagnostic Products        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On February 4, 2020 the HHS Secretary determined that thereis a public health emergency that has a significant potential to affect national security or the health and security of UnitedStates citizens living abroad, and that involves the virus that causes COVID-19. On the basis of this determination, the Secretarythen declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/ordiagnosis of the virus that causes COVID-19.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The diagnostic products that are developed by our collaborators,or by us, are likely to be regulated by the FDA as medical devices. Unless an exemption applies, medical devices must undergo premarketreview (and receive “510(k) clearance”,        <i>         de novo        </i>        510(k) authorization, or pre-market approval (“PMA”)from the FDA, as may be applicable) before they can be marketed in the United States. The FDA’s premarket review processesmay be costly and time consuming, but the process of obtaining PMA approval is typically the most costly, lengthy and uncertain,followed by the        <i>         de novo        </i>        510(k) process, and then the 510(k) process. Regardless of the premarket review pathway that appliesto a particular product, we cannot be sure that we will successfully complete the FDA premarket review process for any productwe propose to market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The FDA decides the premarket review process that applies toa particular device based upon statutory criteria. These criteria include the level of risk that the agency perceives is associatedwith the device and a determination whether the product is a type of device that is similar to devices that are already legallymarketed. Devices deemed to pose relatively less risk are placed in either class I or II, which requires the manufacturer to submita premarket notification requesting 510(k) clearance, unless an exemption applies. In a pre-market notification, the applicantmust demonstrate that the proposed device is “substantially equivalent” in intended use and in safety and effectivenessto a legally marketed “predicate device” that is a “pre-amendment” class III device (i.e., one that waslegally in commercial distribution before May 1976) for which the FDA has not yet called for submission of a PMA application, ora device which has been reclassified from Class III to Class II or I, a device which has been found substantially equivalent throughthe 510(k) process, or a device that was granted marketing authorization via the        <i>         de novo        </i>        classification process that isnot exempt from premarket notification requirement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        After a device receives 510(k) clearance, any modification thatcould significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires anew 510(k) clearance or could require a        <i>         de novo        </i>        510(k) authorization or PMA approval (as applicable). The FDA requires eachmanufacturer to make the determination regarding whether a modification triggers the requirement for a new submission in the firstinstance, but the FDA can review any such decision. If the FDA disagrees with a manufacturer’s decision not to seek premarketreview for the modified device, the agency may retroactively require the manufacturer to do so. The FDA also can require the manufacturerto cease marketing and/or recall the modified device until the premarket review process has been successfully completed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Devices deemed by the FDA to pose the greatest risk, such aslife-sustaining, life-supporting or implantable devices, or deemed not substantially equivalent to a legally marketed class I orclass II predicate device, or to a preamendment class III device, for which PMAs have not been called, are placed in class III.Such devices are required to undergo the PMA approval process in which the manufacturer must provide sufficient valid scientificevidence of the safety and effectiveness of the device. A PMA application typically requires the collection of extensive preclinicaland clinical trial data and also information about the device and its components regarding, among other things, device design,manufacturing and labeling. After approval of a PMA, a new PMA or PMA supplement is required in the event of a modification tothe device, its labeling or its manufacturing process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 21; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         19         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Although clinical investigations of many devices are subjectto the investigational device exemption (“IDE”) requirements, clinical investigations of certain in vitro diagnostic(“IVDs”) tests are exempt from the IDE requirement provided the testing is non-invasive, does not require an invasivesampling procedure that presents a significant risk, does not by design or intention introduce energy into the subject, and isnot used as a diagnostic procedure without confirmation by another medically established test or procedure.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Notwithstanding the above, certain IVD products can be marketedwithout going through the premarket review process if they are intended for use in the laboratory research phase of developmentand not represented as an effective IVD (i.e., labeled for Research Use Only (RUO)) or for use in product testing prior to fullcommercial marketing (i.e. for Investigational Use Only (IUO)). Because RUO and IUO-labeled products are exempt from most regulatoryrequirements that would otherwise apply to medical devices, it is important that they are not distributed for clinical diagnosticuse. Mere placement of an RUO or IUO label on an IVD product does not render the device exempt from otherwise applicable regulatoryrequirements; indeed, FDA may determine that the device is intended for use in clinical diagnosis on the basis of other evidence,including how the device is marketed. FDA recommends that manufacturers assess the totality of the circumstances surrounding thedistribution of their RUO and IUO labeled products to ensure that they are not engaging in practices that conflict with their labeling.The FDA expressed its intent to exercise heightened enforcement with respect to IUO and RUO devices improperly commercialized withoutFDA clearance, authorization or approval in a 2013 final guidance document.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have developed products that we currently distribute in theUnited States on a RUO basis. There can be no assurance that the FDA would agree that our distribution of these products meetsthe requirements for RUO distribution. Furthermore, our failure to comply with the regulatory limitations on the sale and distributionof RUO devices could result in enforcement action by the FDA, including the imposition of restrictions on our distribution of theseproducts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Although FDA has long asserted it has jurisdiction over laboratory-developedtests, the agency has historically exercised discretion enforcement with respect to most such tests and not required laboratoriesthat furnish these tests to comply with FDA’s regulatory requirements for medical devices. In recent years, however, theFDA has indicated that it intends to end enforcement discretion and regulate certain LDTs as medical devices. In October 2014,the FDA officially a draft guidance document that set forth a proposed risk-based regulatory framework that would apply varyinglevels of FDA oversight to LDTs. The FDA has indicated that it does not intend to modify its policy of enforcement discretion untilthe draft guidance documents are finalized. Subsequently, in January 2017, the FDA published a “discussion paper” inwhich the agency outlined a substantially revised “possible approach” to the oversight of LDTs. The discussion paperexplicitly states that it is not a final version of the 2014 draft guidance and that it does not represent the agency’s “formalposition;” rather, the discussion paper describes the evolution of the agency’s thinking on LDTs, which the agencyposted to “spur further dialogue.” Notably, in the discussion paper, the agency expressed its willingness to consider“grandfathering” currently marketed LDTs from most or all FDA regulatory requirements. It is unclear at this time when,or if, the FDA will finalize its plans to end enforcement discretion, and even then, the new regulatory requirements are expectedto be phased-in over time. Nevertheless, the FDA may decide to regulate certain LDTs on a case-by-case basis at any time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Legislative proposals addressing the FDA’s oversight ofLDTs have been introduced in previous Congresses, and we expect that new legislative proposals will be introduced from time totime. The likelihood that Congress will pass such legislation and the extent to which such legislation may affect the FDA’splans to regulate certain LDTs as medical devices is difficult to predict at this time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In so far as the products that we manufacture or distributeare subject to regulation as medical devices, a host of additional regulatory requirements may apply beyond premarket review requirements,including establishment registration, device listing, the Quality System Regulation (which requires manufacturers to follow elaboratedesign, testing, control, documentation and other quality assurance procedures), the Medical Device Reporting regulation (whichrequires that manufacturers report to the FDA certain types of adverse events involving their products), labeling regulations,and the FDA’s general prohibition against promoting products for unapproved or “off label” uses. Class II devicesmay also be subject to special controls such as performance standards, post market surveillance, patient registries, and FDA guidelinesthat do not apply to class I devices. Unanticipated changes in existing regulatory requirements or adoption of new requirementscould hurt our business, financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are subject to inspection and market surveillance by theFDA to determine compliance with regulatory requirements. If the FDA finds that we have failed to comply with applicable requirements,the agency can institute a wide variety of enforcement actions, ranging from a public warning letter to more severe sanctions suchas fines, injunction, civil penalties, recall or seizure of our products, operating restrictions, partial suspension or total shutdownof production, refusal of our requests for 510(k) clearance or PMA approval of new products, withdrawal of PMA approvals alreadygranted, and criminal prosecution.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The FDA also has the authority to request repair, replacementor refund of the cost of any medical device manufactured or distributed by us. Our failure to comply with applicable requirementscould lead to an enforcement action that may have an adverse effect on our financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Unanticipated changes in existing regulatory requirements, ourfailure to comply with such requirements or adoption of new requirements could have a material adverse effect on us. We have employeesto expedite the preparation and filing of documentation necessary for FDA clearances, authorizations, and approvals, as well aspatent issuances and licensing agreements. We cannot assure you that future clinical diagnostic products developed by us or ourcollaborators will not be required to be reviewed by FDA under the more expensive and time consuming pre-market approval process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 22; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         20         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Regulation of Pharmaceutical Products        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        New drugs and biological drug products are subject to regulationunder the Federal Food, Drug, and Cosmetic Act, and biological products are also regulated under the Public Health Service Act.We believe that certain products developed by us or our collaborators will be regulated either as biological products or as newdrugs. Both statutes and regulations promulgated thereunder govern, among other things, the testing, licensing, manufacturing,marketing, distributing, safety, and efficacy requirements, labeling, storage, exporting, record keeping, advertising and otherpromotional practices involving biologics or new drugs, as the case may be. FDA review or approval or other clearances must beobtained before clinical testing, and before manufacturing and marketing, of biologics and drugs. At the FDA, the Center for BiologicalEvaluation and Research (“CBER”) is responsible for the regulation of biological drugs and the Center for Drug Evaluationand Research (“CDER”) is responsible for the regulation of non-biological drugs. Biological drugs are licensed andother drugs are approved before commercialization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Any therapeutic products that we develop will require regulatoryreview before clinical trials, and additional regulatory approval before commercialization. New human gene medicine products aswell as immune regulation products, as therapeutics, are subject to regulation by the FDA and comparable agencies in other countries.The FDA on a case-by-case basis currently reviews each protocol. In addition, the National Institutes of Health (“NIH”)is also involved in the oversight of gene therapies and the FDA has required compliance with certain NIH requirements. Federalrequirements are detailed in Title 21 of the Code of Federal Regulations (21 CFR). In addition, the FDA publishes guidance documentswith respect to the development of therapeutics protocols.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Obtaining FDA approval has historically been a costly and time-consumingprocess. Generally, to gain FDA approval, a developer first must conduct pre-clinical studies in the laboratory evaluating productchemistry, formulation and stability and, if appropriate, in animal model systems, to gain preliminary information on safety andefficacy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Pre-clinical safety tests must be conducted by laboratoriesthat comply with FDA regulations governing Good Laboratory Practices (“GLP”). The results of those studies are submittedwith information characterizing the product and its manufacturing process and controls as a part of an investigational new drug(“IND”) application, which the FDA must review and approve before human clinical trials of an investigational drugcan start. The IND application includes a detailed description of the clinical investigations to be undertaken in addition to otherpertinent information about the product, including descriptions of any previous human experience and the company’s futureplans for studying the drug.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In order to commercialize our pharmaceutical products, we (asthe sponsor) would file an IND application with FDA and will be responsible for initiating and overseeing the clinical studiesto demonstrate the safety and efficacy necessary to obtain FDA marketing approval of any such products. For INDs that we sponsor,we will be required to select qualified clinical sites (usually physicians affiliated with medical institutions) to supervise theadministration of the investigational product. It is the sponsor’s responsibility to ensure that the investigations are conductedand monitored in accordance with FDA regulations, Good Clinical Practices (“GCP”) and the general investigational planand protocols contained in the IND. This may be done using in-house trained personnel or an outside contract research organization(“CRO”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Each clinical study is also reviewed, approved and overseenby an Institutional Review Board (“IRB”). In considering an application to perform a clinical trial, IRB will consider,among other things, ethical factors and the safety of human subjects participating in the trial. Clinical trials are normally conductedin three phases, although the phases might overlap. Phase I trials, concerned primarily with the safety and tolerance of the drug,and its pharmacokinetics (or how it behaves in the body including its absorption and distribution), typically involve fewer than100 subjects. Phase II trials normally involve a few hundred patients and are designed primarily to demonstrate preliminary effectivenessand the most suitable dose or exposure level for treating or diagnosing the disease or condition for which the drug is intended,although short-term side effects and risks in people whose health is impaired may also be examined. Phase III trials are expanded,adequate and well-controlled clinical trials with larger numbers of patients and are intended to gather the additional informationfor proper dosage and labeling of the drug. Clinical trials may take several years to complete, but the period may vary. The FDAreceives reports on the progress of each phase of clinical testing, and it may require the modification, suspension or terminationof clinical trials if an unwarranted risk is presented to patients. There can be no assurance regarding the length of the clinicaltrial period, the number of patients that the FDA will require to be enrolled in the clinical trials in order to establish theefficacy, safety, purity and/or potency of human gene medicine products, or that the clinical and other data generated will beacceptable to the FDA to support marketing approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If a developer obtains designation by the FDA of a biologicor other drug as an “orphan” for a particular use, the developer may request grants from the federal government todefray the costs of qualified testing expenses in connection with the development of such drug. Orphan drug designation is possiblefor drugs for rare diseases, including many genetic diseases, which means the drug is for a disease that has a prevalence of lessthan 200,000 patients in the United States. The first applicant who receives an orphan drug designation and who obtains approvalof a marketing application for such drug acquires the exclusive marketing rights to that drug for that use for a period of sevenyears unless the subsequent drug can be shown to be clinically superior. Accordingly, no other company would be allowed to marketan identical orphan drug with the same active ingredient for the use approved by the FDA for seven years after the approval, unlessshown to be clinically superior. Certain expedited pathways may be available and would shorten the time periods and reduce thenumber of patients required to be tested in the case of certain life-threatening diseases, which lack available alternative treatments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 23; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         21         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        After completion of clinical trials of an investigational product,FDA marketing approval must be obtained before the product can be sold in the United States. If the product is regulated as a newbiologic, CBER requires the submission and approval of a Biologics License Application (“BLA”) before commercial marketingof the biologic product. If the product is classified as a new drug, we must file a New Drug Application (“NDA”) withCDER and receive approval before commercial marketing of the drug. The NDA or BLA must include results of product development,pre-clinical studies and clinical trials. The testing and approval processes require substantial time and effort and there canbe no assurance that any approval will be granted on a timely basis, if at all. The median time to obtain new product approvalsafter submission to the FDA is approximately 10 months and 6 months for priority review. If questions arise during the FDA reviewprocess, approval can take longer. Before completing its review, the FDA may seek guidance from an Advisory Panel of outside expertsat a public or closed meeting. While the advice of these committees is not binding on the FDA, it is often followed. Notwithstandingthe submission of relevant data, the FDA might ultimately decide that the NDA or BLA does not satisfy its regulatory criteria forapproval and, thus, reject the application, refuse to approve it, or require additional clinical, preclinical or chemistry studies.Even after FDA regulatory approval or licensure, a marketed drug product is subject to continual review by the FDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition, if previously unknown problems are discovered orwe fail to comply with the applicable regulatory requirements, we might be restricted from marketing a product, we might be requiredto withdraw the product from the market, and we might possibly become subject to seizures, injunctions, voluntary recalls, or civil,monetary or criminal sanctions. In addition, the FDA may condition marketing approval on the conduct of specific post-marketingstudies to further evaluate safety and effectiveness.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For commercialization of our biological or other drug products,the manufacturing processes described in our NDA or BLA must receive FDA approval and the manufacturing facility must successfullypass an inspection prior to approval or licensure of the product for sale within the United States. The pre-approval inspectionassesses whether, for example, the facility complies with the FDA’s current good manufacturing practices (“cGMP”)regulations. These regulations elaborate testing, control, documentation, personnel, recordkeeping and other quality assuranceprocedure requirements that must be met.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Once the FDA approves our biological or other drug productsfor marketing, we must continue to comply with the cGMP regulations. The FDA periodically inspects biological and other drug manufacturingfacilities to ensure compliance with applicable cGMP requirements. Failure to comply with the statutory and regulatory requirementssubjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product or voluntaryrecall of a product.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Manufacturing and Research Facilities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our integrated laboratory and scientific efforts for our threesegments currently take place primarily at two adjacent facilities in Farmingdale, New York. A major part of one facility is utilizedby Life Science products as its global headquarters, and also for research and manufacturing with special handling capabilitiesand clean rooms suitable for our operations. The Life Sciences segment has centered its US logistics, reagent and kit manufacturingat its facility in Ann Arbor, Michigan, and has European logistics operations in Lausen, Switzerland. We began renovation of anacquired facility in Farmingdale, NY which is adjacent to the other two in July 2020. This facility will be used for manufacturingoperations and some administrative functions. We also contract with qualified third-party contractors to manufacture our productsin cases where we deem it appropriate, for example, when it is not cost-effective to produce a product ourselves or where we seekto leverage the expertise of another manufacturer in a certain area.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Employees        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of July 31, 2020, we employed 408 full-time and 40 part-timeemployees. Of the full-time employees, 111 were engaged in research, development, manufacturing, and marketing of research products,252 in performing testing, marketing and billing our clinical laboratories services and 45 in finance, information technology,administrative and executive functions. Our scientific staff, including 33 individuals with post graduate degrees, possesses awide range of experience and expertise in the areas of recombinant DNA, nucleic acid chemistry, molecular biology and immunology.We believe that we have established good relationships with our employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Information Systems        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Information systems are used extensively in virtually all aspectsof our businesses. In our clinical laboratory services business, our information systems are critical with respect to laboratorytesting, billing, accounts receivable, customer service, logistics, and management of medical data. Our success depends, in part,on the continued and uninterrupted performance of our information technology systems. Computer systems are vulnerable to damagefrom a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 24; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         22         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Moreover, despite network security measures, some of our serversare potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. We have investedheavily in the upgrade of our information and telecommunications systems to improve the quality, efficiency and security of ourbusinesses. In addition, to complement our proprietary physician connectivity solution EnzoDirect, we have a web portal versionwhich allows physicians to receive laboratory results from any personal computer with a browser and an Internet connection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Despite the precautionary measures that we have taken to preventunanticipated problems that could affect our information technology systems, sustained or repeated system failures that interruptour ability to process test orders, deliver test results or perform tests in a timely manner could adversely affect our reputationand result in a loss of customers and net revenues.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Quality Assurance        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We consider the quality of our clinical laboratory tests tobe of critical importance, and, therefore, we maintain a comprehensive quality assurance program designed to help assure accurateand timely test results. In addition to the compulsory external inspections and proficiency programs demanded by the Medicare programand other regulatory agencies, our clinical laboratory has in place systems to emphasize and monitor quality assurance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition to our own internal quality control programs, ourlaboratory participates in numerous externally administered, blind quality surveillance programs, including on-site evaluationby the College of American Pathologists (“CAP”) proficiency testing program and the New York State survey program.The blind programs supplement all other quality assurance procedures and give our management the opportunity to review our technicaland service performance from the client’s perspective.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The CAP accreditation program involves both on-site inspectionsof our laboratory and participation in the CAP’s proficiency testing program for all categories in which our laboratory isaccredited by the CAP. The CAP is an independent nongovernmental organization of board certified pathologists, which offers anaccreditation program to which laboratories can voluntarily subscribe. A laboratory’s receipt of accreditation by the CAPsatisfies the Medicare requirement for participation in proficiency testing programs administered by an external source. Our clinicallaboratory facilities are CAP accredited.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         FORWARD - LOOKING AND CAUTIONARY STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        This Annual Report contains “forward-looking statements”as defined in the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including,without limitation, the statements under “Management’s Discussion and Analysis of Financial Condition and Results ofOperations” are “forward-looking statements.” Forward-looking statements may include the words “believes,”“expects,” “plans,” “intends,” “anticipates,” “continues” or othersimilar expressions. These statements are based on the Company’s current expectations of future events and are subject toa number of risks and uncertainties that may cause the Company’s actual results to differ materially from those describedin the forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptionsprove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligationto revise or update any forward-looking statements for any reason, except as required by law.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company files annual, quarterly and current reports, proxystatements and other information with the Securities and Exchange Commission (the “SEC”). These filings are availableto the public via the Internet at the SEC’s website located at http://www.sec.gov. You may also read and copy any documentthe Company files with the SEC at the SEC’s public reference room located at 100 F Street, N.E., Washington, D.C. 20549.For more information, please call the SEC at 1-800-SEC-0330.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s website is located at        <u>         www.enzo.com.        </u>        The Company makes available on its website a link to all filings that it makes with the SEC. You may request a copy of the Company’sfilings with the SEC (excluding exhibits) at no cost by writing or telephoning us at the following address or telephone number:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo Biochem, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        527 Madison Ave.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        New York, New York 10022       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Tel: (212) 583-0100       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Attn: Investor Relations       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 25; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         23         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <a name="a_003">         </a>         Item 1A.         <u>          Risk Factors         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Business Risks         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Our operating results may vary from period to period.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our operating results may vary significantly from quarter toquarter and from year to year, depending on a variety of factors including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Thecontinued impact on our operations from the COVID-19 pandemic depending on its severity and duration competition from larger commercialclinical laboratories, hospital affiliated laboratories, and physician office laboratories;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            healthcare reform regulations affecting providers and plan sponsors, including those stemming from the Affordable Care Act of 2010 (ACA)or its repeal, amendment or replacement;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changesin reimbursement policies by third party and government payers, especially those stemming from The Protecting Access to MedicareAct of 2014 (“PAMA”);           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            customerdemand for our products due to changes in purchasing requirements and research needs;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            theintroduction of new products by us or our competitors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thetiming of our research and development, sales and marketing expenses;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            generalworldwide economic conditions affecting funding of research;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            seasonalfluctuations in revenues due to the impact of weather and holiday periods           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            expensesassociated with defending our intellectual property portfolio           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            foreigncurrency exchange rate fluctuations;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changesin tax laws, the results of tax audits or the measurement of tax uncertainties; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           ●          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thesuccess of identifying, acquiring and integrating businesses that complement our product offerings, add new technology or addpresence in a market;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Consequently, results for any interim or full year period maynot necessarily be indicative of results in subsequent periods.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         The COVID-19 pandemic has significantly and adversely affectedour consolidated results of operations, financial position and cash flows, and may continue to do so depending on the severityand duration of the COVID-19 pandemic, the pandemic’s impact on the U.S. healthcare system and the timing, scope and effectivenessof federal, state and local governmental responses to the COVID-19 pandemic.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        A novel strain of coronavirus (“COVID-19”)continues to spread and severely impact the economy of the United States and other countries around the world, the Company hasmade substantial investments to expand the amount of COVID-19 testing available and is currently offering direct testing at itsdrive-through testing facilities as well as accepting tests for processing at its clinical laboratory. The Company and its employeesare committed to being a part of the coordinated public and private sector response to this unprecedented challenge. The Companyhas also put preparedness plans in place at its facilities to maintain continuity of operations, while also taking steps to keepcolleagues and customers healthy and safe.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        Beginning in March 2020, the Companyexperienced, and anticipates it will continue to experience, a material decline in its laboratory testing volumes due to the COVID-19pandemic as patients have reduced physician office visits. Additionally, our products customers have reduced or suspended purchasesor temporarily closed and/or reduced operations on a global basis. This decline continued in the fourth fiscal quarter and, dependingon the extent of future COVID-19 recurrence, could continue through the fiscal year ending July 31, 2021. Federal, state and localgovernmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, theaforementioned significant reduction in physician office visits, the cancelation of elective medical procedures, customers closingor severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home orshelter-in-place policies. The Company believes the COVID-19 pandemic may continue to have an impact on the Company’s operatingresults, cash flows and financial condition. Global supply chain issues due to the pandemic may hamper both the manufacturing ofproducts within the life sciences division as well as the testing capabilities in the clinical laboratory services division. Itis possible that the Company may experience an adverse impact on cash collections from customers, clients and payers as a resultof the impact of the COVID-19 pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        The Company expects COVID-19 relatedproducts and services to partially offset revenue declines. Enzo applied its technical expertise in molecular diagnostics to developnext generation COVID-19 diagnostic and antibody testing options which were approved under the FDA Emergency Use Authorization(EUA). This testing had a positive impact on revenue, profitability and cash flow in the fourth quarter of fiscal 2020. However,it is too early to determine the long term significance of any positive impact from increased COVID-19 testing and our proprietaryCOVID-19 product offerings on revenue, profitability and cash flow.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 26; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         24         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe the COVID-19 pandemic’s adverse impact on itsconsolidated results of operations, financial position and cash flows will be primarily driven by: the severity and duration ofthe COVID-19 pandemic; the COVID-19 pandemic’s impact on the U.S. healthcare system and the U.S. economy; and the timing,scope and effectiveness of federal, state and local governmental responses to the COVID-19 pandemic. These primary drivers arebeyond the Company’s knowledge and control, and as a result, at this time the Company cannot reasonably estimate the adverseimpact the COVID-19 pandemic will have on its businesses, consolidated results of operations, financial position and cash flows,but the adverse impact is likely to be material. Even after the COVID-19 pandemic has moderated and the business and social distancingrestrictions have eased, we may continue to experience similar adverse effects to our businesses, consolidated results of operations,financial position and cash flows resulting from a recessionary economic environment that may persist. The impact that the COVID-19pandemic will have on our businesses, consolidated results of operations, financial position and cash flows could exacerbate theadditional risks identified below.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         A significant proportion of our Products revenues are fromacademic centers, funded by government grants in our major markets globally.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Governments around the world have been reviewing long term publicfunding of life science research in response to the problems arising from global financial pressures. As a result, the availablefunds for discretionary purchases from market to market have been capped or reduced based on available National budgets. Reducedgrants for researchers could impact our business, in the amount, price and type of products bought and used by customers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         A significant proportion of our Products revenues are fromcustomers in pharmaceutical and biotech companies.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Globally, pharmaceutical companies are challenging internalbudgets, and the return of investment from their R&amp;D spend. This could impact our business, in the amount, price and type ofproducts bought and used by customers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Our future success will depend in part upon our ability toenhance existing products, develop and introduce new products and realize commercial acceptance of those products, in a rapidlychanging technological environment.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The market for our products is characterized by rapidly changingtechnology, evolving industry standards and new product introductions, which may make our existing products obsolete. Our futuresuccess will depend in part upon our ability to enhance existing products, develop and introduce new products, and realize commercialacceptance of those products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The development of new or enhanced products is a complex anduncertain process requiring the accurate anticipation of technological and market trends as well as precise technological execution.In addition, the successful development of new products will depend on the development of new technologies. We will be requiredto undertake time-consuming and costly development activities and to seek regulatory approval for these new products. We may experiencedifficulties that could delay or prevent the successful development, introduction and marketing of these new products. Regulatoryclearance or approval of any new products may not be granted by the FDA, state-wide agency or foreign regulatory authorities ona timely basis, or at all, and the new products may not be successfully commercialized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         We may be unable to identify, acquire and integrate acquisitiontargets.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our strategy envisions, if an opportunistic target is identified,future growth from acquiring and integrating similar operations and/or product or services lines. There can be no assurance thatwe will be able to identify suitable acquisition candidates and, once identified, to negotiate successfully their acquisition ata price or on terms and conditions favorable to us, or to integrate the operations of such acquired businesses with the existingoperations. In addition, we compete for acquisition candidates with other entities, some of which have greater financial resourcesthan ours. Failure to implement successfully our acquisition strategy would limit our potential growth.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Our inability to carry out certain of our marketing and salesplans may make it difficult for us to grow or maintain our business.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Life Sciences product segment continues a marketing programdesigned to more directly service its end users, while simultaneously promoting the Enzo Life Science brand, with reference toour acquired brands. We will continue to reach out to our customers using our direct field sales force, in-house business team,the on-going enhancement of our interactive websites, continued attendance at top industry trade meetings, and publications tocustomers and in leading scientific journals. In addition to our direct sales, we operate worldwide through wholly-owned subsidiaries(in USA, Switzerland, Belgium, Germany, and the UK), a branch office in France and a network of third-party distributors in mostother significant markets. If we are unable to successfully continue these programs, we may be unable to grow and our businesscould suffer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 27; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         25         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         We face significant competition, which could cause us todecrease the prices for our products or services or render our products uneconomical or obsolete, any of which could reduce ourrevenues and limit our growth.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our competitors in the biotechnology industry in the UnitedStates and abroad are numerous and include major pharmaceutical, energy, food and chemical companies, as well as specialized geneticengineering firms. Many of our large competitors have substantially greater resources than us and have the capability of developingproducts which compete directly with our products. Many of these companies are performing research in the same areas as we are.The markets for our products are also subject to competitive risks because markets are highly price competitive. Our competitorshave competed in the past by lowering prices on certain products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The clinical laboratory services business is highly fragmentedand intensely competitive, and we compete with numerous national and local companies. Some of these entities are larger than weare and have greater resources than we do. We compete primarily on the basis of the quality of our testing, reporting and informationservices, our reputation in the medical community, the pricing of our services and our ability to employ qualified professionals.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        These competitive conditions could, among other things:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            require us to reduce our prices to retain market share;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            require us to increase our marketing efforts which could reduce our profit margins;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            increase our cost of labor to attract qualified personnel;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            render our biotechnology products uneconomical or obsolete or;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reduce our revenue           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Ethical, legal and social concerns surrounding the use ofgenetic information could reduce demand for our products.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Genetic testing has raised ethical issues regarding privacyand the appropriate uses of the resulting information. For these reasons, governmental authorities may call for limits on or regulationof the use of genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those thathave no known cure. Similarly, such concerns may lead individuals to refuse to use genetics tests even if permissible. Any of thesescenarios could reduce the potential markets for our molecular diagnostic products, which could have a material adverse effecton our business, financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         We depend on distributors and contract manufacturers andsuppliers for materials that could impair our ability to manufacture or distribute our products.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We manufacture and distribute our own brand products and theproducts of third party manufacturers and suppliers. Distributors also sell our branded products. To the extent we are unable tomaintain or replace a distributor in a reasonable time period, or on commercially reasonable terms, if at all, our operations couldbe disrupted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Outside distributors, suppliers and contract manufacturers providekey finished goods, components and raw materials used in the sale and manufacture of our products. Although we believe that alternativesources for components and raw materials are available, any supply interruption in a limited or sole source component or raw materialwould harm our ability to manufacture our products until a new source of supply is identified and qualified. In addition, an uncorrecteddefect or supplier’s variation in a component or raw material, either unknown to us or incompatible with our manufacturingprocess, could harm our ability to manufacture products. We might not be able to find a sufficient alternative supplier in a reasonabletime period, or on commercially reasonable terms, if at all. If we fail to obtain a supplier for the components of our products,our operations could be disrupted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         We use hazardous materials in our business. Any claims relatingto improper handling, storage or disposal of these materials could be costly and time-consuming.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our manufacturing, clinical laboratory and research and developmentprocesses involve the storage, use and disposal of hazardous substances, including hazardous chemicals, biological hazardous materialsand radioactive compounds. We are subject to governmental regulations governing the use, manufacture, storage, handling and disposalof materials and waste products. Although we believe that our safety and environmental management practices and procedures forhandling and disposing of these hazardous materials are in accordance with good industry practice and comply with applicable laws,permits, licenses and regulations, the risk of accidental environmental or human contamination or injury from the release or exposureof hazardous materials cannot be completely eliminated. In the event of an accident, we could be held liable for any damages thatresult, including environmental clean-up or decontamination costs, and any such liability could exceed the limits of, or fall outsidethe coverage of, our insurance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We may not be able to maintain insurance on acceptable terms,or at all. We could be required to incur significant costs to comply with current or future environmental and public and workplacesafety and health laws and regulations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 28; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         26         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         We are required to expend significant resources for researchand development for our products in development and these products may not be developed successfully. Failure to successfully developthese products may prevent us from earning a return on our research and development expenditures.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The products we are developing are at various stages of developmentand clinical evaluations and may require further technical development and investment to determine whether commercial applicationis practicable. There can be no assurance that our efforts will result in products with valuable commercial applications. Our cashrequirements may vary materially from current estimates because of results of our research and development programs, competitiveand technological advances and other factors. In any event, we will require substantial funds to conduct development activitiesand pre-clinical and clinical trials, apply for regulatory approvals and commercialize products, if any, that are developed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We do not have any commitments or arrangements to obtain anyadditional financing and there is no assurance that required financing will be available to us on acceptable terms, if at all.Even if we spend substantial amounts on research and development, our potential products may not be developed successfully.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If our product candidates on which we have expended significantamounts for research and development are not commercialized, we will not earn a return on our research and development expenditures,which may harm our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         We rely on network and information systems and other technologywhose failure or misuse could cause a disruption of services or loss or improper disclosure of personal data, business information,including intellectual property, or other confidential information, resulting in increased costs, loss of revenue or other harmto our business.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Network and information systems and other technologies, includingthose related to the Company’s network management, are important to its business activities. The Company also relies on thirdparty providers for certain technology and “cloud-based” systems and services that support a variety of business operations.Network and information systems-related events affecting the Company’s systems, or those of third parties upon which theCompany’s business relies, such as computer compromises, cyber threats and attacks, computer viruses, worms or other destructiveor disruptive software, process breakdowns, denial of service attacks, malicious social engineering or other malicious activities,or any combination of the foregoing, as well as power outages, equipment failure, natural disasters (including extreme weather),terrorist activities, war, human or technological error or malfeasance that may affect such systems, could result in disruptionof the Company’s business and/or loss, corruption or improper disclosure of personal data, business information, includingintellectual property, or other confidential information. In addition, any design or manufacturing defects in, or the improperimplementation of, hardware or software applications the Company develops or procures from third parties could unexpectedly compromiseinformation security. In recent years, there has been a rise in the number of cyber-attacks on companies’ network and informationsystems, and such attacks have become more sophisticated, targeted and difficult to detect and prevent against. As a result, therisks associated with such an event continue to increase, particularly as the Company’s digital businesses expand. Whilethe Company has developed and implemented security measures and internal controls that are designed to protect personal data, businessinformation, including intellectual property, and other confidential information, to prevent data loss, and to prevent or detectsecurity breaches, such security measures cannot provide absolute security and may not be successful in preventing these eventsfrom occurring, particularly given that techniques used to access, disable or degrade service, or sabotage systems change frequently,and any network and information systems-related events could require the Company to expend significant resources to remedy suchevent. Moreover, the development and maintenance of these measures is costly and requires ongoing monitoring and updating as technologieschange and efforts to overcome security measures become more sophisticated. While the Company maintains cyber risk insurance, thisinsurance may not be sufficient to cover all losses from any future breaches of our systems.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        A significant failure, compromise, breach or interruption ofthe Company’s systems, or those of third parties upon which its business relies, could result in a disruption of its operations,customer, audience or advertiser dissatisfaction, damage to its reputation or brands, regulatory investigations and enforcementactions, lawsuits, remediation costs, a loss of customers, advertisers or revenues and other financial losses. If any such failure,interruption or similar event results in the improper disclosure of information maintained in the Company’s information systemsand networks or those of its vendors, including financial, personal, credit card, confidential and proprietary information relatingto personnel, customers, vendors and the Company’s business, including its intellectual property, the Company could alsobe subject to liability under relevant contractual obligations and laws and regulations protecting personal data and privacy. Inaddition, media or other reports of perceived security vulnerabilities to our systems or those of third parties upon which theCompany’s business relies, even if nothing has actually been attempted or occurred, could also adversely impact our brandand reputation and materially affect our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 29; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         27         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Risks relating to our Intellectual Property and RegulatoryApproval         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Protecting our proprietary rights is difficult and costly.If we fail to adequately protect or enforce our proprietary rights, we could lose potential revenue from licensing and royalties.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our potential revenue and success depends in large part on ourability to obtain, maintain and enforce our patents. Our ability to commercialize any product successfully will largely dependon our ability to obtain and maintain patents of sufficient scope to prevent third parties from developing similar or competitiveproducts. In the absence of patent protection, competitors may impact our business by developing and marketing substantially equivalentproducts and technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Patent disputes are frequent and can preclude the commercializationof products. We have in the past been, are currently, and may in the future be, involved in material patent litigation, such asthe matters discussed under “Part I - Item 3. Legal Proceedings” in this report. Patent protection litigation is time-consumingand we have incurred and anticipate continuing to incur significant legal costs. In addition, an adverse decision could force usto either obtain third-party licenses at a material cost or cease using the technology or product in dispute.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have filed applications for United States and foreign patentscovering certain aspects of our technology, but there is no assurance that pending patents will issue or as to the degree of protectionwhich any issued patent might afford.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Lawsuits, including patent infringements, in the biotechnologyindustry are not uncommon. If we become involved in any significant litigation, we would suffer as a result of the diversion ofour management’s attention, the expense of litigation and any judgments against us.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition to intellectual property litigation for infringement,other substantial, complex or extended litigation could result in large expenditures by us and distraction of our management. Patentlitigation is time-consuming and costly in its own right and could subject us to significant liabilities to third parties. In addition,an adverse decision could force us to either obtain third-party licenses at a material cost or cease using the technology or productin dispute. In addition, lawsuits by employees, stockholders, collaborators or distributors could be very costly and substantiallydisrupt our business. Disputes from time to time with companies or individuals are not uncommon in the biotechnology industry,and we cannot assure you that we will always be able to resolve them out of court.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We also utilize certain unpatented proprietary technology andno assurance can be given that others will not independently develop substantially equivalent proprietary technology, that suchproprietary technology will not be disclosed or that we can meaningfully protect our rights to such proprietary technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Our business is subject to governmentallaws and regulations. Changes in the way the FDA regulates the reagents, and other consumables we use when developing, validating,and performing our tests could result in delay or additional expense in bringing our tests to market or performing such tests forour customers         <i>          .         </i>         We may be unable to obtain or maintain regulatory approvals for our products, which could reduce our revenueor prevent us from earning a return on our research and development expenditures.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our research, preclinical development, clinical trials, productmanufacturing and marketing are subject to regulation by the FDA and similar health authorities in foreign countries. The FDA hasregulatory responsibility over, among other areas, instruments, software, test kits, reagents and other devices used by clinicallaboratories to perform diagnostic testing in the U.S. The tests we develop internally are offered as lab developed tests or LDTs.The FDA has claimed regulatory authority over all LDTs, but has stated that it exercised enforcement discretion with regard tomost LDTs performed by high complexity CLIA-certified laboratories. As the FDA moves to regulate more clinical laboratory testing,its approach to regulation is impacting industry practices and participants, new competitors may enter the industry, and competitionmay come in new forms. In late 2018, legislation was introduced in Congress that would enable the FDA to regulate LDTs, in vitrodiagnostics, software and other items used in the diagnosis of disease. If this legislation were to become law, the FDA could regulatediagnostic tests and components and platforms used as part of these tests. If such legislation were to become law, it could havea significant impact on the clinical laboratory testing industry, including regulating LDTs in new ways and creating avenues ofopportunity and competition regarding clinical laboratory testing. New competitors may enter the industry, and competition maycome in new forms. Pursuant to the 21st Century Cures Act, the FDA issued guidance regarding its position on the regulation ofclinical decision software, which may be used in, or in connection with, LDTs. The guidance attempts to clarify whether FDA approvalof certain software is required. In January 2019 the FDA issued draft guidance on a pre-certification pilot program to help softwaredevelopers have a speedier and less restrictive path to clearance or approval of their software.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 30; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         28         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        Wecannot be sure that we can obtain necessary regulatory approvals on a timely basis, if at all, for any of the products we aredeveloping or manufacturing or that we can maintain necessary regulatory approvals for our existing products, and all of the followingcould have a material adverse effect on our business:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            significant delays in obtaining    or failing to obtain required approvals;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            loss of, or changes to, previously obtained    approvals;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            failure to comply with existing or future regulatory    requirements and;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes to manufacturing processes, manufacturing    process standards or Good Manufacturing Practices following approval or changing interpretations of these factors.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Adverseperception and increased regulatory scrutiny of gene medicine and genetic research might limit our ability to conduct our business.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ethical,social and legal concerns about gene medicine, genetic testing and genetic research could result in additional regulations restrictingor prohibiting the technologies we or our collaborators may use. Recently, gene medicine studies have come under increasing scrutiny,which has delayed on-going and could delay future clinical trials and regulatory approvals. Federal and state agencies, congressionalcommittees and foreign governments have expressed interest in further regulating biotechnology. More restrictive regulations orclaims that our products are unsafe or pose a hazard could prevent us from commercializing any products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           FinancialRisks          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Withthe exception of fiscal years 2019 and 2016, we have experienced significant losses in our previous five fiscal years and quarterto quarter over such periods and our losses have resulted in the use of cash in operations. If such losses and cash uses continue,the value of your investment could decline significantly.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Althoughfor fiscal year 2019, when we reported net income of $2.5 million, we incurred net losses of $28.5 million and $11.4 million forthe fiscal years ended July 31, 2020 and 2018 respectively. If our revenues do not increase, or if our operating expenses exceedexpectations or cannot be reduced, we will continue to suffer substantial losses and use cash in operations which could have anadverse effect on our business and adversely affect your investment in our Company.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wemay need additional capital to fund growth, which may not be available on acceptable terms or at all, and could result in ourbusiness plan being limited and our business being harmed.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourability to increase revenue and improve profitability and liquidity will depend in part on our ability to grow our products businesswith higher margin products and increase our market share and continue to grow the Laboratory Services business with new testswith higher reimbursements and increase our service volume which may require significant additional capital that may not be availableto us. We may need additional financing due to future developments, changes in our business plan or failure of our current businessplan to succeed, which could result from increased marketing, distribution or research and development costs. Our actual fundingrequirements could vary materially from our current estimates. If additional financing is needed, we may not be able to raisesufficient funds on favorable terms or at all. If we issue common stock or securities convertible into common stock in the future,such issuance will result in the then-existing stockholders sustaining dilution to their relative proportion of our outstandingequity. If we fail to obtain any necessary financing on a timely basis, then our ability to execute our current business planmay be limited, and our business, liquidity and financial condition could be harmed.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ouroutstanding debt may impair our financial and operating flexibility and a failure to satisfy the covenants under agreements governingour outstanding debt could limit the availability of borrowings or result in an event of default under such agreements.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        The Company had over $48.6 millionin cash, cash equivalents and restricted cash on its balance sheet as of July 31, 2020. Also as of that date, we had approximately$11.5 million of short term debt and $21.4 million in long term debt. The short term debt is primarily related to operating leaseliabilities and a $7 million SBA Payroll Protection Program loan of the CARES Act (“PPP loan”) which may be forgivenby the SBA upon application by the Company. The long term debt is primarily related to operating leases and a ten-year mortgageobligation of approximately $4.2 million with Citibank, N.A., which bears a fixed interest rate of 5.09% per annum and containsvarious restrictive covenants. These restrictions could limit our ability to use operating cash flow in other areas of our businessbecause we must use a portion of these funds to make principal and interest payments on our debt. Our ability to comply with therestrictive financial ratio and liquidity covenants in the mortgage debt agreement will depend upon our future performance andvarious other factors, including but not limited to the impact on our business, consolidated results of operations, financial conditionand cash flows associated with the COVID-19 pandemic, any prolonged recessionary economic environment that may develop and competitiveand regulatory factors, many of which are beyond our control. We may not be able to maintain compliance with all of thecovenants. In that event, we may not be able to find and access any other borrowing availability and we may need to seek waiversto the covenants or amendments to the mortgage agreement or would need to refinance the mortgage. There can be no assurance thatwe can obtain additional waivers of our mortgage agreement covenants, or be able to refinance it, and, even if we were able toobtain a waiver or additional amendment in the future, such relief may only last for a limited period. Any noncompliance by uswith the covenants under our mortgage agreement could result in an event of default under the agreement, which may allow the lenderto accelerate payment of the mortgage. In the event our creditor accelerates the repayment of our mortgage, we cannot assure thatwe would have sufficient assets to make such repayment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <!-- Field: Page; Sequence: 31; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         29         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wemay incur impairment charges on our goodwill and intangibles which would reduce our earnings.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare subject to Statement of Financial Accounting Standards ASC 350, “Intangibles - Goodwill and Other (“ASC 350”)which requires that goodwill and other intangible assets that have an indefinite life be tested at least annually for impairment.Goodwill and other intangible assets with indefinite lives must also be tested for impairment between the annual tests if a triggeringevent occurs that would likely reduce the fair value of the asset below its carrying amount. Intangible assets with finite livesare assessed for impairment when, and if, an indicator of potential impairment is identified.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asof July 31, 2020 and 2019, goodwill and intangible assets represented approximately 7% and 8%, respectively, of our total assets.If we determine that there has been impairment, our financial results for the relevant period would be reduced by the amount ofthe impairment, net of tax effects, if any. The Company has no intangible assets with indefinite lives.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Risksrelating to our Clinical Laboratory Services segment          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Theclinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwisefail to compete effectively it could have a material adverse effect on our revenues and profitability.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theclinical testing business is a fragmented and highly competitive industry. We primarily compete with three types of clinical testingproviders: other commercial clinical laboratories, hospital-affiliated laboratories and physician-office laboratories. We alsocompete with other providers, including anatomic pathology practices and large physician group practices. Hospitals generallymaintain on-site laboratories to perform testing on their patients (inpatient or outpatient). In addition, many hospitals competewith commercial clinical laboratories for outreach (non-hospital patients) testing. Hospitals may seek to leverage their relationshipswith community clinicians and encourage the clinicians to send their outreach testing to the hospital’s laboratory. As a resultof this affiliation between hospitals and community clinicians, we compete against hospital-affiliated laboratories primarilybased on quality and scope of service as well as pricing. In addition, hospitals that own physician practices may require thepractices to refer testing to the hospital’s laboratory. In recent years, there has been a trend of hospitals acquiring physicianpractices, increasing the percentage of physician practices owned by hospitals. Increased hospital ownership of physician practicesmay enhance clinician ties to hospital-affiliated laboratories and may strengthen their competitive position. The diagnostic informationservices industry also is faced with changing technology and new product introductions. Competitors may compete using advancedtechnology, including technology that enables more convenient or cost-effective testing. Competitors also may compete on the basisof new service offerings. Competitors also may offer testing to be performed outside of a commercial clinical laboratory, suchas (1) point-of-care testing that can be performed by physicians in their offices; (2) advanced testing that can be performedby hospitals in their own laboratories; and (3) home testing that can be carried out without requiring the services of outsideproviders.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourclinical laboratory services business is subject to extensive government regulation and our loss of any required certificationsor licenses could require us to cease operating this part of our business, which would reduce our revenue and injure our reputation.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theclinical laboratory industry is subject to significant governmental regulation at the Federal, state and local levels. Under theClinical Laboratory Improvement Act of 1967 and the Clinical Laboratory Improvement Amendments of 1988 (collectively, as amended,“CLIA”) virtually all clinical laboratories, including ours, must be certified by the Federal government. Many clinicallaboratories also must meet other governmental standards, undergo proficiency testing and are subject to inspection. Certificationsor licenses are also required by various state and local laws. The failure of our clinical laboratory to obtain or maintain suchcertifications or licenses under these laws could interrupt our ability to operate our clinical laboratory business and injureour reputation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Reimbursementsfrom third-party payers including managed care organizations and Medicare, upon which our clinical laboratory business is dependent,are subject to varying rates and coverage and legislative reform that are beyond our control. Any reforms that decrease coverageand rates could reduce our earnings and harm our business.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourclinical laboratory services business is primarily dependent upon reimbursement from third-party payers, such as Medicaid, Medicare(which principally serves patients 65 and older) and commercial insurers. We are subject to variances in reimbursement rates amongdifferent third-party payers, as well as constant renegotiation of those reimbursement rates. Government and non-government payershave in the past sought, and continue to seek, to reduce and limit utilization and reimbursement of healthcare services, includingthe areas of clinical and genetic testing. We also are subject to audit by Medicare and the commercial insurers, which can resultin the return of payments made to us under these programs. These variances in reimbursement rates and audit results could reduceour margins and thus our earnings.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 32; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         30         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thehealth care industry continues to undergo significant change as third-party payers’ increase their efforts to control thecost, utilization and delivery of health care services. In an effort to address the problem of increasing health care costs, legislationhas been proposed or enacted at both the Federal and state levels to regulate health care delivery in general and clinical laboratoriesin particular. Some of the proposals include managed competition, global budgeting and price controls. Changes that decrease reimbursementrates or coverage, or increase administrative burdens on billing third-party payers could reduce our revenues and increase ourexpenses.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Sinceeach payer makes its own decision as to whether to establish a policy or enter into a contract to cover our tests, as well asthe amount it will reimburse for a test, seeking these approvals is a time-consuming and costly process. In addition, the determinationby a payer to cover and the amount it will reimburse for our tests will likely be made on an indication by indication basis. Todate, we have obtained policy-level reimbursement approval or contractual reimbursement for some indications for our test froma small number of commercial third-party payers, and have not obtained coverage from Medicare or any state Medicaid program. Further,we believe that establishing adequate reimbursement from Medicare is an important factor in gaining adoption from healthcare providers.Our claims for reimbursement from commercial payers may be denied upon submission, and we must appeal the claims. The appealsprocess is time consuming and expensive, and may not result in payment. In cases where there is not a contracted rate for reimbursement,there is typically a greater co-insurance or co-payment requirement from the patient which may result in further delay or decreasedlikelihood of collection.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weexpect to continue to focus substantial resources on increasing adoption of, and coverage and reimbursement for, our current testsand any future tests we may develop. We believe it may take several years to achieve coverage and adequate contracted reimbursementwith a majority of third-party payers. However, we cannot predict whether, under what circumstances, or at what payment levelspayers will reimburse for our tests. If we fail to establish and maintain broad adoption of, and coverage and reimbursement for,our tests, our ability to generate revenue could be harmed and our future prospects and our business could suffer.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Governmentpayers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, includingclinical testing services. U.S. healthcare reform legislation may result in significant change and our business could be adverselyimpacted if we fail to adapt.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weface efforts by government payers to reduce utilization of and reimbursement for diagnostic information services. We expect effortsto reduce reimbursements, to impose more stringent cost controls and to reduce utilization of clinical test services will continue.Pursuant to The Protecting Access to Medicare Act of 2014 (PAMA), which was implemented in 2018, the Centers for Medicare andMedicaid Services (CMS) promulgated revised reimbursement rate schedules for the years 2018 through 2020 for clinical laboratorytesting services provided under Medicare. Reimbursement rates for clinical laboratory testing were reduced in 2018 and 2019 andwere reduced again by approximately 10% in 2020. PAMA calls for further revision of the Medicare Clinical Laboratory Fee Schedulefor years after 2020, based on future surveys of market rates; reimbursement rate reduction from 2021-23 is capped by PAMA at15% annually.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Privatehealth plans and other third parties have taken steps to reduce the utilization and reimbursement of health services, includingclinical testing services.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weface efforts by non-governmental third-party payers, including health plans, to reduce utilization of and reimbursement for clinicaltesting services. Examples include increased use of prior authorization requirements and increased denial of coverage for services.Since the passage of ACA, there is increased market activity regarding alternative payment models, including bundled payment models.We expect continuing efforts by third-party payers, including in their rules, practices and policies, to reduce reimbursements,to impose more stringent cost controls and to reduce utilization of clinical testing services. The healthcare industry has experienceda trend of consolidation among health insurance plans, resulting in fewer but larger insurance plans with significant bargainingpower to negotiate fee arrangements with healthcare providers, including clinical testing providers. These health plans, and independentphysician associations, may demand that clinical testing providers accept discounted fee structures or assume all or a portionof the financial risk associated with providing testing services to their members through capitated payment arrangements. Somehealth plans also are reviewing test coding, evaluating coverage decisions and requiring preauthorization of certain testing.There are also an increasing number of patients enrolling in consumer driven products and high deductible plans that involve greaterpatient cost-sharing. The increased consolidation among health plans also has increased pricing transparency and bargaining powerand the potential adverse impact of ceasing to be a contracted provider with any such insurer.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 33; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         31         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Changesin provider mix, including continued growth in capitated managed-cost health care and changes in certain third party provideragreements could have a material adverse impact on the Company’s net revenues and profitability.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Certainthird party provider companies have adopted national and regional programs which include multiple managed-care reimbursement models.If the Company is unable to participate in these programs or if the Company would lose a material contract, it could have a materialadverse impact on the Company’s net revenues and profitability.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thenumber of individuals covered under managed care contracts or other similar arrangements has grown over the past several yearsand may continue to grow in the future. In addition, Medicare and other government healthcare programs may continue to shift tomanaged care. Entities providing managed care coverage have reduced payments for medical services, including clinical laboratoryservices, in numerous ways such as entering into arrangements under which payments to a service provider are capitated, limitingtesting to specified procedures, denying payment for services performed without prior authorization and refusing to increase feesfor specified services. These trends reduce our revenues and limit our ability to pass cost increases to our customers. Also,if these or other managed care organizations do not select us as a participating provider, we may lose some or all of that business,which could have an adverse effect on our business, financial condition and results of operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Becauseof competitive pressures, impacts of the economy on patient visits to our customer physician locations and the complexity andexpense of the billing process in our clinical laboratory services business, we must obtain new customers while maintaining existingcustomers to grow our business.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Intensecompetition in the clinical laboratory business, increasing administrative burdens upon the reimbursement process, reduced patienttraffic, and reduced coverage and payments by insurers make it necessary for us to increase our volume of laboratory services.To do so, we must obtain new customers while retaining existing customers. Our failure to attract new customers or the loss ofexisting customers or a reduction in business from those customers could significantly reduce our revenues and impede our abilityto grow.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Compliancewith Medicare administrative policies, including those pertaining to certain automated blood chemistry profiles, may reduce thereimbursements we receive.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Containmentof health care costs, including reimbursement for clinical laboratory services, has been a focus of on-going governmental activity.Clinical laboratories must bill Medicare directly for the services provided to Medicare beneficiaries and may only collect theamounts permitted under this fee schedule. Reimbursement to clinical laboratories under the Medicare Fee Schedule has been steadilydeclining since its inception. Because a significant portion of our costs is fixed, these Medicare reimbursement reductions andchanges have a direct adverse effect on our operating results and cash flows.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Thedevelopment of new, more cost-effective tests that can be performed by our customers or by patients, and the continued internalizationof testing by hospitals or physicians, could negatively impact our testing volume and revenues.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thediagnostic industry is faced with changing technology and new product introductions, including technology that enables more convenientor cost-effective testing. Some of our competitors also may offer testing to be performed outside of a commercial clinical laboratory,such as point-of-care testing that can be performed by physicians in their offices; complex testing that can be performed by hospitalsin their own laboratories; and home testing that can be carried out without requiring the services of outside providers.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Advancesin technology also may lead to the need for less frequent testing. Further, diagnostic tests approved or cleared by the FDA forhome use are automatically deemed to be “waived” tests under CLIA and may be performed by patients in their homes;test kit manufacturers could seek to increase sales to patients of such test kits. Development of such technology and its useby our customers would reduce the demand for our laboratory-based testing services and negatively impact our revenues.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourbusiness could be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changesin, or changing interpretations of, CLIA or state laboratory licensing laws to which we are subject.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theclinical laboratory testing industry is subject to extensive federal and state regulation, and many of these statutes and regulationshave not been interpreted by the courts. The CLIA amendments are federal regulatory standards that apply to virtually all clinicallaboratories (regardless of the location, size or type of laboratory), including those operated by physicians in their offices,by requiring that they be certified by the federal government or by a federally approved accreditation agency. CLIA does not pre-emptstate law, which in some cases may be more stringent than federal law and require additional personnel qualifications, qualitycontrol, record maintenance and proficiency testing. The sanction for failure to comply with CLIA and state requirements may besuspension, revocation or limitation of a laboratory’s CLIA certificate, which is necessary to conduct business, as wellas significant fines and/or criminal penalties. Several states have similar laws and we may be subject to similar penalties.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 34; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         32         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wecannot assure that applicable statutes and regulations will not be interpreted or applied by a prosecutorial, regulatory or judicialauthority in a manner that would adversely affect our business. Potential sanctions for violation of these statutes and regulationsinclude significant fines and the suspension or loss of various licenses, certificates and authorizations, which could have amaterial adverse effect on our business. In addition, compliance with future legislation could impose additional requirementson us, which may be costly.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourbusiness operations and reputation may be materially impaired if we do not comply with privacy laws or information security policies.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         In ourbusiness, we collect, generate, process or maintain sensitive information, such as patient data and other personal information.If we do use or not adequately safeguard that information in compliance with applicable requirements under federal, state andinternational laws, or if it were disclosed to persons or entities that should not have access to it, our business could be materiallyimpaired, our reputation could suffer and we could be subject to fines, penalties and litigation. In the event of a data securitybreach, we may be subject to notification obligations, litigation and governmental investigation or sanctions, and may sufferreputational damage, which could have an adverse impact on our business. We are subject to laws and regulations regarding protectingthe security and privacy of certain healthcare and personal information, including: (a) the federal Health Insurance Portabilityand Accountability Act (HIPPA) and the regulations thereunder, which establish (i) a complex regulatory framework including requirementsfor safeguarding protected health information and (ii) comprehensive federal standards regarding the uses and disclosures of protectedhealth information; (b) state laws; and (c) the European Union’s General Data Protection Regulation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          FDAregulation of laboratory-developed tests, analyte specific reagents, or genetic testing could lead to increased costs and delaysin introducing new genetic tests.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheFDA has regulatory responsibility over, among other areas, instruments, test kits, reagents and other devices used by clinicallaboratories to perform diagnostic testing in the U.S. A number of tests we develop internally are offered as lab developed tests(LDTs). The FDA has claimed regulatory authority over all LDTs, but has stated that it exercised enforcement discretion with regardto most LDTs performed by high complexity CLIA-certified laboratories. The FDA has published a “Discussion Document”that provides the FDA’s views on legislation to govern LDTs. New legislation could significantly impact the clinical laboratorytesting business, including by increasing or modifying the regulation of LDTs, hindering our ability to develop and market newservices, causing an increase in the cost of our services, delaying our ability to introduce new tests or hindering our abilityto perform testing.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Weare subject to federal and state healthcare fraud and abuse and other laws and regulations and could face substantial penaltiesif we are unable to fully comply with such laws.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asa provider of clinical laboratory testing services, we are subject to extensive and frequently changing federal, state and locallaws and regulations governing various aspects of our business. For example, we are subject to healthcare fraud and abuse regulationand enforcement by both the federal government and the states in which we conduct our business. These healthcare laws and regulationsinclude, for example:        </font>       </p>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            federalanti-kickback laws, which constrain our marketing practices, educational programs, pricing policies, and relationships with healthcareproviders or other entities, including third-party laboratories, by prohibiting, among other things, persons or entities fromsoliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referralof an individual for, or the purchase, lease order or recommendation of, any good, facility, item or services for which paymentmay be made, in whole or in part, under a federal healthcare program such as the Medicare and Medicaid programs;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            federalcivil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entitiesfrom knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payersthat are false or fraudulent, and which may apply to entities like us to the extent that our interactions with customers may affecttheir billing or coding practices;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HIPAA,which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information,and also established federal crimes for knowingly and willfully executing a scheme to defraud any healthcare benefit program ormaking false statements in connection with the delivery of or payment for healthcare benefits, items or services, and which imposedcertain requirements relating to privacy, security, and transmission of individually identifiable health information;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thefederal physician self-referral law, commonly known as the Stark Law, which prohibits a physician from making a referral to anentity for certain designated health services reimbursed by Medicare or Medicaid if the physician (or a member of the physician’sfamily) has a financial relationship with the entity, and which also prohibits the submission of any claims for reimbursementfor designated health services furnished pursuant to a prohibited referral;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 35; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         33         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thefederal Physician Payment Sunshine Act, and its implementing regulations, which requires manufacturers of certain drugs, devices,biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program(with certain exceptions) to report annually to the United States Department of Health and Human Services information relatedto payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists andchiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate familymembers;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            federalconsumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentiallyharm consumers; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2.25pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            statelaw equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or servicesreimbursed by any third-party payer, including commercial insurers and state laws governing the privacy and security of healthinformation in certain circumstances, many of which differ from each other in significant ways, with differing effects.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare unable to predict what additional federal or state legislation or regulatory initiatives may be enacted in the future regardingour business or the healthcare industry in general, or what effect such legislation or regulations may have on us. Federal orstate governments may impose additional restrictions or adopt interpretations of existing laws that could have an adverse effecton us.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weincur significant costs in complying with these laws and regulations. Because of the breadth of these laws and the narrownessof available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challengeunder one or more of such laws. If our operations, or our sales techniques or product placement strategies, are found to be inviolation of, or to encourage or assist the violation by third parties of, any of the laws described above or any other governmentalregulations that apply to us, or if we fail to maintain, renew or obtain necessary permits, licenses and approvals related toour in-house laboratory, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion fromthe Medicare and Medicaid programs, disgorgement, contractual damages, reputational harm, diminished profits and future earnings,suspension or revocation of certifications or licenses that are required to operate our business, injunctions and other associatedremedies, the curtailment or restructuring of our operations, denial or withdrawal of product clearances, or private “quitam” actions brought by individual whistleblowers in the name of the government, any of which could have an adverse effecton our business. If we or others determine that any of our existing customer relationships do not comply with applicable lawsand regulations, either due to changes in such laws and regulations or evolving interpretations of such laws and regulations,we may be required to renegotiate or terminate such relationships. Any penalties, damages, fines, exclusions, curtailment or restructuringof our operations could adversely affect our ability to operate our business and our financial results. The risk of our beingfound in violation of these laws is increased by the fact that many of these laws are broad and their provisions are open to avariety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, couldcause us to incur significant legal expenses and divert our management’s attention from the operation of our business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Otherrisks relating to our business          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ifwe fail to maintain or monitor our information systems our businesses could be adversely affected.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wedepend on information systems throughout our Company to control our manufacturing, inventory, distribution and website and theclinical laboratory services processes for: processing specimens, managing inventory, processing test results and submitting claims,collecting from insurers and patients, responding to inquiries, contributing to our overall internal control processes, maintainingrecords of our property, plant and equipment, and recording and paying amounts due vendors and other creditors. If we were toexperience a prolonged disruption in our information systems that involve interactions with customers and suppliers, it couldresult in the loss of sales and customers and/or increased costs, which could adversely affect our business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Cyber                                         security risks and the failure to maintain the confidentiality, integrity, and availability                                         of our computer hardware, software, and Internet applications and related tools and functions                                         could result in damage to the Company’s reputation and/or subject the Company to                                         costs, fines, or lawsuits.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theintegrity and protection of our own data, and that of its customers and employees, is critical to the Company’s business.The regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve.Maintaining compliance with applicable security and privacy regulations may increase the Company’s operating costs and/oradversely impact the Company’s ability to market its products and services to customers. Although the Company’s computerand communications hardware is protected through physical and software safeguards, it is still vulnerable to fire, storm, flood,power loss, earthquakes, telecommunications failures, physical or software break-ins, software viruses, and similar events. Theseevents could lead to the unauthorized access, disclosure and use of non-public information. The techniques used by criminal elementsto attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of theworld. As a result, the Company may not be able to address these techniques proactively or implement adequate preventative measures.If the Company’s computer systems are compromised, it could be subject to fines, damages, litigation, and enforcement actions,customers could curtail or cease using its applications, and the Company could lose trade secrets, the occurrence of which couldharm its business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 36; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         34         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ifwe fail to attract and retain key personnel, including our senior management, our business could be adversely affected.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Mostof our products and services are highly technical in nature. In general, only highly qualified and trained scientists and technicianpersonnel have the necessary skills to develop proprietary technological products and market our products, support our researchand development programs and provide our clinical laboratory services.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Inaddition, some of our manufacturing, quality control, safety and compliance, information technology and e-commerce related positionsare highly technical as well. Further, our sales personnel highly trained and are important to retaining and growing our businesses.Our success depends in large part upon our ability to identify, hire, retain and motivate highly skilled professionals.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weface intense competition for these professionals from our competitors, customers, marketing partners and other companies throughoutthe industries in which we compete. Since our inception we have successfully recruited and hired qualified key employees. Anyfailure on our part to hire, train, and retain a sufficient number of qualified professionals would seriously damage our business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wedepend heavily on the services of our senior management. We believe that our future success depends on the continued servicesof such management. Our business may be harmed by the loss of a significant number of our senior management in a short periodof time.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Theinsurance we purchase to cover our potential business risk may be inadequate.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Althoughwe believe that our present insurance coverage is sufficient to cover our current estimated exposures, we cannot assure that wewill not incur losses or liabilities in excess of our policy limits. In addition, although we believe that will be able to continueto obtain adequate coverage, we cannot assure that we will be able to do so at acceptable costs.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Risksrelating to our international operations          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Foreigncurrency exchange rate fluctuations may adversely affect our business.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Sincewe operate as a multinational corporation that sells and sources products in many different countries, changes in exchange ratescould in the future, adversely affect our cash flows and results of operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Furthermore,reported sales and purchases made in non-U.S. currencies by our international businesses, when translated into U.S. dollars forfinancial reporting purposes, fluctuate due to exchange rate movement. Due to the number of currencies involved, the variabilityof currency exposures and the potential volatility of currency exchange rates, we cannot predict the effect of exchange rate fluctuationson future sales and operating results.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Weare subject to economic, political and other risks associated with our significant international business, which could adverselyaffect our financial results.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weoperate internationally primarily through wholly-owned subsidiaries located in North America and Europe. Revenues outside theUnited States were approximately 16% of total revenues in fiscal 2020. Our sales and earnings could be adversely affected by avariety of factors resulting from our international operations, including        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            future fluctuations in foreign    currency exchange rates;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            complex regulatory requirements and changes    in those requirements;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            trade protection measures and import or export    licensing requirements;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            multiple jurisdictions and differing tax laws,    as well as changes in those laws;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            restrictions on our ability to repatriate investments    and earnings from foreign operations;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in the political or economic conditions    in a country or region, including the potential impact Brexit will have on our UK operations;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in shipping costs; and           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            difficulties in collecting on accounts receivable.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ifany of these risks materialize, we could face substantial increases in costs, the reduction of profit and the inability to dobusiness.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 37; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         35         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Withour commercialization activities outside of the United States, we are subject to the risk of inadvertently conducting activitiesin a manner that violates the U.S. Foreign Corrupt Practices Act and similar laws. If that occurs, we may be subject to civilor criminal penalties which could have a material adverse effect on our business, financial condition, results of operations andgrowth prospects.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare subject to the U.S. Foreign Corrupt Practices Act (“FCPA”), which prohibits corporations and individuals frompaying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staffmember, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a personworking in an official capacity. We are also subject to the UK Anti-Bribery Act, which prohibits both domestic and internationalbribery, as well as bribery across both public and private sectors.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Inthe course of establishing and expanding our commercial operations and seeking regulatory approvals outside of the United States,we will need to establish and expand business relationships with various third parties and we will interact more frequently withforeign officials, including regulatory authorities. Expanded programs to maintain compliance with such laws will be costly andmay not be effective. Any interactions with any such parties or individuals where compensation is provided that are found to bein violation of such laws could result in substantial fines and penalties and could materially harm our business. Furthermore,any finding of a violation under one country’s laws may increase the likelihood that we will be prosecuted and be foundto have violated another country’s laws. If our business practices outside the United States are found to be in violationof the FCPA, UK Anti-Bribery Act or other similar law, we may be subject to significant civil and criminal penalties which couldhave a material adverse effect on our financial condition and results of operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           RisksRelating to our Common Stock          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourstock price has been volatile, which could result in substantial losses for investors.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourcommon stock is quoted on the New York Stock Exchange, and there has been historical volatility in the market price of our commonstock. The trading price of our common stock has been, and is likely to continue to be, subject to significant fluctuations dueto a variety of factors, including:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            fluctuations in our quarterly    operating and earnings per share results;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the gain or loss of significant contracts;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the carrying value of our goodwill and intangible    assets;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            loss of key personnel;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            announcements of technological innovations or    new products by us or our competitors;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delays in the development and introduction of    new products;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            legislative or regulatory changes;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            general trends in the industries we operate;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            recommendations and/or changes in estimates    by equity and market research analysts;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            biological or medical discoveries;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disputes and/or developments concerning intellectual    property, including patents and litigation matters;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            public concern as to the safety of new technologies;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            sales of common stock of existing holders;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            securities class action or other litigation;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            developments in our relationships with current    or future customers and suppliers and;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            general economic conditions, both in the United    States and worldwide.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Inaddition, the stock market in general has experienced extreme price and volume fluctuations that have affected the market priceof our common stock, as well as the stock of many companies in our industries. Often, price fluctuations are unrelated to operatingperformance of the specific companies whose stock is affected.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Inthe past, following periods of volatility in the market price of a company’s stock, securities class action litigation hasoccurred against the issuing company. If we were subject to this type of litigation in the future, we could incur substantialcosts and a diversion of our management’s attention and resources, each of which could have a material adverse effect onour revenue and earnings. Any adverse determination in this type of litigation could also subject us to significant liabilities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <!-- Field: Page; Sequence: 38; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         36         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Becausewe do not intend to pay cash dividends on our common stock, an investor in our common stock will benefit only if it appreciatesin value.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wecurrently intend to retain our retained earnings and future earnings, if any, to finance the expansion of our business and donot expect to pay any cash dividends on our common stock in the foreseeable future. As a result, the success of an investmentin our common stock will depend entirely upon any future appreciation. There is no guarantee that our common stock will appreciatein value or even maintain the price at which investors purchased their shares.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Itmay be difficult for a third party to acquire us, which could inhibit stockholders from realizing a premium on their stock price.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare subject to the New York anti-takeover laws regulating corporate takeovers. These anti-takeover laws prohibit certain businesscombinations between a New York corporation and any “interested shareholder” (generally, the beneficial owner of 20%or more of the corporation’s voting shares) for five years following the time that the shareholder became an interestedshareholder, unless the corporation’s board of directors approved the transaction prior to the interested shareholder becominginterested.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourcertificate of incorporation, as amended, and by-laws contain provisions that could have the effect of delaying, deferring orpreventing a change in control of us that stockholders may consider favorable or beneficial. These provisions could discourageproxy contests and make it more difficult for stockholders to elect directors and take other corporate actions. These provisionscould also limit the price that investors might be willing to pay in the future for shares of our common stock. These provisionsinclude:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a staggered board of directors,    so that it would take three successive annual meetings to replace all directors; and           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            advance notice requirements for the submission    by stockholders of nominations for election to the board of directors and for proposing matters that can be acted upon by    stockholders at a meeting.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Futuresales of shares of our common stock or the issuance of securities senior to our common stock could adversely affect the tradingprice of our common stock and our ability to raise funds in new equity offerings.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare not restricted from issuing additional common stock, preferred stock or securities convertible into or exchangeable for commonstock. Future sales of a substantial number of our shares of common stock or equity-related securities in the public market orprivately, or the perception that such sales could occur, could adversely affect prevailing trading prices of our common stock,and could impair our ability to raise capital through future offerings of equity or equity-related securities. No prediction canbe made as to the effect, if any, that future sales of shares of common stock or the availability of shares of common stock forfuture sale will have on the trading price of our common stock.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourfailure to establish and maintain effective internal controls over financial reporting and information technology access couldresult in material misstatements in our consolidated financial statements, our failure to meet our reporting obligations and causeinvestors to lose confidence in our reported financial information, which in turn could cause the trading price of our commonstock to decline.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         UnderSection 404 of the Sarbanes-Oxley Act of 2002 and rules promulgated by the SEC, companies are required to conduct a comprehensiveevaluation of their internal control over financial reporting. As part of this process, we are required to document and test ourinternal control over financial reporting; management is required to assess and issue a report concerning our internal controlover financial reporting; and our independent registered public accounting firm is required to attest to the effectiveness ofour internal control over financial reporting. Our internal control over financial reporting may not prevent or detect misstatementsbecause of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, orfraud.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Overtime, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policiesor procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud mayoccur and not be prevented or detected timely. Even effective internal controls over financial reporting can provide only reasonableassurance with respect to the preparation and fair presentation of financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         The existenceof a material weakness could result in errors in our financial statements that could result in a restatement of financial statements,which could cause us to fail to meet our reporting obligations, lead to a loss of investor confidence and have a negative impacton the trading price of our common stock.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 39; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         37         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_004">         </a>         Item1B.         <u>          Unresolved Staff Comments         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         None        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Item2.         <u>          <a name="a_005">          </a>          Properties         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing are the principal facilities of the Company:        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold">           Leased /          </td>          <td style="text-align: center; font-weight: bold">          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           Square          </td>          <td style="text-align: center; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">           Location          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">           Primary use          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">           Segments          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">           owned          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           footage          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 25%; text-align: left; text-indent: -10pt; padding-left: 10pt">           Farmingdale, NY           <br/>           (Note 1)          </td>          <td style="width: 1%">          </td>          <td style="vertical-align: top; width: 25%; text-align: left">           Clinical laboratory and research          </td>          <td style="width: 1%">          </td>          <td style="vertical-align: top; width: 25%; text-align: left">           Clinical Laboratory Services          </td>          <td style="width: 1%">          </td>          <td style="text-align: left; width: 10%; vertical-align: top">           Leased          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: right">          </td>          <td style="vertical-align: top; width: 9%; text-align: right">           43,000          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -10pt; padding-left: 10pt">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Farmingdale, NY          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           Manufacturing, research, sales and administrative office          </td>          <td>          </td>          <td style="text-align: left">           Life Sciences Products, Therapeutics          </td>          <td>          </td>          <td style="text-align: left; vertical-align: top">           Owned          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="vertical-align: top; text-align: right">           22,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -10pt; padding-left: 10pt">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Farmingdale, NY           <br/>           (Note 2)          </td>          <td>          </td>          <td style="text-align: left">           Manufacturing and administrative office          </td>          <td>          </td>          <td style="text-align: left">           Clinical Laboratory Services and Life Sciences Products          </td>          <td>          </td>          <td style="text-align: left; vertical-align: top">           Owned          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="vertical-align: top; text-align: right">           36,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -10pt; padding-left: 10pt">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           New York, NY           <br/>           (Note 3)          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           Corporate headquarters          </td>          <td>          </td>          <td style="text-align: left; vertical-align: top">           Other          </td>          <td>          </td>          <td style="text-align: left; vertical-align: top">           Leased          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="vertical-align: top; text-align: right">           11,300          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -10pt; padding-left: 10pt">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="vertical-align: top; text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Lausen, Switzerland           <br/>           (Note 4)          </td>          <td>          </td>          <td style="text-align: left">           Operational headquarters in Europe, including sales and distribution          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           Life Sciences Products          </td>          <td>          </td>          <td style="text-align: left; vertical-align: top">           Leased          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="vertical-align: top; text-align: right">           9,626          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -10pt; padding-left: 10pt">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Ann Arbor, Michigan           <br/>           (Note 5)          </td>          <td>          </td>          <td style="text-align: left">           Manufacturing, research, and distribution          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           Life Sciences Products          </td>          <td>          </td>          <td style="text-align: left; vertical-align: top">           Leased          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td style="vertical-align: top; text-align: right">           26,820          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 12pt Cambria, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 7%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Note 1           </font>          </td>          <td style="width: 93%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On October 9, 2015, this lease was amended and extended through March 31, 2027.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Note 2           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On November 27, 2018 we closed on the $6 million purchase of this facility, which was subleased through June 30, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Note 3           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In June 2017, the lease, which includes 4,100 square feet under a sublease rental agreement through December 31, 2019, was extended through June 2028.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Note 4           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In June 2019, the lease was amended and extended through July 2020 and automatically extended for one year.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Note 5           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In March 2009, the lease was amended and extended through May 2021.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve the current facilities are suitable and adequate for the Company’s current operating needs for its clinical laboratoriesservices, life science products and therapeutics segments and that the production capacity in various locations is sufficientto manage services and product requirements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_006">         </a>         Item3.         <u>          Legal Proceedings         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany has brought cases in the United States District Court for the District of Delaware (“the Court”), allegingpatent infringement against various companies. In 2017, the Court ruled that the asserted claims of the ‘180 and ‘405Patents are invalid for nonenablement in cases involving Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche. That rulingwas affirmed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) in June 2019. Enzosubsequently filed a petition for certiorari regarding the invalidity ruling for the ‘180 and ‘405 Patents in February2020; the Supreme Court denied Enzo’s petition on March 30, 2020. There are currently two cases that were originally broughtby the Company in the Court. In those two cases, Enzo alleges patent infringement against Becton Dickinson Defendants and RocheDefendants, respectively. The claims in those cases involve the ‘197 Patent. Both cases are stayed.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Inseparate inter partes review proceedings before the U.S. Patent and Trademark Office involving, among others, Becton Dickinson,certain claims of the ‘197 Patent were found unpatentable as anticipated or obvious and cancelled by the Patent Trial andAppeals Board (“Board”). Enzo appealed that decision to the Federal Circuit. On August 16, 2019, the Federal Circuitaffirmed the Board’s decision, finding that each of the challenged claims is unpatentable. The Company filed a petitionfor rehearing and rehearing en banc on October 30, 2019, which the Federal Circuit denied on December 4, 2019. The Company fileda petition for certiorari with the Supreme Court on March 3, 2020, which is pending.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 40; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         38         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InApril 2019, the Company entered into an agreement with Hologic and Grifols, resolving litigation resulting from four cases originallybrought by the Company in the Court.  As a result, Enzo dismissed (1) a stayed patent litigation regarding the ’180and ’197 Patent against Hologic in the Court; (2) the Consolidated Appeals against Gen-Probe and Hologic resulting fromtwo cases filed in the Court, and (3) the Company’s appeal in the litigation involving the ’581 Patent that involvedboth Hologic and Grifols. As a result of the agreement with Hologic, Hologic withdrew from Enzo’s Federal Circuit appealof the Board’s adverse rulings in the         <i>          inter partes         </i>         review proceedings regarding the ’197 Patent filed by Hologicand joined by Becton Dickinson mentioned above.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OnFebruary 5, 2020, Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (“Plaintiffs”) broughtan action in the United States District Court for the Southern District of New York against the Company and five of its presentor former Directors, Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce A. Hanna, Dov Perlysky and Rebecca Fischer (“defendants”).On March 26, 2020, Plaintiffs filed an amended complaint against the same defendants. Count I asserted the Company violated Section14(a) of the Securities and Exchange Act of 1934 and Rule 14a-9 thereunder by disseminating proxy materials that made two purportedlyfalse statements: (a) a “January 28, 2020 Enzo press release [that purportedly] falsely stated that the Annual Meeting wouldbe ‘delayed’ by action of the Board to February 25, 2020 when, in fact, the Annual Meeting would convene as plannedon January 31, 2020”, and (b) a “January 31 Enzo Proxy [that purportedly] falsely stated that the Proposed By-LawAmendment [to Article II, Section 9] would be approved if it received…a majority of the votes….rather than the requiredSupermajority Vote as provided for in the Charter. ”Count II asserted a claim against the individual defendants under Section209a) of the Exchange Act premised on Enzo’s purported violation of Section 14(a) and Rule 14a-9. Count III asserted theindividual defendants breached their fiduciary duty, based on the same conduct and by seeking to entrench themselves. Count IVpurported to assert a derivative claim for a declaration that any amendment to Article II Section 2 requires the approval of 80%of Enzo’s shareholders. On July 16, 2020, the day before the defendant’s motion to dismiss was due, plaintiffs askedthe Court to dismiss their claims without prejudice. Defendants asked plaintiffs to dismiss the claims with prejudice, but theyrefused. On July 17, 2020, the Court dismissed the claims without prejudice. If plaintiffs reassert the claims, defendants intendto vigorously defend against them.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Therecan be no assurance that the Company will be successful in any of these litigations. Even if the Company is not successful, managementdoes not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims,legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that anyliability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a materialadverse effect on its financial position or results of operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asdescribed in Note 3 to the consolidated financial statements, third-party payers, including government programs, may decide todeny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against theircoverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), andwe may be required to refund payments already received. During the third fiscal quarter of 2019, a significant third-party payerinformed us outside of their typical business practice that they believe it overpaid the Company during certain periods of fiscal2018. The Company disputed these claims and formally sent legal appeal letters to the payer. During the fiscal 2020 period, werecorded $0.8 million in legal and related expenses as a result of reduced reimbursements this payer made to us. In April 2020,we and the payer entered into a settlement agreement and release whereby the parties agreed that the $0.8 million previously withheldby the payer shall fully and completely satisfy the dispute.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing legal settlements are included in the statement of operations under Legal settlements, net within the Life Science segmentfor the 2019 period:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany, along with its subsidiaries Enzo Life Sciences, Inc. entered into a Settlement Agreement as of February 5, 2019 (the“Agreement) with Roche Diagnostics GmbH and Roche Molecular Systems, Inc. (together, “Roche”) with respect toan action between the Company and Roche before the U.S. District Court, Southern District of New York, Case No 04-CV4046. Rocheagreed to pay the Company $21 million in settlement pursuant to the Agreement. The Company received $19.4 million net of attorneycontingency payments. This settlement does not affect the Company’s civil action for patent infringement against Roche inthe U.S. District Court for the State of Delaware, Enzo Life Sciences Inc. v. Roche Molecular Systems Inc., et al., civil actionNo. 12 cv-00106, which remains pending on appeal.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany, along with its subsidiaries Enzo Life Sciences, Inc. entered into a settlement and license agreement as of April 16,2019 (the “Agreement”) with Hologic, Inc. (“Hologic”), Grifols, S.A., and Grifols Diagnostic SolutionsInc. (together, “Grifols”) to settle all outstanding patent disputes among the parties.  The terms of the agreementinclude one-time payments totaling $14 million to the Company in exchange for fully paid-up, worldwide licenses to Hologic andGrifols. The Company received $9.5 million net of attorney contingency payments.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_007">         </a>         Item4.         <u>          Mine Safety Disclosures         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         NotApplicable        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 41; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         39         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt">        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">         <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          <b>           <a name="a_008">           </a>           PartII          </b>         </font>        </p>       </div>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Item5.         <u>          <a name="a_009">          </a>          Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thecommon stock of the Company is traded on the New York Stock Exchange (Symbol: ENZ). The following table sets forth the closinghigh and low price of the Company’s common stock for the periods indicated as reported on the New York Stock Exchange.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt">           <u>            2020 Fiscal Year (August 1, 2019 to July 31, 2020):           </u>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: right">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2">          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           High          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           Low          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%">           1st Quarter          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           3.79          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           3.01          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           2nd Quarter          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           3.21          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           2.42          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           3rd Quarter          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           3.87          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           1.82          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           4th Quarter          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           3.14          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           2.15          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt">           <u>            2019 Fiscal Year (August 1, 2018 to July 31, 2019):           </u>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: right">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2">          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           High          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           Low          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%">           1st Quarter          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           4.94          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           3.10          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           2nd Quarter          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           3.77          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           2.46          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           3rd Quarter          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           4.02          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           2.54          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           4th Quarter          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           4.31          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           3.05          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asof September 30, 2020, the Company had approximately 888 stockholders of record of its common stock.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany has not paid a cash dividend on its common stock and intends to continue a policy of retaining earnings to finance andbuild its operations. Accordingly, the Company does not anticipate the payment of cash dividends to holders of common stock inthe foreseeable future.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <!-- Field: Page; Sequence: 42; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         40         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_010">         </a>         Item6.         <u>          Selected Financial Data         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table, which is derived from the audited consolidated financial statements of the Company for the fiscal years 2016through 2020 should be read together with the discussion in “Management’s Discussion and Analysis of Financial Conditionand Results of Operations” and the Company’s consolidated financial statements and notes to those statements includedelsewhere in this Annual Report on Form 10-K.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           For the fiscal year ended July 31,           <br/>           (In thousands, except per share amounts)          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">           Operating Results          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2018          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2017          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">           2016          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 40%">           Revenues (2)          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           76,021          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           81,170          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           101,013          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           105,086          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           102,773          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Operating (loss) income          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (30,367          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           1,733          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (12,164          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (3,148          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           46,848          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Net (loss) income (1)          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (28,520          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           2,489          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (10,321          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (2,504          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           45,286          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Basic net (loss) income per common share:          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (0.60          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.05          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (0.22          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (0.05          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.98          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -8.65pt; padding-left: 8.65pt">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Diluted net (loss) income per common share:          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (0.60          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           0.05          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (0.22          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (0.05          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           0.97          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           July 31,          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">           Financial Position (in thousands)          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2018          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2017          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2016          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 40%; text-align: left">           Working capital          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           35,964          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           65,444          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           63,014          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           71,274          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           70,829          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Total assets          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           112,538          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           106,640          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           101,660          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           107,665          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           111,821          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Stockholders’ equity          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           58,381          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           86,028          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           81,121          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           88,872          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           89,554          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Notesto Selected Financial Data:         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Infiscal years 2019 and 2016, the Company recorded legal settlements, net of approximately $28.9 million and $57.3 million, respectively.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 39.75pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Revenuesfor the years ended July 31, 2018 and 2017 have been restated to reflect the impact of new revenue recognition rules that becameeffective August 1, 2018 and were adopted on a retrospective basis. Revenues for the year ended July 31, 2016 has not been restated.See Note 3 to the consolidated financial statements for further details on the adoption of the new revenue recognition standard.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Page; Sequence: 43; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         41         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin-top: 0; margin-bottom: 0">       </p>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">        <a name="a_011">        </a>        Item7.        <u>         Management’s Discussion and Analysis of Financial Condition and Results of Operations        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Seein this Form 10-K for the fiscal year ended July 31, 2020 Part 1. Item 1.         <i>          Business         </i>         , for Forward Looking Cautionary Statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany’s Enzo Clinical Laboratory Services and Enzo Life Sciences Products reporting units, as described below, are affectedby different US and global economic conditions which are included in Item 1A, Risk Factors.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        With the coronavirus pandemic affecting people on a regionaland global basis, the Company launched a rapid response to market demand for COVID-19 testing products and services. Enzo is deliveringtesting and lab services to schools, institutions, urgent care facilities, and core multi-state network of medical practices. Furthermore,the Company’s GENFLEX™ platform received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA)in July for its proprietary product for the detection of SARS-CoV-2. FDA EUA demonstrates the Company’s unique integratedin-house capability in developing low cost, high throughput sensitive detection platforms for COVID-19 as well as other diseases.The Authorization was for a comprehensive platform enabling rapid scalability of testing, including internal use within Enzo’sClinical Lab as well as for the sale of instrumentation, consumables, and reagents to other diagnostic testing customers. The Authorizationincludes three diverse platforms: Enzo’s proprietary GENFLEX™ automated high-throughput platform, a medium-throughputindustry standard platform, and Enzo’s manual workflow. Launching a COVID-19 test on its proprietary GENFLEX ™ moleculardiagnostics platform serves as representative of the Company’s capabilities as it develops other tests on the platform includingan upper respiratory panel, STDs and expanded women’s health panels. The Company is well positioned to replicate this successin response to new emerging health issues and needs, including, but not limited to, upper respiratory, sexually transmitted diseases,viral load, and women’s health.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare comprised of three operating companies that have evolved out of our core competence: the use of nucleic acids as informationalmolecules and the use of compounds for immune modulation. These wholly-owned operating companies and the foreign subsidiariesof Enzo Life Sciences conduct their operations through three reportable segments. Below are brief descriptions of each of thethree operating segments (see Note 17 in the Notes to Consolidated Financial Statements):        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <u>           EnzoClinical Laboratory Services          </u>         </b>         is a regional clinical laboratory serving the greater New York and New Jersey medical communitiesand expanding into Connecticut. The Company believes having clinical diagnostic services allows us to capitalize first hand onour extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics.We offer a menu of routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians toestablish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. We operatea full-service clinical laboratory in Farmingdale, New York, a network of 34 patient service centers throughout greater New Yorkand New Jersey, a free-standing “STAT” or rapid response laboratories in New York City and Connecticut, and a full-servicephlebotomy center and an in-house logistics department. Payments for clinical laboratory testing services are made by the Medicareprogram, healthcare insurers and patients.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheClinical Laboratory Services reporting unit is impacted by various risk factors, including among others, reduced reimbursementsfrom third party payers for testing performed and from recent health care legislation. Despite the growth we have experiencedin previous years, there can be no assurance future growth can be achieved. The introduction of new molecular and esoteric testsis expected to increase our revenue per test and could offset impacts from the above factors. The Company anticipates improvedprofitability with increased service volume.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <u>           EnzoLife Sciences Products          </u>         </b>         manufactures, develops and markets products and tools to life sciences, drug development and clinicalresearch customers world-wide and has amassed a large patent and technology portfolio. Enzo Life Sciences, Inc. is a recognizedleader in labeling and detection technologies across research and diagnostic markets. Our strong portfolio of proteins, antibodies,peptides, small molecules, labeling probes, dyes and kits provides life science researchers tools for target identification/validation,high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.We are globally recognized and acknowledged as a leader in manufacturing, in-licensing, and commercialization of over 40,000 products.Our strategic focus is directed to innovative high quality research reagents and kits in the primary key research areas of genomics,immunohistochemistry, immunoassays, cellular analysis, and small molecule chemistry. The segment is an established source fora comprehensive panel of products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders,diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity and renal injury.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <u>           EnzoTherapeutics          </u>         </b>         is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal,infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The Companyhas focused its efforts on developing treatment regimens for diseases and conditions in which current treatment options are ineffective,costly, and/or cause unwanted side effects. This focus has generated a clinical and preclinical pipeline, as well as more than100 patents and patent applications.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table summarizes the sources of revenues for the fiscal years ended July 31, 2020, 2019 and 2018 (in $000’s andpercentages):        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2018          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">           Clinical laboratory services          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           47,964          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           63          </td>          <td style="width: 1%; text-align: left">           %          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           51,115          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           63          </td>          <td style="width: 1%; text-align: left">           %          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           71,077          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           70          </td>          <td style="width: 1%; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Product revenues          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           26,561          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           35          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           30,055          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           37          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           29,224          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           29          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">           Grant and royalty and license fee income          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,496          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           712          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           76,021          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           81,170          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           101,013          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 44; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         42         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Resultsof Operations          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Fiscalyear ending July 31, 2020 compared to July 31, 2019           <br/>           (in 000s)          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          ComparativeFinancial Data for the Fiscal Years Ended July 31,         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Favorable (Unfavorable)          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           % Change          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%">           Revenues          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           76,021          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           81,170          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (5,149          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           (6          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Operating costs and expenses:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Cost of revenues          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           52,251          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           57,922          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5,671          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Research and development          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,448          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,175          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (1,273          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (40          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Selling, general and administrative          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           42,960          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           44,265          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,305          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Legal and related expenses          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6,729          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (3,729          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (124          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt">           Legal settlements, net          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (28,925          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (28,925          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           (100          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           Total operating costs, expenses and legal settlements, net          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           106,388          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           79,437          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (26,951          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           (34          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Operating (loss) income          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (30,367          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,733          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (32,100          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Other income (expense):          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Interest          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           454          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,056          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (602          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (57          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           Other          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           488          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           382          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           106          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           28          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt">           Foreign currency gain (loss)          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           905          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (682          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,587          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           (Loss) income before income taxes          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (28,520          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2,489          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (31,009          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          **not meaningful         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          ConsolidatedResults:         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         The“2020 period” and the “2019 period” refer to the fiscal year ended July 31, 2020 and 2019, respectively.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Clinicalservices revenues for the 2020 period were $49.5 million compared to $51.1 million in the 2019 period, a decrease of $1.6 millionor 3%. Revenues for the 2020 period include two CARES Act Relief Payment grants totaling $1.5 million. Due to COVID-19, diagnostictesting volume measured by the total number of accessions for all our testing services decreased 7% period over period, resultingin the 2020 period’s revenue decrease. COVID-19 testing services provided in the four months of the 2020 period partiallyoffset the impact of the decline in total testing volume and also contributed to liquidation rate improvement. In the latter partof our third quarter, while accessions had not returned to prior year levels, we started to see accession volume rebound. Dueto the addition of COVID-19 testing, accession volume in the month of July 2020 exceeded July 2019 volume. In the normal courseof business, estimated collection amounts are subject to the complexities and ambiguities of third party payer billing, reimbursementregulations and claims processing, as well as issues unique to Medicare and Medicaid programs, and require us to consider thepotential for adjustments when estimating variable consideration in the recognition of revenue in the period that the relatedservices are rendered. The impact from the Protecting Access to Medicare Act (“PAMA”) continues to negatively impactreimbursements from Medicare and third party payers.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Productrevenues for the 2020 and 2019 periods were $26.6 million and $30.1 million, respectively. The decrease of $3.5 million or 12%is the result of the policies and initiatives ordered by national and local governments designed to reduce the transmission ofCOVID-19. The negative effect of these government policies on our products revenues was greater in the U.S. market than marketsin the rest of the world, and began in the latter half of the third quarter of the 2020 period.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thecost of Clinical Services was $38.9 million in the 2020 period and $44.2 million in the 2019 period, a decrease of $5.3 million,attributable to the overall decline in testing volume, resulting in reduction in reagent usage and outside reference testing expense.The gross profit margin on Clinical Services revenues, excluding the grants in the 2020 period, was 19.0% in the 2020 period and13.4% in the 2019 period. In the 2020 period, liquidation rate improvements and the higher margin on COVID-19 testing helped tooffset the effect of reduced volumes of our genetics and core testing services.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thecost of product revenues was $13.4 million in the 2020 period and $13.7 million in the 2019 period, a decrease of $0.3 millionor 2% due to the decrease in revenues. The gross profit margin on products was 49.6% in the 2020 period and 54.4% in the 2019period, negatively impacted by the decline of higher margin sales in the U.S. market from COVID-19.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 45; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         43         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Research and development expenses were $4.4 million in the 2020period and $3.2 million in the 2019 period, an increase of $1.2 million or 38%. The increase is entirely attributed to the ClinicalServices division for lab developed tests (LDTs) including those based on our proprietary GENFLEX™ platform. During the 2020period, our research was focused on lab developed tests for the detection of COVID-19 and for the detection of COVID-19 antibodies.Our lab developed test for the detection of COVID-19 was approved under the FDA’s Emergency Use Authorization (EUA) authority.Other tests based on GENFLEX™ were approved by The New York State Department of Health.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Selling,general and administrative expenses were $43.0 million during the 2020 period versus $44.3 million during the 2019 period, a decreaseof $1.3 million or 3%. The Clinical Services expense decreased $0.7 million due to cost savings initiatives and lower commissions.The Life Sciences Products expense decreased $1.4 million due to reductions in sales, marketing and administrative salaries andrelated costs, travel expenses, and intangibles amortization. The other segment increased $0.8 million primarily for higher self-insuredhealthcare benefit costs and occupancy costs.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Legaland related expenses were $6.7 million during the 2020 period compared to $3.0 million in the 2019 period, an increase of $3.7million. During the 2020 period, we incurred $4.1 million for contested proxy costs relating to our February 2020 annual shareholdersmeeting. Third-party payers, including government programs, may decide to deny payment or recoup payments for testing that theycontend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe theyhave otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received.During the third fiscal quarter of 2019, a significant third-party payer informed us outside of their typical business practicethat they believed it overpaid us during certain periods of fiscal 2018. We disputed these claims and sent legal appeal lettersto the payer. In the 2020 period, we recorded $0.8 million in legal and related expenses as a result of reduced reimbursementsthis payer made to us. In the third quarter of the 2020 period, we and the payer entered into a settlement agreement and releasewhereby the parties agrees that the $0.8 million previously withheld by the payer fully and completely satisfied the dispute.Legal expense associated with other legal activity including costs associated with on-going litigation and contract disputes decreased$1.2 million due to the timing of activities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Legalsettlements, net were $28.9 million in the 2019 period versus none in the 2020 period. During the 2019 period the Company as plaintifffinalized and executed settlement agreements with Roche ($19.4 million, net), and Hologic Inc. ($9.5 million, net).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Interestincome, net was $0.5 million in the 2020 period and $1.1 million in the 2019 period and represents interest on cash and cash equivalentsnet of interest expense. During the 2020 period, the amount of investable cash was lower as were interest rates earned on deposits.Due to the actions by the Federal Reserve to cut its target interest rates near zero in response to COVID-19, we expect therewill be substantially no interest earned on our cash and cash equivalents for the foreseeable future.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theforeign currency revaluation gain recognized by the Life Sciences Products segment during the 2020 period was $0.9 million comparedto a loss of $0.7 million in the 2019 period, a favorable variance of $1.6 million. The gain was due to year over year appreciationof the British pound and Swiss franc versus the U.S. dollar as of the end of the 2020 period, compared to their year over yeardepreciation as of the end of the 2019 period.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <!-- Field: Page; Sequence: 46; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         44         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          <i>           Resultsof Operations          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Fiscalyear ended July 31, 2019 compared to July 31, 2018          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           (in000s)          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td colspan="17" style="padding-bottom: 1.5pt">           <u>            Comparative Financial Data for the Fiscal Years Ended July 31,           </u>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2018          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Increase           <br/>           (Decrease)          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           % Change          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%">           Revenues          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           81,170          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           101,013          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (19,843          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           (20          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Operating costs, expenses and legal settlements, net:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Cost of revenues          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           57,922          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           60,385          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (2,463          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (4          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Research and development          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,175          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,210          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (35          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (1          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Selling, general and administrative          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           44,265          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           44,455          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (190          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Legal fee expense          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5,127          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (2,127          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (41          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Legal settlements, net          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (28,925          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (28,925          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Total operating costs, expenses and legal settlements, net          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           79,437          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           113,177          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (33,740          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           (30          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Operating income (loss)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,733          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (12,164          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,897          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Other income (expense):          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           Interest          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,056          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           853          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           203          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           24          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Other          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           382          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           168          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           214          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Foreign currency loss          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (682          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (275          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (407          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Income (loss) before income taxes          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2,489          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (11,418          </td>          <td style="padding-bottom: 4pt; text-align: left">           )          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (13,907          </td>          <td style="padding-bottom: 4pt; text-align: left">           )          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          **not meaningful         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          ConsolidatedResults:         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         The“2019 period” and the “2018 period” refer to the fiscal year ended July 31, 2019 and 2018, respectively.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Clinicalservices revenues for the 2019 period were $51.1 million compared to $71.1 million in the 2018 period, a decrease of $20.0 millionor 28%.  Services revenues were negatively affected by lower genetics testing volume approximating $8.8 million, attributableto increased competition.  Services revenues were negatively affected by lower reimbursement rates of $9.8 million, of which$6.4 million is attributable to reduced genetics testing reimbursements as a result of an increase in denial rates and changesto medical and procedural requirements, and $3.4 million attributable to reimbursement rate declines from third party payers andthe impact from the Protecting Access to Medicare Act (“PAMA”).  During the 2019 period, adjustments to estimatedcollection amounts from third party payers and HMO’s also decreased services revenues by $1.4 million.  Total diagnostictesting volume measured by the number of accessions decreased approximately 1%.  In the normal course of business, estimatedcollection amounts are subject to the complexities and ambiguities of third party payer billing, reimbursement regulations andclaims processing, as well as issues unique to Medicare and Medicaid programs, and require us to consider the potential for adjustmentswhen estimating variable consideration in the recognition of revenue in the period that the related services are rendered.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Productrevenues for the 2019 and 2018 periods was $30.1 million compared to $29.2 during 2018. The increase of $0.9 million or 3% isdue to higher product order volume in the U.S. market, which was partially offset by lower product order volume in the internationalmarket and the negative impact of foreign exchange translation. There was no royalty income in the 2019 period as the licenseagreement expired during the 2018 period. Royalty income in 2018 period was $0.7 million.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thecost of Clinical Services during the 2019 period was $44.2 million as compared to $46.0 million in the 2018 period, a decreaseof $1.8 million or 4% primarily due to the change in test mix, especially the decline in genetic testing volume. The componentsof the decrease are $3.1 million from a decrease in outside reference lab genetic testing costs, partially offset by increasesin reagent and other test supplies of $0.7 million and compensation related expenses of $0.6 million.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 47; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         45         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         Thecost of product revenues was $13.7 million in the 2019 period and $14.4 million in the 2018 period, a decrease of $0.6 millionor 4% due to due to the mix of products sold and a decrease in compensation expense. The gross profit margin on products was 54.4%in the 2019 period and 51.0% in the 2018 period. The 2019 improvement was due to favorable mix of products sold and lower discounting.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Researchand development expenses were $3.2 million in the 2019 and 2018 periods. The expense for Life Sciences Products was $2.2 millionfor the 2019 period and $2.3 million for the 2018 period. The expense for Enzo Therapeutics was $0.9 million in both periods.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Selling,general and administrative expenses were approximately $44.3 million during the 2019 period versus $44.5 million during the 2018period, a decrease of $0.2 million. Clinical Services expense decreased $0.4 million, primarily due to a $0.8 million reductionin outside billing and collections expenses, partially offset by increased costs to nationally market our new molecular diagnosticproducts for use by other reference labs of approximately $0.2 million, increased information technology costs to support ourclients of $0.1 million, and increased office rent and utility costs of $0.1 million. Life Sciences Products expense increased$0.2 million due to higher business development salaries and related costs. Other segment expense remained the same during bothperiods.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Legalfee expense was $3.0 million during the 2019 period compared to $5.1 million in the 2018 period, a decrease of $2.1 million dueto the timing of legal activity and related costs associated with on-going litigation and contract dispute where the Company isthe plaintiff.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.2pt 0 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Legalsettlements, net were $28.9 million in the 2019 period versus none in the 2018 period. During the 2019 period the Company as plaintifffinalized and executed settlement agreements with Roche ($19.4 million, net), and Hologic Inc. ($9.5 million, net).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Interestincome, net increased $0.2 million in the 2019 period due to increased interest rates earned on cash and cash equivalents.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theforeign currency loss incurred by the Life Sciences Products segment during the 2019 period was $0.7 million compared to $0.3million in the 2018 period, an unfavorable variance of $0.4 million. During the 2019 period, there were greater revaluation lossesdue to the significant depreciation of the British pound and Euro versus the U.S. dollar compared to that of the 2018 period.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 48; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         46         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Liquidityand Capital Resources         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         AtJuly 31, 2020, the Company had cash and cash equivalents of $47.9 million of which $0.9 million was in foreign accounts, as comparedto cash and cash equivalents of $60.1 million, of which $0.7 million was in foreign accounts at July 31, 2019. It is the Company’scurrent intent to permanently reinvest these funds outside of the United States, and its current plans do not demonstrate a needto repatriate them to fund its United States operations. The Company had working capital of $36.0 million at July 31, 2020 comparedto $65.4 million at July 31, 2019. The decrease in working capital of $29.4 million was primarily due to the recognition of $28.5million in net loss for the fiscal year ended July 31, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Netcash used in operating activities in fiscal 2020 was approximately $17.2 million as compared to net cash provided by operatingactivities of $4.8 million in fiscal 2019, an increase in net cash used in operations of approximately $22.0 million. This increasein net cash used in operating activities in the 2020 period versus 2019 was due to the year over year increase of $31.0 millionin net loss, partially by a positive net change in adjustments and operating assets and liabilities of $9.0 million. Net cashprovided by operating activities in fiscal 2019 was approximately $4.8 million as compared to net cash used in operating activitiesof $2.7 million in fiscal 2018, an increase of approximately $7.5 million. The increase in net cash provided by operating activitiesin the 2019 period versus the 2018 period was primarily due to an increase in net income of $12.8 million derived from legal settlementsreached in the 2019 period, offset by a net change in adjustments and operating assets and liabilities of $5.3 million.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Netcash used in investing activities in fiscal 2020 was approximately $2.2 million as compared to $8.1 million in the 2019 period,a decrease of $5.9 million. The decrease in the 2020 period is primarily due to the impact in 2019 of the purchase of a facilityin that period. Net cash used in investing activities in fiscal 2019 was approximately $8.1 million as compared to $1.9 millionin the 2018 period, an increase of $6.2 million. The increase in the 2019 period is primarily due to the purchase of our new facility.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        Net cash provided by financing activities in fiscal 2020 was approximately$7.0 million as compared to $4.2 million in fiscal 2019. The increase of $2.8 million was primarily due to proceeds from the SmallBusiness Administration Paycheck Protection Program loan. The PPP loan bears interest of 1% per annum. All or a portion of thePPP Loan, including interest, could be forgiven by the SBA by applying for forgiveness and providing acceptable documentationthat demonstrates the funds were used as required by the terms of forgiveness and in accordance with the SBA’s requirements.Due to complexities with respect to loan forgiveness calculations and government pronouncements with respect to expenditure eligibility,we did not recognize any loan forgiveness as of July 31, 2020 and have classified the loan as other short term debt as we expectto earn loan forgiveness on most, if not all of the loan in less than a year. See Note 8 in the notes to consolidated financialstatements. Net cash provided by financing activities in fiscal 2019 was approximately $4.2 million as compared to cash providedof $0.6 million in fiscal 2018. The 2019 increase of $3.6 million was due to proceeds from a ten year mortgage agreement enteredinto for the purchase of our new facility, which bears a fixed interest rate of 5.09% per annum and requires monthly mortgagepayments of $30. The Company’s obligations under the mortgage agreement are secured by the new facility and by a $750 cashcollateral deposit with the mortgagee as additional security. This restricted cash is included in other assets as of July 31,2020. As of July 31, 2020, the Company was not in compliance with a financial ratio covenant related to this mortgage. EffectiveOctober 19, 2020, the Company and the mortgagee agreed to a covenant restructure whereby the mortgagee waived the Company’sfinancial ratio covenant for the fiscal period ended July 31, 2020 and modified the mortgage to replace that covenant with a liquiditycovenant. The liquidity covenant requires that we own and maintain at all times and throughout the remaining term of the loanat least $25 million of liquid assets, defined as time deposits, money market accounts and obligations issued by the U.S. governmentor any of its agencies. The cash collateral agreement was also modified to require compliance with the liquidity covenant fortwo consecutive fiscal years before the collateral is released back to us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany believes that its current cash and cash equivalents level, and utilization of the Controlled Equity Offering program ifnecessary, as disclosed in Note 12 in the Notes to Consolidated Financial Statements are sufficient for its foreseeable liquidityand capital resource needs over at least the next twelve (12) months, although there can be no assurance that future events willnot alter such view. Although there can be no assurances, in the event additional capital is required, the Company believes ithas the ability to raise additional funds through equity offerings or other sources. Our liquidity plans are subject to a numberof risks and uncertainties, including those described in the Item 1A. “Risk Factors” section of this Form 10-K forthe year ended July 31, 2020, some of which are outside our control. Macroeconomic conditions could limit our ability to successfullyexecute our business plans and therefore adversely affect our liquidity plans.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Effectof New Accounting Pronouncements          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          RecentlyAdopted Accounting Pronouncements         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OnAugust 1, 2019, the Company adopted a new accounting standard issued by the Financial Accounting Standards Board (“FASB”)on accounting for leases using the modified retrospective method. This new accounting standard requires a lessee to recognizean asset and liability for most leases on its balance sheet. The Company elected the optional transition method that allowed fora cumulative-effect adjustment to the opening balance of retained earnings recorded on August 1, 2019 and did not restate previouslyreported results in the comparative periods. The Company also elected the package of practical expedients, which among other things,allowed it to carry forward its historical lease classification.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 49; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         47         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asa result of adoption of the new standard, the Company recorded right-of-use assets and lease liabilities of approximately $24.4million and $25.1 million, respectively as of August 1, 2019. The operating lease liability was determined based on the presentvalue of the remaining minimum rental payments and the right-of-use asset was determined based on the value of the lease liability,adjusted for deferred rent balances of approximately $0.7 million, which were previously included in accrued expenses. There wasno cumulative effect adjustment to the opening balance of accumulated deficit. Accounting for the Company’s finance leasesremains substantially unchanged. The adoption of the new standard did not materially impact the Company’s consolidated resultsof operations or cash flows. The adoption of this new accounting standard resulted in increased qualitative and quantitative disclosuresregarding the amount, timing, and uncertainty of cash flows arising from leases.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany elected the package of three practical expedients. As such, the Company did not reassess whether expired or existing contractsare or contain a lease and did not need to reassess the lease classifications or reassess the initial direct costs associatedwith expired or existing leases. The Company did not elect the hindsight practical expedient. Further, the land easement practicalexpedient was not elected as the practical expedient is not applicable to the Company. The Company elected to take the practicalexpedient to not separate lease and non-lease components of all asset classes entered into or modified after the effective date.For further details, see Note 9 in the notes to the consolidated financial statements        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OnAugust 1, 2018, the Company adopted a new accounting standard issued by FASB on revenue recognition using the full retrospectivemethod. This new accounting standard outlines a single comprehensive model to use in accounting for revenue arising from contractswith customers. This standard supersedes existing revenue recognition requirements and eliminates most industry-specific revenuerecognition guidance from accounting principles generally accepted in the United States of America (“GAAP”). The coreprinciple of the revenue recognition standard is to require an entity to recognize as revenue the amount that reflects the considerationwhich it expects to be entitled to when control of goods or services are transferred to its customers.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asa result of the Company’s adoption of this standard, the majority of the amounts that were historically classified as bad debtexpense, primarily related to patient responsibility, are now considered an implicit price concession in determining net revenuesfrom clinical services. Accordingly, the Company reports estimated uncollectible balances associated with patient responsibilityas a reduction of the transaction price and therefore as a reduction in net revenues, when historically these amounts were classifiedand separately reported as a provision for uncollectible accounts receivable. The adoption of this standard has no impact on revenuesreported for life sciences products. The adoption of this new accounting standard resulted in increased disclosure, includingqualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising fromcontracts with customers. For further details, see Note 3 in Notes to Consolidated Financial Statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theimpact of the adoption of the standard on prior period consolidated operations, cash flows and balance sheet is presented in thetable below:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>         </i>        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; font-weight: bold">           <b>            Consolidated Statements of Operations for the year ended July 31, 2018:           </b>          </td>          <td style="padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <b>            As Previously Reported           </b>          </td>          <td style="padding-bottom: 1.5pt">           <b>           </b>          </td>          <td style="padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <b>            Adjustment for New Accounting Standard on Revenue Recognition           </b>          </td>          <td style="padding-bottom: 1.5pt">           <b>           </b>          </td>          <td style="padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <b>            Reclassification of Residual           </b>          </td>          <td style="padding-bottom: 1.5pt">           <b>           </b>          </td>          <td style="padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <b>            As Restated           </b>          </td>          <td style="padding-bottom: 1.5pt">           <b>           </b>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; text-align: left">           Total Revenues          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           104,713          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="white-space: nowrap; width: 1%; text-align: left">           ($          </td>          <td style="width: 9%; text-align: right">           3,700          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           —          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           101,013          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Provision for uncollectible accounts receivable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,690          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: left">          </td>          <td style="text-align: right">           (3,700          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Selling, general and administrative expenses          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           44,465          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (10          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           44,455          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Net loss          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (10,321          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (10,321          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Consolidated Statements of Cash Flows July 31, 2018:             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>             </b>            </font>           </p>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Provision for uncollectible accounts receivable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,690          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: left">          </td>          <td style="text-align: right">           (3,700          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Changes in operating assets and liabilities: Accounts receivable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (1,775          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: left">          </td>          <td style="text-align: right">           3,700          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (10          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,915          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold">           Consolidated balance sheet July 31, 2018:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Accounts receivable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           15,815          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: left">          </td>          <td style="text-align: right">           (2,523          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,292          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1.5pt; text-align: left">           Less: Allowance for doubtful accounts          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2,668          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (2,523          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           145          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Accounts receivable, net of allowance for doubtful accounts          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,147          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,147          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <i>         </i>        </font>       </p>       <!-- Field: Page; Sequence: 50; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         48         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OnAugust 1, 2018, the Company adopted a new accounting standard issued by FASB which provides guidance about which changes to theterms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Adoption ofthis standard requires that amendments in the update be applied prospectively to an award modified on or after the adoption date.For the foreseeable future, any excess income tax benefits or deficiencies from stock-based compensation, which would be recognizedas discrete items within income tax expense rather than additional paid in capital, will be offset by an equivalent adjustmentto the deferred tax valuation allowance. Accordingly, adoption of this standard had no impact on our reported operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          PronouncementsIssued but Not Yet Adopted         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InJune 2016, FASB issued ASU No. 2016-13         <i>          Financial Instruments – Credit Losses (Topic 326)         </i>         . This standard, as amended,changes the impairment model for most financial instruments, including trade receivables, from an incurred loss method to a newforward-looking approach, based on expected losses. The estimate of expected credit losses will require entities to incorporateconsiderations of historical information, current information and reasonable and supportable forecasts. Adoption of this standardis required for our annual and interim periods beginning August 1, 2023, and must be adopted using a modified retrospective transitionapproach. We are currently assessing the impact of the adoption of this standard on our results of operations, financial positionand cash flows.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wereviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to besignificant to the accounting for our operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           ContractualObligations          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany has entered into various real estate and equipment operating leases, reagent rental agreements, and employment agreementswith certain executive officers. The real estate lease for the Company’s Farmingdale Clinical Lab and Research facilityis with a related party. See Item 2, Properties, and Note 9 and Note 15 in the Notes to the Consolidated Financial Statementsfor a further description of these leases and obligations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Managementis not aware of any material claims, disputes or settled matters concerning third-party reimbursements that would have a materialeffect on our financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Off-BalanceSheet Arrangements         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany does not have any “off-balance sheet arrangements” as such term is defined in Item 303(a) (4) of RegulationS-K.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          CriticalAccounting Policies and Estimates         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          <u>           General          </u>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany’s discussion and analysis of its financial condition and results of operations are based upon Enzo Biochem, Inc.’sconsolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in theUnited States. The preparation of these financial statements requires the Company to make estimates and judgments that affectthe reported amounts of assets, liabilities, revenues and expenses. These estimates and judgments also affect related disclosureof contingent assets and liabilities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Onan on-going basis, we evaluate our estimates, including those related to contractual expense, allowance for uncollectible accounts,inventory, intangible assets and income taxes. The Company bases its estimates on experience and on various other assumptionsthat are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about thecarrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from theseestimates under different assumptions or conditions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          <u>           Contingencies          </u>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Contingenciesare evaluated in accordance with ASC 450-20, Contingencies, and a liability is recorded when the matter is both probable and reasonablyestimable.  Gain contingencies are evaluated and not recognized until the gain is realizable or realized.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 51; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         49         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          <u>           Productrevenues and royalty income          </u>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Productsrevenues consist of the sale of single-use products used in the identification of genomic information and are recognized at apoint in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Paymentterms for shipments to end-user and distributor customers may range from 30 to 90 days. Any claims for credit or return of goodsmay be made generally within 30 days of receipt. Revenues are reduced to reflect estimated credits and returns, although historicallythese adjustments have not been material. Taxes collected from customers relating to product sales and remitted to governmentalauthorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while therelated shipping and handling costs are reflected in cost of products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Royaltyincome is based on net sales of the Company’s licensed products by a third party. We recognize royalty income in the periodthe sales occur based on third party evidence received        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          <u>           Revenues- Clinical laboratory services          </u>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Netrevenues in the Company’s clinical services business are primarily comprised of a high volume of relatively low-dollar transactions.The services business, which provides clinical testing services, satisfies its performance obligation and recognizes revenuesupon completion of the testing process for a specific patient and reporting to the ordering physician. The Company may also performclinical testing services for other laboratories and will recognize revenue from those services when reported to the orderinglaboratory. The Company estimates the amount of consideration it expects to receive from customer groups using the portfolio approach.These estimates of the expected consideration include the impact of contractual allowances and price concessions on our customergroup portfolios consisting of healthcare insurers, government payers, client payers and patients. Contracts with customers inour laboratory services business do not contain a financing component, based on the typically limited period of time between performanceof services and collection of consideration. The transaction price includes variable consideration in the form of the contractualallowance and price concessions as well as the collectability of the transaction based on patient intent and ability to pay. TheCompany uses the expected value method in estimating the amount of the variability included in the transaction price.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          ContractualAdjustment         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany’s estimate of contractual adjustment is based on significant assumptions and judgments, such as its interpretationof payer reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approvedas reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. The contractualadjustment is an estimate that reduces gross revenue based on gross billing rates to amounts expected to be approved and reimbursed.Gross billings are based on a standard fee schedule we set for all third party payers, including Medicare, health maintenanceorganizations (“HMO’s”) and managed care. The Company adjusts the contractual adjustment estimate quarterly,based on its evaluation of current and historical settlement experience with payers, industry reimbursement trends, and otherrelevant factors. The other relevant factors that affect our contractual adjustment include the monthly and quarterly review of:1) current gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) thegrowth of in-network provider arrangements and managed care plans specific to our Company.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourclinical laboratory services business is primarily dependent upon reimbursement from third-party payers, such as Medicare (whichprincipally serves patients 65 and older) and insurers. We are subject to variances in reimbursement rates among different third-partypayers, as well as constant changes of reimbursement rates. Changes that decrease reimbursement rates or coverage would negativelyimpact our revenues. The number of individuals covered under managed care contracts or other similar arrangements has grown overthe past several years and may continue to grow in the future. In addition, Medicare and other government healthcare programscontinue to shift to managed care. These trends will continue to reduce our revenues.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Duringthe years ended July 31, 2020, 2019 and 2018, the contractual adjustment percentages, determined using current and historicalreimbursement statistics, were approximately 88%, 88% and 85%, respectively, of gross billings. The Company believes a declinein reimbursement rates or a shift to managed care, or similar arrangements may be offset by the positive impact of an increasein the number of tests we perform. However, there can be no assurance that we can increase the number of tests we perform or thatif we do increase the number of tests we perform, that we can maintain that higher number of tests performed, or that an increasein the number of tests we perform would result in increased revenue.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany estimates (by using a sensitivity analysis) that each 1% point change in the contractual adjustment percentage could resultin a change in clinical laboratory services revenues of approximately $3.9 million, $4.4 million, and $5.0 million, for the yearsended July 31, 2020, 2019, and 2018, respectively, and a change in the net accounts receivable of approximately $0.5 and $0.4million as of July 31, 2020 and 2019, respectively.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <!-- Field: Page; Sequence: 52; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         50         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourclinical laboratory financial billing system records gross billings using a standard fee schedule for all payers and does notrecord contractual adjustment by payer at the time of billing. Therefore, we are unable to quantify the effect of contractualadjustment recorded during the current period that relate to revenue recorded in a previous period. However, we can reasonablyestimate our monthly contractual adjustment to revenue on a timely basis based on our quarterly review process, which includes:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            an analysis of industry reimbursement    trends;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            an evaluation of third-party reimbursement rates    changes and changes in reimbursement arrangements with third-party payers;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a rolling monthly analysis of current and historical    claim settlement and reimbursement experience statistics with payers;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            an analysis of current gross billings and receivables    by payer.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          <u>           AccountsReceivable          </u>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Accountsreceivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the periodof the related revenue.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing is a table of the Company’s net accounts receivable by segment. The Clinical Laboratory Services segment’snet receivables are detailed by billing category and as a percent to its total net receivables. As of July 31, 2020 and 2019,approximately 68% and 63% respectively, of the Company’s net accounts receivable relates to its Clinical Laboratory Servicesbusiness, which operates in the New York, New Jersey and Connecticut medical communities. The Life Sciences products segment’saccounts receivable includes approximately $1.0 million or 34% and $1.2 million or 32% of foreign receivables as of July 31, 2020and 2019, respectively.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Netaccounts receivable (in thousands)         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <u style="text-decoration: none">         </u>        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <b>           </b>          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <b>            July 31, 2020           </b>          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">           <b>           </b>          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <b>            July 31, 2019           </b>          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">           <b>           </b>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <b>            Clinical Labs (by billing category)           </b>          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <b>            Total Amount           </b>          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">           <b>           </b>          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <b>            %           </b>          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">           <b>           </b>          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <b>            Total Amount           </b>          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">           <b>           </b>          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">           <b>           </b>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <b>            %           </b>          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">           <b>           </b>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; text-align: left">           Third party payers          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,455          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           40          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,956          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           44          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Patient self-pay          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,044          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           33          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,360          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           35          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           Medicare          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           884          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           910          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1.5pt">           HMO’s          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           797          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           13          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           574          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           8          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 4pt">           Total Clinical Labs          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           6,180          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           6,800          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt">           Total Life Sciences          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2,961          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,938          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 4pt">           Total accounts receivable – net          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           9,141          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           10,738          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany’s ability to collect outstanding receivables from third party payers is critical to its operating performance andcash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patientportion remains outstanding. The Company also assesses the current state of its billing functions in order to identify any knowncollection or reimbursement issues in order to assess the impact, if any, on the allowance estimates, which involves judgment.The Company believes that the collectability of its receivables is directly linked to the quality of its billing processes, mostnotably, those related to obtaining the accurate patient information in order to bill effectively for the services provided. Shouldcircumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimatesof net realizable value of receivables could be reduced by a material amount. As of July 31, 2020, approximately 11% of ClinicalLabs receivables are from one payer.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Billingfor laboratory services is complicated because of many factors, especially: the differences between our standard gross fee schedulefor all payers and the reimbursement rates of the various payers we deal with, disparity of coverage and information requirementsamong the various payers, and disputes with payers as to which party is responsible for reimbursement.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 53; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         51         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing tables indicate the Clinical Laboratory Services segment aged gross receivables for the periods indicated by payer group(in thousands), which is prior to adjustment to gross receivables for: 1) contractual adjustment, 2) fully reserved balances notyet written off, and 3) other revenue adjustments.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">           As of July 31, 2020          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Total           <br/>           Amount          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           %          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Third Party Payers Amount          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           %          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Medicare           <br/>           Amount          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           %          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Self pay           <br/>           Amount          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           %          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           HMO’s           <br/>           Amount          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           %          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 20%">           1-30 days          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           21,074          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           44          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           13,620          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           46          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           3,897          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           42          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           1,769          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           27          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           1,788          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           94          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           31-60 days          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           7,080          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           15          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,588          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           15          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,081          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,307          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           20          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           104          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           61-90 days          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,616          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           8          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,358          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           618          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           7          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           632          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           8          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           91-120 days          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,474          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           940          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           243          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           284          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           7          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           121-150 days          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,614          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,594          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           367          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           649          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt">           Greater than 150 days          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           11,506          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           24          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6,518          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           22          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,051          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           32          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,936          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           29          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 4pt">           Totals          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           47,364          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           29,618          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           9,257          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           6,577          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1,912          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; border-bottom: Black 1.5pt solid">           As of July 31, 2019          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Total           <br/>           Amount          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Third Party Payers Amount          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Medicare           <br/>           Amount          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Self pay           <br/>           Amount          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           HMO’s           <br/>           Amount          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 20%">           1-30 days          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           22,031          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           50          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           14,232          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           53          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           4,114          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           52          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           1,236          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           20          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 5%; text-align: right">           2,449          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 5%; text-align: right">           90          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           31-60 days          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6,659          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           15          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,473          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           17          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           952          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,109          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           18          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           125          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           61-90 days          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,185          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,742          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           495          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           903          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           15          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           45          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           91-120 days          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,786          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,708          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           316          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           736          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           26          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           121-150 days          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,014          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,137          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           256          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           610          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           11          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt">           Greater than 150 days          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6,007          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           14          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2,684          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           10          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,709          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           22          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,563          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           25          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           51          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 4pt">           Totals          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           43,682          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           26,976          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           7,842          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           6,157          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2,707          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          <u>           IncomeTaxes          </u>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferredtax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statementcarrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any taxbenefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is notmore likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measuredusing enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected tobe recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax ratesis recognized in income in the period that includes the enactment date. It is the Company’s policy to provide for uncertaintax positions, if any, and the related interest and penalties based upon management’s assessment of whether a tax benefitis more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters forwhich a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, theCompany’s effective tax rate in a given financial statement period may be affected.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          <u>           Inventory          </u>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany values inventory at the lower of cost (first-in, first-out) or net realizable value. Work-in-process and finished goodsinventories consist of material, labor, and manufacturing overhead. Write downs of inventories to net realizable value are basedon a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand.Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downsof inventory which would impact our results of operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          <u>           Goodwilland Intangible Assets          </u>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Goodwillrepresents the excess of the cost of an acquisition over the fair value of the net assets acquired. Intangible assets (exclusiveof patents), arose primarily from acquisitions, and primarily consist of customer relationships, trademarks, licenses, and websiteand database content. Finite-lived intangible assets are amortized according to their estimated useful lives, which range from4 to 15 years. Patents represent capitalized legal costs incurred in pursuing patent applications. When such applications resultin an issued patent, the related capitalized costs, if any, are amortized over a ten year period or the life of the patent, whicheveris shorter, using the straight-line method. The Company reviews its issued patents and pending patent applications, and if itdetermines to abandon a patent application or that an issued patent no longer has economic value, the unamortized balance in deferredpatent costs relating to that patent is immediately expensed.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <!-- Field: Page; Sequence: 54; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         52         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany tests goodwill annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairmentexist. In assessing goodwill for impairment, the Company has the option to first perform a qualitative assessment to determinewhether the existence of events or circumstances leads to a determination that it is more likely than not that the fair valueof a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the fairvalue of a reporting unit is less than its carrying amount, the Company is not required to perform any additional tests in assessinggoodwill for impairment. However, if the Company concludes otherwise or elects not to perform the qualitative assessment, thenit identifies the reporting units and compares the fair value of each of these reporting units to their respective carrying amount.If the carrying amount of the reporting unit is less than its fair value, no impairment exists. If the carrying amount of thereporting unit is higher than its fair value, the impairment charge is the amount by which the carrying amount exceeds its fairvalue, not to exceed the total amount of goodwill allocated to the reporting unit.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany reviews the recoverability of the carrying value of long-lived assets (including intangible assets with finite lives)of an asset or asset group for impairment annually as of the end of the fiscal year, or more frequently if indicators of potentialimpairment exist. Should indicators of impairment exist, the carrying values of the assets are evaluated in relation to the operatingperformance and future undiscounted cash flows of an asset or asset group. The net book value of the long lived asset is adjustedto fair value if its expected future undiscounted cash flow is less than its book value.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Duringfiscal years 2020, 2019 and 2018, there was no impairment of goodwill or long-lived assets.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_012">         </a>         Item7A.         <u>          Quantitative and Qualitative Disclosures About Market Risk         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare exposed to market risk from changes in foreign currency exchange rates resulting from activities in foreign locations (SeeItem 1A. Risk Factors and Note 2 in the Notes to Consolidated Financial Statements) that could impact our results of operationsand financial position. We do not currently engage in any hedging or market risk management tools.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          ForeignCurrency Exchange Rate Risk         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefinancial reporting of our non-U.S. subsidiaries is denominated in currencies other than the U.S. dollar. Since the functionalcurrency of our non-U.S. subsidiaries is the local currency, foreign currency translation adjustments are accumulated as a componentof accumulated other comprehensive income in stockholders’ equity. Assuming a hypothetical decline of 10% in the exchangerates of foreign currencies against the U.S. dollar at July 31, 2020, our assets and liabilities would decrease by $0.4 millionand $0.1 million, respectively, and our net sales and net earnings (loss) would decrease by $0.8 million and $0.1 million, respectively,on an annual basis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wealso maintain intercompany balances and loans receivable with subsidiaries with different local currencies. These amounts areat risk of foreign exchange losses if exchange rates fluctuate. Assuming a hypothetical increase of 10% in the exchange ratesof foreign currencies against the U.S. dollar at July 31, 2020, our pre-tax earnings (loss) would be unfavorably impacted by approximately$1.7 million on an annual basis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          InterestRate Risk         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asof July 31, 2020, we have fixed interest rate financing on mortgage debt and equipment finance leases.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_013">         </a>         Item8.         <u>          Financial Statements and Supplementary Data         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theresponse to this item is submitted in a separate section of this report. See Item 15(a) (1) and (2).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_014">         </a>         Item9.         <u>          Changes in and Disagreements with Accountants on Accounting and Financial Disclosure         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         None.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_015">         </a>         Item9A.         <u>          Controls and Procedures         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          1.  DisclosureControls and Procedures         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wemaintain disclosure controls and procedures (Disclosure Controls) within the meaning of Rules 13a-15(e) and 15d-15(e) of the SecuritiesExchange Act of 1934, as amended, or the Exchange Act. Our Disclosure Controls are designed to ensure that information requiredto be disclosed by us in the reports we file or submit under the Exchange Act, such as this Annual Report on Form 10-K, is recorded,processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules andforms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management,including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding requireddisclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matterhow well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and managementnecessarily applied its judgment in evaluating and implementing possible controls and procedures.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 55; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         53         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asof the end of the period covered by this Annual Report on Form 10-K, we evaluated the effectiveness of the design and operationof our Disclosure Controls, which was done under the supervision and with the participation of our management, including our ChiefExecutive Officer and our Chief Financial Officer. Based on the evaluation of our Disclosure Controls, our Chief Executive Officerand Chief Financial Officer have concluded that, as of July 31, 2020, our Disclosure Controls were effective to ensure that informationrequired to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized andreported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to our management,including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding requireddisclosure.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          2.Change in Internal Control over Financial Reporting         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Therewere no changes in our internal control over financial reporting that occurred during the year ended July 31, 2020, that havematerially affected, or are reasonably likely to materially affect, our internal control over financial reporting.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          3.         </b>        </font>        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          Management’s Report on Internal Control Over Financial Reporting         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourmanagement is responsible for establishing and maintaining adequate internal control over financial reporting. Internal controlover financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designedby, or under the supervision of, a company’s principal executive and principal financial officers and effected by the company’sboard of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reportingand the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.  Ourinternal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of recordsthat, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonableassurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generallyaccepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations ofour management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorizedacquisition, use or disposition of our assets that could have a material effect of our consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thereare inherent limitations on the effectiveness of any system of internal controls and procedures, including the possibility ofhuman error and the circumvention or overriding of the controls and procedures. Also, projections of any evaluation of effectivenessto future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degreeof compliance with the policies and procedures may deteriorate. Accordingly, even effective internal controls and procedures canonly provide reasonable assurance of achieving their control objectives.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Changesin Internal Control Over Financial Reporting         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Managementassessed the effectiveness of our internal control over financial reporting as of July 31, 2020. In making this assessment, managementused the criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizationsof the Treadway Commission (“COSO”).  Based on this assessment, management has concluded that, as of July 31,2020, our internal control over financial reporting was effective.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_016">         </a>         Item9B.         <u>          Other Information         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         None        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 56; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         54         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_017">          </a>          PARTIII         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_018">         </a>         Item10.         <u>          Directors, Executive Officers and Corporate Governance         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theinformation required under this item will be set forth in the Company’s proxy statement to be filed with the Securitiesand Exchange Commission on or before November 27, 2020 and is incorporated herein by reference.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_019">         </a>         Item11.         <u>          Executive Compensation         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theinformation required under this item will be set forth in the Company’s proxy statement to be filed with the Securitiesand Exchange Commission on or before November 27, 2020 and is incorporated herein by reference.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_020">         </a>         Item12.         <u>          Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theinformation required under this item will be set forth in the Company’s proxy statement to be filed with the Securitiesand Exchange Commission on or before November 27, 2020 and is incorporated herein by reference.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_021">         </a>         Item13.         <u>          Certain Relationships and Related Transactions, and Director Independence         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theinformation required under this item will be set forth in the Company’s proxy statement to be filed with the Securitiesand Exchange Commission on or before November 27, 2020 and is incorporated herein by reference.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_022">         </a>         Item14.         <u>          Principal Accountant Fees and Services         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theinformation required under this item will be set forth in the Company’s proxy statement expected to be filed with the Securitiesand Exchange Commission on or before November 27, 2020 and is incorporated herein by reference.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_023">          </a>          PARTIV         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="a_024">         </a>         Item15.         <u>          Exhibits, Financial Statement Schedules         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 9%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 4%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (a)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 4%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 83%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Consolidated Financial Statements           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <a href="#fin_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Balance Sheets - July 31, 2020    and 2019            </font>           </a>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <a href="#fin_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Operations - Years    ended July 31, 2020, 2019 and 2018            </font>           </a>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">           <a href="#fin_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Comprehensive Income    (Loss) - Years ended July 31, 2020, 2019 and 2018            </font>           </a>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">           <a href="#fin_006">            Consolidated Statements of Stockholders’ Equity - Years ended July 31, 2020, 2019 and 2018           </a>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <a href="#fin_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Cash Flows - Years    ended July 31, 2020, 2019 and 2018            </font>           </a>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <a href="#fin_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Notes to Consolidated Financial Statements            </font>           </a>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Financial Statement Schedule           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 -0.5in; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         ScheduleII - Valuation and Qualifying Accounts        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Allother schedules have been omitted because the required information is included in the consolidated financial statements or thenotes thereto or because they are not required.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <!-- Field: Page; Sequence: 57; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         55         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 9%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">           </p>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 4%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 4%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 83%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Exhibits           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         Thefollowing documents are filed as Exhibits to this Annual Report on Form 10-K:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 9%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Exhibit            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 90%">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             No.            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Description            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3(a)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Incorporation (1)           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3(b)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Incorporation, as amended on March 17, 1980. (1)           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3(c)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment of the Certificate of Incorporation as amended on June 16, 1981. (2)           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3(d)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certificate of Amendment to the Certificate of Incorporation as of July 22, 1988. (3)           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3(e)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041313000254/c72341_ex3-ii.htm">             Amended and restated Bylaws. (4)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3(f)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041318003408/c92357_ex3-1.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Amended and restated Bylaws (29)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3(g)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041320000690/c95361_ex3-1.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Amended and restated Bylaws (31)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10(a)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000091205795009076/0000912057-95-009076.txt">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             1994 Stock Option Plan. (5)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (b)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000104746999035882/0001047469-99-035882.txt">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             1999 Stock Option Plan. (6)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (c)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041304005490/c34455.txt">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             2005 Equity Compensation Incentive Plan (7)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (d)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041310005679/c63251_defc14a.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             2011 Incentive Plan (8)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (e)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041305007123/c39477_ex-10v.txt">             Lease agreement with Pari Management (9)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (f)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041306006850/c44362_ex10-1.txt">             Settlement and Release Agreement between the Company and Sigma Aldrich (10)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (g)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041307004854/c48679_ex2-1.txt">             Stock Purchase Agreement By and Among Enzo Life Sciences, Inc., Axxora Life Sciences Inc., and the Stock holders, Option holders and Warrant holders (12)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (h)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041308002968/c53469_ex2-1.htm">             Stock Asset Purchase Agreement By and Among Buyer Parties and Seller Parties with respect to the Biomol International and affiliate acquisition (13)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (i)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041309001405/c56940_ex2-1.htm">             Asset Purchase Agreement By and Among Enzo Life Sciences, Acquisition, Inc. and Assay Designs, Inc.(14)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (j)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041317000087/c87026_ex10-1.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Amendment No. 1 to Amended and Restated Employment Agreement with Elazar Rabbani (15)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (k)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041317000087/c87026_ex10-2.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Amendment No. 1 to Amended and Restated Employment Agreement with Barry Weiner (15)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (l)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041313001948/c73251_ex1-1.htm">             Controlled Equity Offering Sales Agreement with Cantor Fitzgerald &amp; Co, as sales agent (16)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (m)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041313004942/c75252_ex10m.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Revolving Loan and Security Agreement among the Enzo Biochem, Inc., Enzo Clinical Labs, Inc., Enzo Life Sciences, Inc., Axxora, LLC and Enzo Realty, LLC as borrowers, and Enzo Therapeutics, Inc. as a guarantor, and Healthcare Finance Group, LLC as Lender (17)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (n)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041314001903/c77355_ex10-1.htm">             Settlement and Release Agreement between the Company and Affymetrix (18)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (o)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041314002964/c77910_ex10-1.htm">             Settlement and Release Agreement between the Company and PerkinElmer (19)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (p)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041314004315/c78862_ex10p.htm">             Settlement and Release Agreement between the Company and U.S. Department of Justice (20)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (q)           </font>          </td>          <td>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041315003026/c81919_ex99-2.htm">             Settlement and Release Agreement between the Company and Luminex Corporation (21)            </a>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">           </p>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (r)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041315003120/c82013_ex99-2.htm">             Settlement    and Release Agreement between the Company and Siemens Healthcare Diagnostics Inc. (22)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (s)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041315003965/c82714_ex10s.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Amendment of Lease with Pari Management (23)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (t)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041315003966/c82737_ex10-1.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Settlement and Release Agreement between the Company and Affymetrix (24)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (u)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041316008464/c86264_ex10-u.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Settlement and Release Agreement between the Company and Illumina, Inc. (25)            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (v)           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041318003072/c92149_ex10v.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Purchase and Sale Agreement by and between Building Blocks Realty Co. LLC (seller) and Enzo Realty LLC (Purchaser) (26)            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 58; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         56         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (w)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041320000450/c95299_ex99-1.htm">             Settlement Release Agreement between the Company and Roche Diagnostics GmbH and Roche Molecular Systems Inc. (27)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (y)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041319001248/c93482_ex10-1.htm">             Settlement Release Agreement between the Company and Hologic, Inc., Grifolds, S.A. and Grifolds Diagnostic Solutions Inc. (28)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (z)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041318003506/c92425_ex99-1.htm">             Fee and Leasehold Mortgage and Security Agreement from the Town of Babylon Industrial Development Agency and Enzo Realty II, LLC, to Citibank, N.A. (30)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (aa)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041320001201/c95791_ex99-1.htm">             Paycheck Protection Program Loan Note (32)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10 (ab)*           </font>          </td>          <td>          </td>          <td>           <a href="f10k2020ex10ab_enzobiochem.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Amended and Restated 2011 Incentive Plan            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            14 (a)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/316253/000093041303003142/c29687_ex14.txt">             Code of Ethics (11)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            21*           </font>          </td>          <td>          </td>          <td>           <a href="f10k2020ex21_enzobiochem.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             List of subsidiaries of the Company            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            23.1*           </font>          </td>          <td>          </td>          <td>           <a href="f10k2020ex23-1_enzobiochem.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consent of Independent Registered Public Accounting Firm            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31 (a)*           </font>          </td>          <td>          </td>          <td>           <a href="f10k2020ex31a_enzobiochem.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; padding-left: 12.55pt; text-indent: -12.55pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31    (b)*           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 90%">           <a href="f10k2020ex31b_enzobiochem.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification of CFO Pursuant    to Section 302 of the Sarbanes-Oxley Act of 2002            </font>           </a>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32 (a)*           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <a href="f10k2020ex32a_enzobiochem.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification of CEO Pursuant to Section 906    of the Sarbanes-Oxley Act of 2002            </font>           </a>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32 (b)*           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <a href="f10k2020ex32b_enzobiochem.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification of CFO Pursuant to Section 906    of the Sarbanes-Oxley Act of 2002            </font>           </a>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.INS**           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Instance Document           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.SCH**           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Schema Document           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.CAL**           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Calculation Linkbase    Document           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.DEF**           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Definitions Linkbase    Document           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.LAB**           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Label Linkbase Document           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.PRE**           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Presentation Linkbase    Document           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <!-- Field: Page; Sequence: 59; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         57         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 5%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 94%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Notes to exhibits            </b>           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Filed herewith           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL (Extensible Business Reporting Language)    information is being furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section    18 of the Securities Exchange Act of 1934.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The exhibits were filed as exhibits to the Company’s    Registration Statement on Form S-18 (File No. 2-67359) and are incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed as an exhibit to the    Company’s Annual Report on Form 10-K for the year ended July 31, 1981 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Annual Report on Form 10-K for the year ended July 31, 1989 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Current Report on Form 8-K dated January 22, 2013 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Annual Report on Form 10-K for the year ended July 31, 1995 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Registration Statement on Form S-8 (333-87153) and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Proxy Statement on Schedule 14A filed on November 26, 2004 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed as appendix B to the    Company’s Definitive Proxy Statement on Schedule 14A, which was filed on November 16, 2010 and is incorporated herein    by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (9)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Annual Report on Form 10-K for the year ended July 31, 2005 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Current Report on Form 8-K on September 21, 2006 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (11)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Annual Report on Form 10-K for the year ended July 31, 2003 and is incorporated here by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (12)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Current Report on Form 8-K on May 30, 2007 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (13)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Current Report on Form 8-K on May 8, 2008 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (14)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Current Report on Form 8-K on March 13, 2009 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (15)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Current Report on Form 8-K on January 10, 2017 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (16)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Current Report on Form 8-K on March 28, 2013 and incorporated herein by reference.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (17)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s    Current Report on Form 10-K for the year ended July 31, 2013 and incorporated herein by reference.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <!-- Field: Page; Sequence: 60; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         58         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 5%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (18)           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 94%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Current Report on Form 8-K on April 24, 2014 and incorporated herein by reference.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (19)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Current Report on Form 8-K on June 23, 2014 and incorporated herein by reference.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (20)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Current Report on Form 10-K for the year ended July 31, 2014 and is incorporated herein by reference.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (21)           </font>          </td>          <td>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">            This exhibit was filed with the Company’s Current Report on        Form 8-K on July 7, 2015 and incorporated herein by reference.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (22)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Current Report on Form 8-K on July 22, 2015 and incorporated herein by reference           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (23)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Annual Report on Form 10-K for the year ended July 31, 2015 and is incorporated herein by reference           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (24)           </font>          </td>          <td>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">            This exhibit was filed with the Company’s Current Report on        Form 8-K on October 13, 2015 and incorporated herein by reference.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (25)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Annual Report on Form 10-K for the year ended July 31, 2016           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (26)           </font>          </td>          <td>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">            This exhibit was filed with the Company’s Annual Report on        Form 10-K for the year ended July 31, 2018 and is incorporated herein by reference.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (27)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Current Report on Form 8-K on February 11, 2019 and is incorporated herein by reference           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (28)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Current Report on Form 8-K on April 22, 2019 and is incorporated herein by reference           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (29)           </font>          </td>          <td>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">            This exhibit was filed with the Company’s Current Report on        Form 8-K on December 3, 2018 and is incorporated herein by reference           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (30)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Current Report on Form 8-K on November 21, 2018 and is incorporated herein by reference           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (31)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Current Report on Form 8-K on March 2, 2020 and is incorporated herein by reference           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (32)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This exhibit was filed with the Company’s Current Report on Form 8-K on April 24, 2020 and is incorporated herein by reference           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 61; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         59         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          SIGNATURES         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Pursuantto the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this reportto be signed on its behalf by the undersigned, thereunto duly authorized.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ENZO BIOCHEM, INC.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 4%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Date: October 19, 2020           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/ Elazar    Rabbani Ph.D.           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           Elazar Rabbani Ph.D.          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chairman of the Board, Chief Executive Officer           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Pursuantto the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalfof the registrant and in the capacities and on the dates indicated.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:    /s/ Elazar Rabbani           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 40%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 20%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            October 19, 2020           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Elazar Rabbani, Ph.D.,           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chairman of Board of Directors and Secretary           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Principal Executive Officer)           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:    /s/ Barry W. Weiner           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            October 19, 2020           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Barry W. Weiner,           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President and Treasurer           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:    /s/ David Bench           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            October 19, 2020           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            David Bench,           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Financial Officer,           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Principal Accounting Officer           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:     Fabian Blank           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            October 19, 2020           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Fabian Blank, Director           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:    /s/ Rebecca J. Fischer           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            October 19, 2020           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Rebecca J. Fischer, Director           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By: /s/ Peter Clemens           </font>          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            October 19, 2020           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Peter Clemens, Director           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:    /s/ Dov Perlysky           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            October 19, 2020           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dov Perlysky, Director           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <!-- Field: Page; Sequence: 62; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         60         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        FORM 10-K, ITEM 15(a) (1) and (2)       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        ENZO BIOCHEM, INC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="fin_001">        </a>        LIST OF CONSOLIDATED FINANCIAL STATEMENTSAND       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        FINANCIAL STATEMENT SCHEDULE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following consolidated financial statements and financialstatement schedule of Enzo Biochem, Inc. are included in Item 15(a):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; width: 94%">           <a href="#fin_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             List of Consolidated Financial Statements and Financial Statements Schedule            </font>           </a>          </td>          <td style="vertical-align: top; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 9%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-1           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#fin_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Report of Independent Registered Public Accounting Firm            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-2           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#fin_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Balance Sheets - July 31, 2020 and 2019            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-3           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#fin_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Operations - Years ended July 31, 2020, 2019 and 2018            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-4           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#fin_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Comprehensive Income (Loss) - Years ended July 31, 2020, 2019 and 2018            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-5           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#fin_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Stockholders’ Equity - Years ended July 31, 2020, 2019 and 2018            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-6           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#fin_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Cash Flows - Years ended July 31, 2020, 2019 and 2018            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-7           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#fin_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Notes to Consolidated Financial Statements            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-8           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#fin_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Schedule II - Valuation and Qualifying Accounts – As of and for the Years ended July 31, 2020, 2019 and 2018            </font>           </a>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            S-1           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        All other schedules for which provision is made in the applicableaccounting regulation of the Securities and Exchange Commission are not required under the related instructions or are inapplicable,and therefore have been omitted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 63; Options: NewSection -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            1            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <b>         <a name="fin_002">         </a>         REPORT OF INDEPENDENT REGISTERED PUBLICACCOUNTING FIRM        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        To the Board of Directors and Stockholdersof       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Enzo Biochem, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Opinion on the Financial Statements         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        We have audited the accompanying consolidatedbalance sheets of Enzo Biochem, Inc. and Subsidiaries (the “Company”) as of July 31, 2020 and 2019, and the relatedconsolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of theyears in the three-year period ended July 31, 2020 and the related notes and the financial statement schedule identified in Item15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly,in all material respects, the consolidated financial position of the Company as of July 31, 2020 and 2019 and the consolidatedresults of their operations and their cash flows for each of the years in the three-year period ended July 31, 2020, in conformitywith accounting principles generally accepted in the United States of America.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Basis for Opinion         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        These financial statements are the responsibilityof the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements basedon our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicablerules and regulations of the Securities and Exchange Commission and the PCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        We conducted our audits in accordance withthe standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whetherthe financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are requiredto obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on theeffectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        Our audits included performing proceduresto assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing proceduresthat respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosuresin the financial statements. Our audits also included evaluating the accounting principles used and significant estimates madeby management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide areasonable basis for our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        /s/ EisnerAmper LLP       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have served as the Company’s auditorsince 2013.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        EISNERAMPER LLP       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        New York, New York       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        October 19, 2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 64 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="fin_003">         </a>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CONSOLIDATED BALANCE SHEETS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (in thousands, except share and per sharedata)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             July 31,            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             2020            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             July 31,            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             2019            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">           ASSETS          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">           Current assets:          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Cash and cash equivalents          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,865          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           60,146          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Accounts receivable, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           9,141          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10,738          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Inventories          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7,784          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7,842          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Prepaid expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,975          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,727          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Total current assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           68,765          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           81,453          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Property, plant, and equipment, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           14,482          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           14,254          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Right-of-use assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           19,916          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Goodwill          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7,452          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7,452          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Intangible assets, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           538          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,032          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Other, including restricted cash of $750          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,385          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,449          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Total assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           112,538          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           106,640          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           LIABILITIES AND STOCKHOLDERS’ EQUITY          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Current liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Accounts payable - trade          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,503          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7,256          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Accrued liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12,833          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,362          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Current portion of operating lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,121          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Other current liabilities and finance leases short term          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           344          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           391          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Other short term debt          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           7,000          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Total current liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           32,801          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16,009          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Other liabilities and finance leases long term          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           192          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           424          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Operating lease liabilities, non-current          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16,679          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Long term debt - net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,485          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,179          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Total liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           54,157          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           20,612          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Commitments and contingencies – see Notes 15 and 16          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Stockholders’ equity:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">           Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued           <br/>           and outstanding: 47,895,050 at July 31, 2020 and 47,556,807 at July 31, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           479          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           476          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Additional paid-in capital          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           334,473          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           332,704          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Accumulated deficit          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (278,252          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (249,732          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Accumulated other comprehensive income          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,681          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,580          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Total stockholders’ equity          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           58,381          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           86,028          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Total liabilities and stockholders’ equity          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           112,538          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           106,640          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        The accompanying notes are an integral partof these consolidated financial statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 65 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            3            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="fin_004">         </a>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CONSOLIDATED STATEMENTS OF OPERATIONS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (in thousands, except per share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Years ended July 31,          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2018          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Revenues          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           76,021          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           81,170          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           101,013          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Operating costs, expenses and legal settlements, net:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Cost of revenues          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           52,251          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           57,922          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           60,385          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Research and development          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,448          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,175          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,210          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Selling, general, and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           42,960          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           44,265          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           44,455          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Legal and related expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           6,729          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,127          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Legal settlements, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,925          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Total costs, expenses and legal settlements, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           106,388          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           79,437          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           113,177          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Operating (loss) income          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (30,367          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,733          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (12,164          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Other income (expense):          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Interest          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           454          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,056          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           853          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Other          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           488          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           382          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           168          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Foreign exchange gain (loss)          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           905          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (682          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (275          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           (Loss) income before income taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,520          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,489          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (11,418          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Benefit for income taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,097          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Net (loss) income          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,520          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,489          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,321          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Net (loss) income per common share:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Basic          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.60          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           0.05          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.22          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Diluted          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.60          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           0.05          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.22          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Weighted average common shares outstanding:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Basic          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,696          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,351          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           46,972          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Diluted          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,696          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,476          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           46,972          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        The accompanying notes are an integral partof these consolidated financial statements       </p>       <!-- Field: Page; Sequence: 66 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            4            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="fin_005">         </a>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CONSOLIDATED STATEMENTS OF COMPREHENSIVEINCOME (LOSS)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (in thousands)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Years Ended July 31,          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2018          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">           Net (loss) income          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,520          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,489          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,321          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">           Other comprehensive (loss)  income:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -8.8pt; padding-left: 8.8pt">           Foreign currency translation adjustments          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (899          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           480          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           87          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -8.8pt; padding-left: 8.8pt">           Comprehensive (loss) income          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (29,419          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,969          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,234          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        The accompanying notes are an integral partof these consolidated financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 67 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            5            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="fin_006">         </a>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CONSOLIDATED STATEMENTS OF STOCKHOLDERS’EQUITY        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Years ended July 31, 2020, 2019, and2018        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (in thousands, except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Common           <br/>           Stock           <br/>           Shares Issued          </td>          <td style="padding-bottom: 1.5pt; font: italic bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Treasury Stock Shares          </td>          <td style="padding-bottom: 1.5pt; font: italic bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Common Stock Amount          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Additional Paid-in Capital          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Treasury Stock Amount          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Accumulated Deficit          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Accumulated Other Comprehensive Income          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Total Stockholders’ Equity          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 36%; font: bold 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Balance at July 31, 2017          </td>          <td style="width: 1%; font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 5%; font: italic 10pt Times New Roman, Times, Serif; text-align: right">           46,506,176          </td>          <td style="width: 1%; font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">           465          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">           328,294          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (241,900          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,013          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">           88,872          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Net (loss) for the year ended July 31, 2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,321          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,321          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Vesting of restricted stock          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           2,874          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Share-based compensation charges          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           813          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           813          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Issuance of common and treasury stock for employee 401(k) plan match          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           37,580          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (106,911          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           204          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,014          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,218          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Cashless options exercise and acquisition of Treasury stock          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           340,898          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           106,911          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           576          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,014          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (434          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Exercise of stock options          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           294,726          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           883          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           886          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Foreign currency translation adjustments          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           87          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           87          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Balance at July 31, 2018          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right">           47,182,254          </td>          <td style="padding-bottom: 1.5pt; font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           472          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           330,770          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (252,221          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,100          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           81,121          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Net income for the year ended July 31, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,489          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,489          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Vesting of restricted stock          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           986          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Share-based compensation charges          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           939          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           939          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Net issuance of common  stock for employee 401(k) plan match          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           315,472          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           829          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           832          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Net issuance of common stock for options exercise by Directors          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           23,376          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Net exercise of stock options          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           34,719          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           166          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           167          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Foreign currency translation adjustments          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           480          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           480          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Balance at July 31, 2019          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right">           47,556,807          </td>          <td style="padding-bottom: 1.5pt; font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           476          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           332,704          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (249,732          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,580          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           86,028          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Net (loss) for the year ended July 31, 2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,520          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,520          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Vesting of restricted stock          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           811          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Issuance of common stock for share-based compensation          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           4,167          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Share-based compensation charges          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           923          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           923          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Issuance of common  stock for employee 401(k) plan match          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right">           333,265          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           836          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           839          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Foreign currency translation adjustments          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (899          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (899          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Balance at July 31, 2020          </td>          <td style="border-bottom: Black 4pt double; font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="padding-bottom: 4pt; font: italic 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: italic 10pt Times New Roman, Times, Serif; text-align: right">           47,895,050          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           479          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           334,473          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (278,252          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,681          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           58,381          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        The accompanying notes are an integral partof these consolidated financial statements       </p>       <!-- Field: Page; Sequence: 68 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            6            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="fin_007">         </a>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CONSOLIDATED STATEMENTS OF CASH FLOWS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (in thousands)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Years ended July 31,          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">           Cash flows from operating activities:          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Net (loss) income          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,520          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,489          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,321          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; text-align: left; padding-left: 0.125in">           Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Depreciation and amortization of property, plant and equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,256          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,194          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,138          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Amortization of intangible assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           524          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           842          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           992          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Share-based compensation charges          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           933          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           939          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           813          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Share-based 401(k) employer match expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           836          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           855          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           829          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Foreign exchange (gain) loss          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,165          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           493          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           475          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Changes in operating assets and liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Accounts receivable          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,617          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,404          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,915          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Inventories          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           85          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (572          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (413          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Prepaid expenses and other assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (216          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (182          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,177          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Accounts payable - trade          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,214          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,508          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (887          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Accrued liabilities, other current liabilities and other liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,257          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,148          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,901          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Total adjustments          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           11,341          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,317          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           7,586          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Net cash (used in) provided by operating activities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (17,179          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,806          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,735          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Cash flows from investing activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Capital expenditures          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,170          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,126          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,888          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Increase in security deposits and other          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (56          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Net cash used in investing activities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,170          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,126          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,944          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Cash flows from financing activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Proceeds from borrowings under government programs and mortgage agreement          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7,412          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,500          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Repayments under mortgage agreement and capital leases          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (411          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (404          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Installment loan payments          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (327          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Cost to obtain loan          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (70          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Proceeds from exercise of stock options          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           167          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           886          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Net cash provided by financing activities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           7,001          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,193          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           559          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Effect of exchange rate changes on cash and cash equivalents          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           67          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (18          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (6          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           (Decrease) increase in cash and cash equivalents and restricted cash          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (12,281          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           855          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (4,126          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Cash and cash equivalents and restricted cash - beginning of year          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           60,896          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           60,041          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           64,167          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Cash and cash equivalents and restricted cash - end of year          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           48,615          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           60,896          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           60,041          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Composition of cash and cash equivalents and restricted cash is as follows:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Cash and cash equivalents          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           47,865          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           60,146          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           60,041          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Restricted cash          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           750          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           750          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Total cash and cash equivalents and restricted cash          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           48,615          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           60,896          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           60,041          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        The accompanying notes are an integral partof these consolidated financial statements       </p>       <!-- Field: Page; Sequence: 69 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            7            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="fin_008">         </a>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 1 - Summary of significant accounting policies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Nature of business       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Enzo Biochem, Inc. (the “Company”) is an integrateddiagnostics, clinical lab, and life sciences company engaged in research, development, manufacturing and marketing of diagnosticand research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosisof and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information andare distributed in the United States and internationally. The Company is conducting research and development activities in thedevelopment of therapeutic products based on the Company’s technology platform of genetic modulation and immune modulation.The Company also operates a clinical laboratory that offers and provides molecular and esoteric diagnostic medical testing servicesin the New York, New Jersey, and Connecticut medical communities. The Company operates in three segments (see Note 17).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        A novel strain of coronavirus (“COVID-19”) continuesto spread and severely impact the economy of the United States and other countries around the world. Through the first two quartersof fiscal 2020, we had experienced growth in our laboratory testing services accessions and our products volume compared to theprior year period. This growth continued into February 2020. However, beginning in March 2020, the Company experienced a materialdecline in its laboratory testing volumes due to the COVID-19 pandemic as patients have reduced physician office visits. Additionally,customers of our products have reduced or suspended purchases because they have temporarily reduced or closed their operationson a global basis. The COVID-19 impact on the Company’s operations is consistent with the overall industry and publicly issuedstatements from competitors, partners, and vendors. The decline in our laboratory accessions and customer orders for products continuedduring most of the remainder of the third fiscal quarter (ended April 30, 2020) and began to show some improvement in the monthof April. In our fiscal fourth quarter, while accessions did not return to prior year levels, we continued to see accession volumerebound. Due to the addition of COVID-19 testing, July 2020 accession volume exceeded July 2019 accession volume.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Federal, state and local governmental policies and initiativesdesigned to reduce the transmission of COVID-19 have resulted in, among other things, the aforementioned significant reductionin physician office visits, the cancellation of elective medical procedures, customers of our products closing or severely curtailingtheir operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies.The Company believes the COVID-19 pandemic may continue to have a negative impact on the Company’s operating results, cashflows and financial condition for an undetermined amount of time. Global supply chain issues due to the pandemic hamper both productionof products within the life science division as well as testing capabilities in the clinical laboratory. It is possible that theCompany may experience an adverse impact on cash collections from customers, clients and payers as a result of the impact of theCOVID-19 pandemic. The extent to which our businesses may be affected by the COVID-19 pandemic will largely depend on both currentand future developments, including its duration, spread and treatment, and related work and travel advisories and restrictions,all of which are highly uncertain and cannot be reasonably predicted at this time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the fourth quarter of fiscal 2020 our COVID-19 relatedservices partially offset revenue declines in our traditional lab services business. Enzo has been granted FDA Emergency Use Authorization(EUA) for its molecular diagnostic and serological testing for COVID-19 and related antibody testing options. Enzo’s innovationsinclude virus-inactivating specimen collection media to lessen transmission risks for healthcare providers and clinical laboratorypersonnel, the development of more relevant positive controls for the tests, and improved sensitivity. However, it is too earlyto determine the long term significance of any positive impact from increased testing and the Company’s proprietary productofferings on revenue, profitability and cash flow.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Coronavirus Aid, Relief, and Economic Security Act (“CARESAct”) was passed in March 2020 and addresses the various economic impacts of, and otherwise responds to, the COVID-19 (coronavirus)outbreak. Under the CARES Act, we received a loan, an advance payment, and two income grants from Medicare during the latter halfof our fiscal year ended July 31, 2020, all of which are further described in Note 3, Note 8 and Note 10.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 70 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            8            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Principles of consolidation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The accompanying consolidated financial statements have beenprepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) and includethe accounts of the Company and its wholly-owned subsidiaries, Enzo Clinical Labs, Inc., Enzo Life Sciences, Inc. (and its wholly-ownedforeign subsidiaries), Enzo Therapeutics, Inc., Enzo Realty LLC (“Realty”) and Enzo Realty II, LLC (“Realty II”).All intercompany transactions and balances have been eliminated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Use of Estimates        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The preparation of financial statements in conformity with U.S.GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosureof contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expensesduring the reporting periods. Actual results could differ from those estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The extent to which the COVID-19 pandemic impacts the Company’sbusiness and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and durationof the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including, but not limited to,employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactionsto the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial informationin context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of July 31, 2020and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s revenueconcessions and credit losses, accounts receivable and the carrying value of goodwill and other long-lived assets. The Company’sfuture assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impactsto the Company’s consolidated financial statements in future reporting periods.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Contingencies        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Contingencies are evaluated and a liability is recorded whenthe matter is both probable and reasonably estimable.  Gain contingencies are evaluated and not recognized until the gainis realizable or realized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Foreign Currency Translation/Transactions        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has determined that the functional currency forits foreign subsidiaries is the local currency. For financial reporting purposes, assets and liabilities denominated in foreigncurrencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates.Resulting translation gains and losses are included as a separate component of stockholders’ equity as accumulated othercomprehensive income or loss. Gains or losses resulting from transactions entered into in other than the functional currency arerecorded as foreign exchange gains and losses in the consolidated statements of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Cash and cash equivalents        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Cash and cash equivalents consist of demand deposits with banksand highly liquid money market funds. At July 31, 2020 and 2019, the Company had cash and cash equivalents in foreign bank accountsof $0.9 million and $0.7 million, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Concentration of Credit Risk        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Financial instruments that potentially subject the Company toconcentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company believes thefair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of theseitems.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Concentration of credit risk with respect to the Company’sLife Sciences products segment is mitigated by the diversity of the Company’s customers and their dispersion across manydifferent geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently,believes that its accounts receivable credit exposure with respect to these customers is limited.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 71 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            9            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company believes that the concentration of credit risk withrespect to the Clinical Laboratory services accounts receivable is mitigated by the diversity of third party payers that insureindividuals. To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believesthat its accounts receivable credit risk exposure, with respect to these payers, is limited. While the Company also has receivablesdue from the Federal Medicare program, the Company does not believe that these receivables represent a credit risk since the Medicareprogram is funded by the federal government and payment is primarily dependent on our submitting the appropriate documentation.Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “HealthMaintenance Organizations” (“HMO’s”) categories represents approximately 24%, 36% and 39% of Clinical Servicesnet revenue for the years ended July 31, 2020, 2019 and 2018 respectively, and also represents 16% of the Clinical Services net accountsreceivable as of July 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Accrual for Self-Funded Medical Insurance        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Accruals for self-funded medical insurance are determined basedon a number of assumptions and factors, including historical payment trends, claims history and current estimates. These estimatedliabilities are not discounted. If actual trends differ from these estimates, the financial results could be impacted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Contractual Adjustment        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s estimate of contractual adjustment is basedon significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change.The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versusthe corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenuebased on gross billing rates to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedulethe Company sets for all third-party payers, including Medicare, HMO’s and managed care providers. The Company adjusts thecontractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience with payers,industry reimbursement trends, and other relevant factors which include the monthly and quarterly review of: 1) current gross billingsand receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) the growth of in-network providerarrangements and managed care plans specific to our Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the years ended July 31, 2020, 2019 and 2018, the contractualadjustment percentages, determined using current and historical reimbursement statistics, were approximately 88%, 88% and 85%,respectively, of gross billings.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Accounts Receivable        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Accounts receivable are reported at realizable value, net ofallowances for doubtful accounts, which is estimated and recorded in the period of the related revenue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s ability to collect outstanding receivablesfrom third-party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsuredpatients or patients for whom primary insurance has paid but a patient portion remains outstanding. In the case of COVID-19 diagnosticand antibody testing, collection risk for uninsured patients is minimized. Federal Reimbursement for Uninsured Patients Testingis processed by submitting a claim to the Health Resources and Services Administration COVID 19 Uninsured Program. This governmentprogram provides reimbursement to the Company for COVID-19 diagnostic and antibody testing provided to uninsured patients and requiresspecific information along with an attestation of attempts to obtain this information accurately in order to submit claims. The program will perform its own validation process and there is required information about the patient that the Company must provideto be considered for reimbursement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company also assesses the current state of its billing functionsin order to identify any known collection issues and to assess the impact, if any, on the allowance estimates which involves judgment.The Company believes that the collectability of its receivables is directly linked to the quality of its billing processes, mostnotably, those related to obtaining the correct information in order to bill effectively for the services provided. Should circumstanceschange (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of netrealizable value of receivables could be reduced by a material amount.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 72 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            10            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Clinical Laboratory Services segment’s net receivablesare detailed by billing category and as a percent to its total net receivables.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At July 31, 2020 and 2019, approximately 68% and 63% respectively,of the Company’s net accounts receivable relates to its Clinical Laboratory Services business, which operates in the NewYork, New Jersey and Connecticut medical communities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following is a table of the Company’s net accountsreceivable by segment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           July 31, 2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           July 31, 2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid">           Net accounts receivable by segment          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Amount          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Amount          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">           Clinical Labs (by billing category)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Third party payers          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,455          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           40          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,956          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           44          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Patient self-pay          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,044          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           33          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,360          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           35          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Medicare          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           884          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           14          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           910          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           13          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">           HMO’s          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           797          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           13          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           574          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           8          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">           Total Clinical Labs          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,180          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,800          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Total Life Sciences          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,961          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,938          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">           Total accounts receivable – net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           9,141          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           10,738          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Inventories        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company values inventory at the lower of cost (first-in,first-out) or net realizable value. Work-in-process and finished goods inventories consist of material, labor, and manufacturingoverhead. Write downs of inventories to net realizable value are based on a review of inventory quantities on hand and estimatedsales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significantimpact on the value of our inventory and require additional write downs of inventory which would impact our results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Property, plant and equipment        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Property, plant and equipment is stated at cost, and depreciatedon the straight-line basis over the estimated useful lives of the various asset classes as follows: building and building improvements:15-30 years; laboratory machinery and equipment, office furniture and computer equipment: 3-10 years. Leasehold improvements areamortized over the term of the related leases or estimated useful lives of the assets, whichever is shorter.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Goodwill and Intangible Assets        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Goodwill represents the excess of the cost of an acquisitionover the fair value of the net assets acquired.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Intangible assets (exclusive of patents), arose primarily fromacquisitions, and primarily consist of customer relationships, trademarks, licenses, and website and database content. Our intangibleassets are all finite-lived and are amortized according to their estimated useful lives, which range from 4 to 15 years. Patentsrepresent capitalized legal costs incurred in pursuing patent applications. When such applications result in an issued patent,the related capitalized costs, if any, are amortized over a ten year period or the life of the patent, whichever is shorter, usingthe straight-line method. The Company reviews its issued patents and pending patent applications, and if it determines to abandona patent application or that an issued patent no longer has economic value, the unamortized balance in deferred patent costs relatingto that patent is immediately expensed.       </p>       <!-- Field: Page; Sequence: 73 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            11            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Impairment testing for Goodwill and Long-Lived Assets        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company tests goodwill annually as of the first day of thefourth quarter, or more frequently if indicators of potential impairment exist. In assessing goodwill for impairment, the Companyhas the option to first perform a qualitative assessment to determine whether the existence of events or circumstances leads toa determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If theCompany determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount,the Company is not required to perform any additional tests in assessing goodwill for impairment. However, if the Company concludesotherwise or elects not to perform the qualitative assessment, then it identifies the reporting units and compares the fair valueof each of these reporting units to their respective carrying amount. If the carrying amount of the reporting unit is less thanits fair value, no impairment exists. If the carrying amount of the reporting unit is higher than its fair value, the impairmentcharge is the amount by which the carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocatedto the reporting unit. The Company performed a quantitative assessment in 2020, 2019 and 2018, and concluded there were no goodwillimpairments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company reviews the recoverability of the carrying valueof long-lived assets (including its intangible assets, all of which have finite lives) of an asset or asset group for impairmentannually as of the end of the fiscal year, or more frequently if indicators of potential impairment exist. Should indicatorsof impairment exist, the carrying values of the assets are evaluated in relation to the operating performance and future undiscountedcash flows of an asset or asset group. The net book value of the long lived asset is adjusted to fair value if its expected futureundiscounted cash flow is less than its book value. There were no long-lived asset impairments in 2020, 2019 or 2018. Should theimpact of the COVID-19 pandemic be significantly worse than currently expected, it is possible that we could incur impairment chargeson goodwill and other long lived assets in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Comprehensive income (loss)        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Comprehensive income (loss) consists of the Company’sconsolidated net income (loss) and foreign currency translation adjustments. Foreign currency translation adjustments includedin comprehensive income (loss) were not tax effected as the Company has a full valuation allowance at July 31, 2020. Accumulatedother comprehensive income is a separate component of stockholders’ equity and consists of the cumulative foreign currencytranslation adjustments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Shipping and Handling Costs        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Shipping and handling costs associated with the distributionof finished goods to customers are recorded in cost of goods sold.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Research and Development        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Research and development costs are charged to expense as incurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Advertising        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        All costs associated with advertising are expensed as incurred.Advertising expense, included in selling, general and administrative expense, approximated $437, $374 and $580 for the years endedJuly 31, 2020, 2019 and 2018, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Income Taxes        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company accounts for income taxes under the liability methodof accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future taxconsequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities andtheir respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwardsand other items be reduced by a valuation allowance when it is more likely than not that the benefits may not be realized. Deferredtax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which thosetemporary differences are expected to be recovered or settled.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Under the liability method, the effect on deferred tax assetsand liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.       </p>       <!-- Field: Page; Sequence: 74 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            12            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        It is the Company’s policy to provide for uncertain taxpositions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likelythan not to be sustained upon examination by tax authorities. At July 31, 2020, the Company believes it has appropriately accountedfor any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized taxbenefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a givenfinancial statement period may be affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Segment Reporting        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company separately reports information about each operatingsegment that engages in business activities from which the segment may earn revenues and incur expenses, whose separate operatingresults are regularly reviewed by the chief operating decision maker regarding allocation of resources and performance assessmentand which exceed specific quantitative thresholds related to revenue and profit or loss. The Company’s operating activitiesare reported in three segments (see Note 17).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Net income (loss) per share        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Basic net income (loss) per share represents net income (loss)divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential commonshares, consisting of outstanding stock options and unvested restricted stock, is determined using the treasury stock method. Dilutedweighted average shares outstanding for fiscal 2020 and 2018 do not include the potential common shares from stock options andunvested restricted stock because to do so would have been antidilutive and as such is the same as basic weighted average sharesoutstanding for 2020 and 2018. For 2019, approximately 125,000 weighted average stock options were included in the calculationof diluted weighted average shares outstanding. The number of potential common shares (“in the money options”) andunvested restricted stock excluded from the calculation of diluted weighted average shares outstanding for the years ended July31, 2020 and 2018 was 40,000, and 624,000, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the years ended July 31, 2020, 2019 and 2018, the effectof approximately 1,904,000, 1,324,000 and 291,000 respectively, of outstanding “out of the money” options to purchasecommon shares were excluded from the calculation of diluted weighted average shares outstanding because their effect would be anti-dilutive.The following table sets forth the computation of basic and diluted net income (loss) per share for the years ended July 31:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">           Net (loss) income          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="width: 1%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,520          </td>          <td style="width: 1%; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="width: 1%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,489          </td>          <td style="width: 1%; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="width: 1%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,321          </td>          <td style="width: 1%; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Weighted-average common shares outstanding - basic          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           47,696          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           47,351          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           46,972          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Add: effect of dilutive stock options and restricted stock          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           125          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">           Weighted-average common shares outstanding - diluted          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,696          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,476          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           46,972          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Net (loss) income per share – basic          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.05          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.22          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Net (loss) income per share – diluted          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.05          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.22          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Share-Based Compensation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company records compensation expense associated with stockoptions and restricted stock based upon the fair value of stock based awards as measured at the grant date. The Company determinesthe award values of stock options using the Black Scholes option pricing model. The expense is recognized by amortizing the fairvalues on a straight-line basis over the vesting period, adjusted for forfeitures when they occur.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the years ended July 31, 2020, 2019 and 2018,share-based compensation expense relating to the fair value of stock options, restricted shares and restricted stock unitswas approximately $923, $939 and $813, respectively (see Note 12). During the year ended July 31, 2020, the Company issuedcommon stock as employee compensation in the amount of $10. No excess tax benefits were recognized for the year ended July31, 2020, 2019 and 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 75 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            13            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table sets forth the amount of expense relatedto share-based payment arrangements included in specific line items in the accompanying statement of operations for the years endedJuly 31:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Cost of clinical laboratory services          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           46          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Selling, general and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           887          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           939          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           813          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           933          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           939          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           813          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of July 31, 2020, there was $861 of total unrecognized compensationcost related to non-vested share-based payment arrangements granted under the Company’s incentive stock plans, which willbe recognized over a weighted average remaining life of approximately fourteen months.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Effect of New Accounting Pronouncements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Recently Adopted Accounting Pronouncements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On August 1, 2019, the Company adopted a new accounting standardissued by the Financial Accounting Standards Board (“FASB”) on accounting for leases using the modified retrospectivemethod. This new accounting standard requires a lessee to recognize an asset and liability for most leases on its balance sheet.The Company elected the optional transition method that allowed for a cumulative-effect adjustment to the opening balance of retainedearnings recorded on August 1, 2019 and did not restate previously reported results in the comparative periods. The Company alsoelected the package of practical expedients, which among other things, allowed it to carry forward its historical lease classification.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As a result of adoption of the new standard, the Company recordedright-of-use assets and operating lease liabilities of approximately $24.4 million and $25.1 million, respectively as of August1, 2019. The operating lease liability was determined based on the present value of the remaining minimum rental payments and theright-of-use asset was determined based on the value of the lease liability, adjusted for deferred rent balances of approximately$0.7 million, which were previously included in accrued expenses. There was no cumulative effect adjustment to the opening balanceof accumulated deficit. Accounting for the Company’s finance leases remains substantially unchanged. The adoption of thenew standard did not materially impact the Company’s consolidated results of operations or cash flows. The adoption of thisnew accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertaintyof cash flows arising from leases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company elected the package of three practical expedients.As such, the Company did not reassess whether expired or existing contracts are or contain a lease and did not need to reassessthe lease classifications or reassess the initial direct costs associated with expired or existing leases. The Company did notelect the hindsight practical expedient. Further, the land easement practical expedient was not elected as the practical expedientis not applicable to the Company. The Company elected to take the practical expedient to not separate lease and non-lease componentsof all asset classes entered into or modified after the effective date. For further details, see Note 9.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On August 1, 2018, the Company adopted a new accounting standardissued by FASB on revenue recognition using the full retrospective method. This new accounting standard outlines a single comprehensivemodel to use in accounting for revenue arising from contracts with customers. This standard supersedes existing revenue recognitionrequirements and eliminates most industry-specific revenue recognition guidance from U.S. GAAP. The core principle of the revenuerecognition standard is to require an entity to recognize as revenue the amount that reflects the consideration which it expectsto be entitled to when control of goods or services are transferred to its customers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As a result of the Company’s adoption of this standard, themajority of the amounts that were historically classified as bad debt expense, primarily related to patient responsibility, arenow considered an implicit price concession in determining net revenues from clinical services. Accordingly, the Company reportsestimated uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore asa reduction in net revenues, when historically these amounts were classified and separately reported as a provision for uncollectibleaccounts receivable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 76 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            14            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The adoption of this standard has no impact on revenues reportedfor life sciences products. The adoption of this new accounting standard resulted in increased disclosure, including qualitativeand quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contractswith customers. For further details, see Note 3.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The impact of the adoption of the standard on prior period consolidatedoperations, cash flows and balance sheet is presented in the table below:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">           Consolidated Statements of    Operations for fiscal year ended July 31, 2018:          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           As Previously Reported          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Adjustment for New Accounting Standard on Revenue Recognition          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Reclassification of Residual          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           As Restated          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">           Total Revenues          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           104,713          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           ($          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,700          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           101,013          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Provision for uncollectible accounts receivable          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,690          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (3,700          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Selling, general and administrative expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           44,465          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (10          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           44,455          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Net loss          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,321          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,321          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">           Consolidated Statements of Cash Flows July 31, 2018:          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           As Previously Reported          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Adjustment for New Accounting Standard on Revenue Recognition          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             Reclassification of Residual            </b>           </p>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             As Restated            </b>           </p>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">           Provision for uncollectible accounts receivable          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">           3,690          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           (3,700          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">           10          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Changes in operating assets and liabilities: Accounts receivable          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,775          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,700          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (10          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,915          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif">           Consolidated balance sheet July 31, 2018:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Accounts receivable          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           15,815          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,523          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           13,292          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">           Less: Allowance for doubtful accounts          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,668          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,523          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           145          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Accounts receivable, net of allowance for doubtful accounts          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           13,147          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           13,147          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On August 1, 2018, the Company adopted a new accounting standardissued by FASB which provides guidance about which changes to the terms or conditions of a share-based payment award require anentity to apply modification accounting in Topic 718. Adoption of this standard requires that amendments in the update be appliedprospectively to an award modified on or after the adoption date. For the foreseeable future, any excess income tax benefits ordeficiencies from stock-based compensation, which would be recognized as discrete items within income tax expense rather than additionalpaid in capital, will be offset by an equivalent adjustment to the deferred tax valuation allowance. Accordingly, adoption of thisstandard had no impact on our reported operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Pronouncements Issued but Not Yet Adopted        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In June 2016, FASB issued ASU No. 2016-13 Financial Instruments– Credit Losses (Topic 326). This standard changes the impairment model for most financial instruments, including trade receivables,from an incurred loss method to a new forward-looking approach, based on expected losses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 77 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            15            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The estimate of expected credit losses will require entitiesto incorporate considerations of historical information, current information and reasonable and supportable forecasts. Adoptionof this standard is required for our annual and interim periods beginning August 1, 2023, the effective date for smaller reportingcompanies and must be adopted using a modified retrospective transition approach. We are currently assessing the impact of theadoption of this standard on our results of operations, financial position and cash flows.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We reviewed all other recently issued accounting pronouncementsand have concluded they are not applicable or not expected to be significant to the accounting for our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Reclassification        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Certain prior period amounts have been reclassified to conformto the current period presentation. These reclassifications had no effect on the reported results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 2 - Goodwill and intangible assets        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Goodwill        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s net carrying amount of goodwill is in theClinical Laboratory Services segment and is $7,452 as of July 31, 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Intangible assets        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s change in the net carrying amount of intangibleassets, all in the Life Sciences Products segment is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Gross          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Accumulated           <br/>           Amortization          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Net          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif">           July 31, 2018          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           27,347          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (25,461          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,886          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Amortization expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (842          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (842          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Foreign currency translation          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (109          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           97          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (12          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           July 31, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           27,238          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (26,206          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,032          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Amortization expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (524          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (524          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Foreign currency translation          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           448          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (418          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           30          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">           July 31, 2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           27,686          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (27,148          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           538          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Intangible assets, all finite-lived, consist of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           July 31, 2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           July 31, 2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Gross          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Accumulated           <br/>           Amortization          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Net          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Gross          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Accumulated           <br/>           Amortization          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Net          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">           Patents          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           11,027          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (11,014          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           13          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           11,027          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,996          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           31          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Customer relationships          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12,003          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (11,478          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           525          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           11,746          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,745          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,001          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Website and acquired content          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,022          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,022          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,008          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,008          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Licensed technology and other          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           483          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (483          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           483          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (483          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Trademarks          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,151          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (3,151          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,974          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,974          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           27,686          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (27,148          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           538          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           27,238          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (26,206          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,032          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 78 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            16            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At July 31, 2020, information with respect to acquired intangiblesis as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             Useful life            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             assigned            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             Weighted average            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             remaining useful life            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 76%">           Customer relationships          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8-15 years           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2 years           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At July 31, 2020, the weighted average remaining useful lifeof intangible assets was approximately two years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Estimated amortization expense relatedto these finite-lived intangible assets for the five succeeding fiscal years ending July 31 is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: left; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left">           2021          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           295          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2022          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           243          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2023          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2024          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2025          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Amortization expense for the years ended July 31, 2020, 2019,and 2018 was $524, $842 and $992, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 3 – Revenue Recognition        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Clinical Services Revenue        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Service revenues in the Company’s clinical services businessaccounted for 63%, 63% and 71% of the Company’s total revenues for fiscal years ended July 31, 2020, 2019, and 2018, respectivelyand are primarily comprised of a high volume of relatively low-dollar transactions. The services business, which provides clinicaltesting services, satisfies its performance obligation and recognizes revenues upon completion of the testing process for a specificpatient and reporting to the ordering physician. The Company may also perform clinical testing services for other laboratoriesand will recognize revenue from those services when reported to the ordering laboratory. The Company estimates the amount of considerationit expects to receive from customer groups using the portfolio approach. These estimates of the expected consideration includethe impact of contractual allowances and price concessions on our customer group portfolios consisting of healthcare insurers,government payers, client payers and patients as described below. Contracts with customers in our laboratory services businessdo not contain a financing component, based on the typically limited period of time between performance of services and collectionof consideration. The transaction price includes variable consideration in the form of the contractual allowance and price concessionsas well as the collectability of the transaction based on patient intent and ability to pay. The Company uses the expected valuemethod in estimating the amount of the variability included in the transaction price.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following are descriptions of our laboratory services businessportfolios:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Third party payers and Health Maintenance Organizations (HMO’s)        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Reimbursements from third party payers, primarily healthcareinsurers and HMO’s are based on negotiated fee-for-service schedules and on capitated payment rates. Revenues consist ofamounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Companyexpects to receive from such payers, which considers historical collection and denial experience and the terms of the Company’scontractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payers, are recorded uponsettlement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Collection of the consideration the Company expects to receiveis normally a function of providing complete and correct billing information to these third party payers within the various filingdeadlines, and typically occurs within 30 to 90 days of billing. Provided the Company has billed healthcare insurers accuratelywith complete information prior to the established filing deadline, there has historically been little to no collection risk. Ifthere has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, andif so, will reserve accordingly for the billing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 79 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            17            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Third-party payers, including government programs, may decideto deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against theircoverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), andwe may be required to refund payments already received. Our revenues may be subject to adjustment as a result of these factorsamong others, including without limitation, differing interpretations of billing and coding guidance and changes by governmentagencies and payers in interpretations, requirements, and “conditions of participation” in various programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Government Payer - Medicare        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Reimbursements from Medicare are based on fee-for-service schedulesset by Medicare, which is funded by the government. Revenues consist of amounts billed net of contractual allowances for differencesbetween amounts billed and the estimated consideration the Company expects to receive from Medicare, which considers historicalcollection and denial experience and other factors. Adjustments to the allowances, based on actual receipts from the governmentpayers, are recorded upon settlement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Collection of consideration the Company expects to receive isnormally a function of providing the complete and correct billing information within the various filing deadlines and typicallyoccurs within 60 days of billing. Provided the Company has billed the government payer accurately with complete information priorto the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing,the Company determines if the amounts in question will likely go past the filing deadline, and, if so, it will reserve accordinglyfor the billing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Patient self pay        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Uninsured patients are billed based on established patient feeschedules or fees negotiated with physicians on behalf of their patients. Coinsurance and deductible responsibilities based onfees negotiated with healthcare insurers are also billed to insured patients and included in this portfolio. Collection of billingsfrom patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discountsprovided to uninsured patients in accordance with the Company’s policies and implicit price concessions. Implicit price concessionsrepresent differences between amounts billed and the estimated consideration the Company expects to receive from patients, whichconsiders historical collection experience and other factors including current market conditions. Adjustments to the estimatedallowances, based on actual receipts from the patients, are recorded upon settlement. Patient responsibility is invoiced and ifit reaches 91 days outstanding, the account is sent to a collection agency for further processing. After the account has been withthe collection agency for at least 105 days, and is determined to be uncollectable it is written off.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table represents clinical services net revenuesand percentages by type of customer:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Year ended July 31,           <br/>           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Year ended July 31,           <br/>           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Year ended July 31,           <br/>           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">           Revenue category          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Revenue          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Revenue          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Revenue          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           %          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Third-party payers          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           24,893          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           52          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           26,653          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           52          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           41,370          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           58          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Medicare          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10,825          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           23          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10,898          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           21          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12,111          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           17          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           HMO’s          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,983          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           6,213          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           11,359          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Patient self-pay          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,263          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           13          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           7,351          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           15          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,237          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           9          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,964          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           51,115          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           71,077          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           100          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For fiscal years ended July 31, 2020, 2019, and 2018 all ofthe Company’s clinical services revenues were generated within the United States.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Grant income         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Under the CARES Act, we were eligible for and received two incomegrants in April and June 2020 totaling $1,496 under the Department of Health and Human Services (HHS) Public Health and SocialServices Emergency Fund for provider relief. The purpose of the payments is to reimburse the Company for health care related expensesor lost revenues attributable to COVID-19.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 80 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            18            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have certified that the grant funds were accepted per theregulations and have recognized it as Grant income for the fiscal year ended July 31, 2020 in the Clinical Services segment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Products Revenue and royalty income        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Products revenues consist of the sale of single-use productsused in the identification of genomic information and are recognized at a point in time following the transfer of control of suchproducts to the customer, which generally occurs upon shipment. Payment terms for shipments to end-user and distributor customersmay range from 30 to 90 days. Any claims for credit or return of goods may be made generally within 30 days of receipt. Revenuesare reduced to reflect estimated credits and returns, although historically these adjustments have not been material. Taxes collectedfrom customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed tocustomers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in costof products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Royalty income is based on net sales of the Company’slicensed products by a third party. We recognize royalty income in the period the sales occur based on third party evidence received.For fiscal years ended July 31, 2020, 2019 and 2018, royalty income was $0, $0 and $712, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Products and royalty revenue by geography is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">           United States          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           14,580          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           16,966          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           16,220          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Europe          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7,484          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,551          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           9,050          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Rest of the world          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,497          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,538          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,666          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">           Products revenue          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           26,561          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           30,055          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           29,936          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 4 - Supplemental disclosure for statement of cash flows        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In the years ended July 31, 2020, 2019, and 2018, interest paidby the Company approximated $266, $138 and $76, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the year ended July 31, 2020, the net reductions in themeasurement of right of use assets and liabilities included in cash flows from operating activities was approximately $884. Thechanges are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statement of cashflows.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the years ended July 31, 2020, 2019 and 2018, tax on capitalpaid by the Company was $90, $94 and $65, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the years ended July 31, 2020 and 2019, the Company issuedcommon stock in connection with its share-based 401(k) employer match in the amount of $839 and $832, respectively. During theyear ended July 31, 2018, the Company issued common and treasury stock in connection with its share-based 401(k) employer matchin the amount of $1,218. During the year ended July 31, 2020, the Company issued common stock as employee compensation in the amountof $10.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the year ended July 31, 2020, non-cash activities relatedto the adoption of the new accounting standard for leases are detailed in Note 1.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During fiscal 2019, the Company entered into capital lease agreementstotaling $381 and none during fiscal years 2020 or 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 5 - Inventories        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Inventories consisted of the following at July 31:       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Raw materials          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,019          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           876          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Work in process          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,587          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,566          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Finished products          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,178          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,400          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           7,784          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           7,842          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 81 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            19            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 6 - Property, plant, and equipment        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At July 31, 2020 and 2019, property, plant, and equipment consistof:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center; font-size: 10pt">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Building and building improvements          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           10,089          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           10,334          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Machinery and equipment (includes assets under finance leases - see Note 9)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,548          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,538          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Office furniture and computer equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16,578          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16,229          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Leasehold improvements          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,377          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,270          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           40,592          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           40,371          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Accumulated depreciation and amortization          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,172          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,179          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12,420          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12,192          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Land and land improvements          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,062          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,062          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           14,482          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           14,254          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 7 - Income taxes        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The benefit for income taxes for fiscal years ended July 31is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif">           Federal          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,097          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           State and local          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Foreign          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Deferred benefit          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">           Benefit for income taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,097          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In December 2017, the Tax Cuts and Jobs Act of 2017 (the “TaxAct”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to,a corporate tax rate decrease from 34% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S.international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemedrepatriation of cumulative foreign earnings as of December 31, 2017. The Staff of the Securities and Exchange Commission issuedStaff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrantdoes not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to completethe accounting for certain income tax effects on the Tax Act. As a result of the Tax Act, the Company remeasured its U.S. Federaldeferred tax assets and liabilities at the rate they are expected to reverse in the future and recorded a cumulative charge of$11.5 million for the fiscal year ended July 31, 2018, which was fully offset by an equivalent adjustment to the deferred tax valuationallowance. The Company recorded a cumulative benefit of $1.1 million for the fiscal year ended July 31, 2018 related to a creditfor alternative minimum taxes (AMT) paid in prior years. During the fiscal year ended July 31, 2019, the Company finalized itscomputation of the impact of the Tax Act with no change to the benefit amount.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In January 2018, the FASB released guidance on the accountingfor tax on the global intangible low-taxed income (“GILTI”) provisions of the Tax Act. The GILTI provisions imposea tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The guidance allows companiesto make an accounting policy election to either (i) account for GILTI as a component of tax expense in the period in which theyare subject to the rules (the period cost method), or (ii) account for GILTI in the Company’s measurement of deferred taxes(the deferred method). After completing the analysis of the GILTI provisions, the Company elected to account for GILTI using theperiod cost method.       </p>       <!-- Field: Page; Sequence: 82 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            20            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Deferred tax assets and liabilities arise from temporary differencesbetween the tax basis of assets and liabilities and their reported amounts in the financial statements. The components of deferredtax assets (liabilities) as of July 31 are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">           Deferred tax assets:          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Federal tax carryforward losses          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           18,173          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           12,558          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Provision for uncollectible accounts receivable          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,079          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,116          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           State and local tax carry forward losses          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,187          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           144          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Accrued royalties          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           101          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           101          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Stock compensation          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           898          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           769          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">           Depreciation          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           799          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           682          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Research and development and other tax credit carryforwards          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,477          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,350          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,520          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Foreign tax carryforward losses          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,357          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,783          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Intangibles and goodwill          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,162          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,479          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">           Inventory          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,156          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,086          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Accrued expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,176          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,127          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">           Other, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           37          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           82          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Deferred tax assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           36,122          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           24,277          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Right of use assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (5,288          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">           Prepaid expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (705          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (626          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">           Other, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (52          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (124          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Deferred tax liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (6,045          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (750          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Net deferred tax assets before valuation allowance          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           30,077          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           23,527          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Less: valuation allowance          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (30,077          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (23,527          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">           Net deferred tax liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company recorded a valuation allowanceduring the years ended July 31, 2020 and 2019 equal to domestic and foreign net deferred tax assets. The Company believes thatthe valuation allowance is necessary as it is not more likely than not that the deferred tax assets will be realized in the foreseeablefuture based on positive and negative evidence available at this time. This conclusion was reached because of uncertainties relatingto future taxable income, in terms of both its timing and its sufficiency, which would enable the Company to realize the deferredtax assets. For fiscal year 2020 and 2019, the change in the valuation allowance was $6.6 million and $(0.9) million, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of July 31, 2020, the Company had U.S. federal net operatingloss carryforwards of approximately $85.8 million of which $59.0 million, if not fully utilized, expire between 2030 and 2038 andwhich $26.8 million do not expire. Utilization is dependent on generating sufficient taxable income prior to expiration of thetax loss carryforwards. In addition, the Company has research and development tax credit carryforwards of approximately $1.5 millionwhich expire between 2025 and 2040. As of July 31, 2020, the Company has state net operating loss carryforwards of approximately$22.5 million, which if not fully utilized, expire between 2038 and 2040. As of July 31, 2020, the Company had foreign loss carryforwardsof approximately $15.5 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The geographic components of (loss) income before income taxesconsisted of the following for the years ended July 31:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">           United States operations          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (27,690          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,618          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (9,540          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           International operations          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (830          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,129          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,878          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">           (Loss) income before taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,520          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,489          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (11,418          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 83 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            21            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The benefit (provision) for income taxes was at rates differentfrom U.S. federal statutory rates for the following reasons for the years ended July 31:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Federal statutory rate          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           21.0          </td>          <td style="white-space: nowrap; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (21.0          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )%          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           26.4          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Compensation and other expenses not deductible for income tax return purposes          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1.1          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (15.3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Change in valuation allowance          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (19.9          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           33.6          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           73.9          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           State tax law change          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Impact of Tax Act on valuation allowance          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (100.1          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           AMT refund under Tax Act          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           9.6          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">           Other          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2.7          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           0.8          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           9.6          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Because there are no undistributed earnings at the Company’sforeign subsidiaries at July 31, 2020, no U.S. federal income taxes have been provided. As of July 31, 2020, the Company has noliabilities for uncertain tax positions. It is the Company’s policy to record interest and penalties as a component of taxexpense. The Company files income tax returns in the U.S. Federal jurisdiction, various U.S. state jurisdictions and several foreignjurisdictions. With few exceptions, the fiscal years that remain subject to examination are July 31, 2017 through July 31, 2020.During fiscal 2020, the Company received notification from the Swiss Federal Tax Administration of an examination for the fiscalyears 2015 through 2018.  As of July 31, 2020, we had received no preliminary audit findings and no reserves have been recordedwith respect to this audit.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 8 – Long term debt        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In connection with the purchase of our new facility on November27, 2018, a wholly-owned subsidiary (the “mortgagor subsidiary”) of the Company entered into a Fee Mortgage and SecurityAgreement (the “mortgage agreement”) with Citibank, N.A. (the “mortgagee”). The mortgage agreement providesfor a loan of $4,500 for a term of 10 years, bears a fixed interest rate of 5.09% per annum and requires monthly mortgage paymentsof principal and interest of $30. Debt issuance costs of $72 are being amortized over the life of the mortgage agreement. The balanceof unamortized debt issuance cost was $60 at July 31, 2020. At July 31, 2020, the balance owed by the subsidiary under the mortgageagreement was $4.3 million. The Company’s obligations under the mortgage agreement are secured by the new facility and bya $750 cash collateral deposit with the mortgagee as additional security. This restricted cash is included in other assets as ofJuly 31, 2020. We assumed from the seller an operating lease for a tenant at the facility which expired on June 30, 2020. Rentalincome from the assumed lease is included in other income.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The mortgage agreement includes affirmative and negative covenantsand events of default, as defined. Events of default include non-payment of principal and interest on debt outstanding, non-performanceof covenants, material changes in business, breach of representations, bankruptcy or insolvency, and changes in control. The mortgageincludes certain financial covenants. As of July 31, 2020, the Company was not in compliance with a financial ratio covenant relatedto this mortgage. Effective October 19, 2020, the Company and the mortgagee agreed to a covenant restructure whereby the mortgageewaived the Company’s financial ratio covenant for the fiscal period ended July 31, 2020 and modified the mortgage to replacethat covenant with a liquidity covenant. The liquidity covenant requires that we own and maintain at all times and throughoutthe remaining term of the loan at least $25 million of liquid assets, defined as time deposits, money market accounts and obligationsissued by the U.S. government or any of its agencies. The cash collateral agreement was also modified to require compliance withthe liquidity covenant for two consecutive fiscal years before the collateral is released back to us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In April 2020, our subsidiary in Switzerland received a loanof CHF 0.4 million ($ 0.4 million, based on the foreign exchange rate as of July 31, 2020) from the Swiss government under the“Corona Krise” emergency loan program in response to the pandemic. This loan is uncollateralized, bears 0% interest,is due in 5 years, and may be repaid at any time. This loan is included in long term debt – net as of July 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The CARES Act expanded the U.S. Small Business Administration’s(SBA) business loan program to create the Paycheck Protection Program (PPP), which provides employers with uncollateralized loanswhose primary purpose is to retain or maintain workforce and salaries for a twenty four week period (“covered period”)following receipt of the loan. Currently, PPP loans have a 1% fixed interest rate and are due from two to five years. The primaryfeatures of the PPP loan program are to provide funding to companies to cover eligible expenses, and the potential for forgivenessof that portion of the loan spent on payroll and other permitted operating expenses during the covered period, subject to reductionsif the borrower fails to maintain or restore employee and salary levels. We applied for the PPP loan based on the eligibility andneed requirements established when the program was announced and in April 2020 received $7,000 through Citibank N.A., the Company’sexisting lender, pursuant to the PPP (the “PPP Loan”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 84 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            22            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The PPP Loan matures on April 17, 2022 (the “MaturityDate”), accrues interest at 1% per annum and may be prepaid in whole or in part without penalty. No interest payments aredue within the initial six months of the PPP Loan. The interest accrued during the initial six-month period is due and payable,together with the principal, on the Maturity Date. The Company intends to use all proceeds from the PPP Loan to retain employees,maintain payroll and make lease and utility payments to support business continuity throughout the COVID-19 pandemic. All or aportion of the PPP Loan, including interest, could be forgiven by the SBA by applying for forgiveness and providing acceptabledocumentation that demonstrates the funds were used as required by the terms of forgiveness and in accordance with the SBA’srequirements. Due to complexities with respect to loan forgiveness calculations and government pronouncements with respect to expenditureeligibility, we did not recognize any loan forgiveness as of July 31, 2020 and have classified the loan as other short term debtas we expect to earn loan forgiveness on most, if not all of the loan in less than a year. The SBA has announced its intentionto audit loans in excess of $2.0 million. No assurance can be given that we will obtain forgiveness of the PPP loan in whole orin part.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Minimum future annual principal payments under these agreementsas of July 31, 2020 are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">           July 31,          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Total          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left">           2021          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           7,144          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2022          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           152          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2023          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           160          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2024          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           167          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2025          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           595          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">           Thereafter          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,471          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Total principal payments          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           11,689          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Less: current portion, included in other current liabilities and other short term debt          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (7,144          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">           Unamortized mortgage cost          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (60          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">           Long term debt - net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,485          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 9 - Leases        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At the beginning of fiscal 2020, the Company adopted ASU No.2016-02 “Leases (Topic 842)”, which requires leases with durations greater than twelve months to be recognized on thebalance sheet. The Company adopted the standard using the modified retrospective approach with an effective date of August 1, 2019.The Company did not apply the new standard to comparative periods and therefore those amounts are not presented below.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company determines if an arrangement is or contains a leaseat contract inception. The Company leases buildings, office space, patient service centers, and equipment primarily through operatingleases, and equipment through a limited number of finance leases. Generally, a right-of-use asset, representing the right to usethe underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease,are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases,expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liabilityis recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basisover the shorter of the estimated useful life of the asset or the lease term. Short-term leases with an initial term of 12 monthsor less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis overthe lease term.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company primarily uses its incremental borrowing rate indetermining the present value of lease payments as the Company’s leases generally do not provide an implicit rate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has lease agreements with (i) right-of-use assetpayments and (ii) non-lease components (i.e. payments related to maintenance fees, utilities, etc.,) which have generally beencombined and accounted for as a single lease component.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s leases have remaining terms of less than1 year to 9 years, some of which include options to extend the leases for up to 5 years. The Company’s lease terms may includerenewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 85 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            23            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Certain of the Company’s lease agreements include rentalpayments adjusted periodically for inflation or a market rate which are included in the lease liabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">           Leases          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Balance Sheet Classification          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           July 31, 2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif">           Assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-left: 9pt">           Operating          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 37%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Right-of-use assets          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           19,916          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt">           Finance          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Property, plant and equipment, net (a)          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           385          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Total lease assets          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           20,301          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif">           Liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Current:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt">           Operating          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Current portion of operating lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,121          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt">           Finance          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Finance leases short term          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           201          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Non-current:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt">           Operating          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Operating lease liabilities, non-current          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16,679          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt">           Finance          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Other liabilities and finance leases long term          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           161          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Total lease liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           21,162          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (a)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accumulatedamortization of finance lease assets was approximately $1.0 million as of July 31, 2020.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Components of lease cost were as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">           Lease cost          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           July 31, 2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Operating lease cost          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,813          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Finance lease cost:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Amortization of leased assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           251          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">           Interest on lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           35          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Total lease cost          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,099          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The maturity of the Company’s lease liabilities as ofJuly 31, 2020 is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: left; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">           Maturity of lease liabilities, years ending July 31,          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Operating leases          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Finance leases          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Total          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">           2021          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,291          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           171          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,462          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2022          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,957          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           88          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,045          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2023          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,299          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           88          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,387          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2024          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,274          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           45          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,319          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2025          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,275          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,275          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">           Thereafter          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,402          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,402          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Total lease payments          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           25,498          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           392          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           25,890          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Less: Interest (a)          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (4,698          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (30          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (4,728          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">           Present value of lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           20,800          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           362          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           21,162          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (a)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Primarilycalculated using the Company’s incremental borrowing rate.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 86 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            24            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Lease term and discount rate for the year ended July 31, 2020were as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">           Lease term and discount rate          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">           Weighted-average remaining lease term (years):          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Operating leases          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6.2 years           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Finance leases          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.7 years           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt">           Weighted-average discount rate:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Operating leases          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           4.9          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Finance leases          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8.6          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        See Note 4 for cash flow information on cash paid for amountsincluded in the measurement of lease liabilities for the year ended July 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 10 - Accrued Liabilities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At July 31, accrued liabilities consist of:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Payroll, benefits, and commissions          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,227          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,123          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Professional fees          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           710          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           774          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Legal          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,647          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           164          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Deferred revenue          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,526          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">           Other          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,723          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,301          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           12,833          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           8,362          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Deferred revenue        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In order to increase cash flow to providers of services andsuppliers impacted by the pandemic, the Centers for Medicare and Medicaid Services (CMS) expanded its Accelerated and Advance PaymentProgram to a broader group of Medicare providers. We applied for and received a $2,526 payment advance from this program in April2020. The recoupment by CMS of our advance payment had been scheduled to begin 120 days after the date of receipt, at which timeevery claim we submit from that point would be automatically offset to repay the advance payment. Any unrecouped advance balanceremaining after 90 days of the recoupment process was to be repaid such that 210 days after receiving the advance it would be entirelyrepaid. In October 2020, the Continuing Appropriations Act, 2021 and Other Extensions Act amended the repayment terms of the AdvancePayment Program. The recoupment period was extended and the automatic recoupment will begin one year after the date the advancepayment was received, which in our case means recoupment will start April 2021. Additionally, during the first 11 months afterrecoupment begins, the rate will be 25% and repayment will occur through an automatic recoupment of our Medicare payments. At theend of the 11 month period, the recoupment rate will increase. If the total amount of the advance payment is not recovered within29 months from the date the advance was received, a demand letter for the outstanding balance will be issued. Since the Companyhas the right to repay the advance at any time, the entire balance is considered current.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Self-Insured Medical Plan        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company self-funds medical insurance coverage for certainof its U.S. based employees. The risk to the Company is believed to be limited through the use of individual and aggregate stoploss insurance. As of July 31, 2020 and 2019, the Company has established a reserve of $0.3 and $0.2 million, respectively, whichis included in accrued liabilities, for claims that have been reported but not paid and for claims that have been incurred butnot reported. The reserve is based upon the Company’s historical payment trends, claim history and current estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 87 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            25            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 11 - Other current liabilities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At July 31, other current liabilities consist of:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Finance lease obligations, current portion          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           200          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           255          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Current portion of mortgage loan          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           144          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           136          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           344          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           391          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 12 - Stockholders’ equity        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Controlled Equity Offering         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany has a Controlled Equity Offering         <sup>          SM         </sup>         Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald&amp; Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time,through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). The Companypays Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligatedto make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminateupon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreementby Cantor or the Company, as permitted therein. The initial agreement contemplated the sale of shares of the Company’s commonstock having an aggregate offering price of up to $20.0 million.        </font>        In December 2014, the Sales Agreement was amended in orderfor the Company to offer and sell additional shares of Common Stock having an aggregate offering price of $20.0 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On September 1, 2017, the Company filed with the SEC a “shelf”registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued andsold under the existing Sales Agreement in an aggregate amount of up to $19.2 million. A total of $150 million of securities maybe sold under this shelf registration, which was declared effective September 15, 2017.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the years ended July 31, 2020, 2019, and 2018 the Companydid not sell any shares of common stock under the Sales Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Treasury stock        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During fiscal year 2018, certain officers of the Company exercised340,898 stock options in non-cash transactions. The officers surrendered 106,911 previously acquired shares of the Company’scommon stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares,as treasury stock. All of the treasury shares were subsequently reissued in the share-based 401(k) employer match made during fiscalyear ended July 31, 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Common stock        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In fiscal 2020, the Company issued 333,265 shares of commonstock for its employees’ 401(k) matching contribution obligation. The Company recorded an expense of $839 for the match representingthe fair value of the shares at the date of issuance. The Company also issued 4,167 shares of common stock as employee compensationand recorded an expense of $10.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In fiscal 2019, the Company issued 315,472 shares of commonstock for its employees’ 401(k) matching contribution obligation. The Company recorded an expense of $832 for the match representingthe fair value of the shares at the date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In fiscal 2018, the Company used 106,911 shares of treasurystock and issued 37,580 shares of common stock for its employees’ 401(k) matching contributions obligation. The Company recordedan expense of $782 for the match, representing the fair value of the shares at the date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 88 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            26            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Incentive stock plans        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In January 2011, the Company’s stockholders approved theadoption of the 2011 Incentive Plan (the “2011 Plan”) which provides for the issuance of equity awards, including amongothers, options, restricted stock and restricted stock units for up to 3,000,000 Common Shares. The exercise price of options grantedunder the 2011 Plan, and consistent with other Plans, is equal to or greater than fair market value of the Common Stock on thedate of grant. Unless terminated earlier by the Board of Directors, the 2011 Plan will terminate at the earliest of; (a) such timeas no shares of Common Stock remain available for issuance under the 2011 Plan or (b) tenth anniversary of the effective date ofthe 2011 Plan. On January 5, 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan toincrease the number of shares available for issuance by 2,000,000 bringing the total number of shares available for award underthe 2011 Plan to 5,000,000. As of July 31, 2020, there were approximately 937,000 shares available for grant under the 2011 Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The 2011 Plan as amended and restated was approved by theBoard of Directors on October 7, 2020 and became effective on such date (the “effective date”). The 2011 Plan wasfurther amended and restated to increase the shares available for issuance by 4,000,000 shares bringing the total number ofshares available for award under the 2011 Plan to 9,000,000. The 2011 Plan shall remain in effect until terminated by actionof the Board; provided however that no awards or incentive stock options may be granted ten years after the effective date,or October 7, 2030. Awards outstanding under the 2011 Plan after October 7, 2030 shall remain in effect until they have beenexercised, terminated, or have expired.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company estimates the fair value of each stock option awardon the measurement date using a Black-Scholes option pricing model. The fair value of awards is amortized to expense on a straightline basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, primarilytime elapsed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Options granted pursuant to the plans may be either incentivestock options or non-statutory options. The 2011 Plan provides for the issuance of stock options, restricted stock and restrictedstock unit awards which generally vest over a two to four year period. A summary of the activity pursuant to the Company’sstock option plans for the years ended July 31, 2020, 2019, and 2018 is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Options          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Weighted -           <br/>           Average           <br/>           Exercise           <br/>           Price          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Options          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Weighted -           <br/>           Average           <br/>           Exercise           <br/>           Price          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Options          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Weighted -           <br/>           Average           <br/>           Exercise           <br/>           Price          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Outstanding at beginning of year          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,351,040          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           4.53          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,882,116          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           4.96          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,132,995          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           4.26          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           New Grants          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           773,032          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.40          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           715,321          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.81          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           415,580          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.57          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Exercised          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (238,230          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.69          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (635,624          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.98          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Expired or forfeited          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (487,576          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right">           3.71          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,167          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right">           6.55          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (30,835          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right">           5.97          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Outstanding at end of year          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,636,496          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">           4.05          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,351,040          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">           4.53          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,882,116          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">           4.99          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Exercisable at end of year          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,457,162          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">           $          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">           5.10          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,342,564          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">           5.16          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,149,489          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">           4.28          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Weighted average fair value of options granted during year          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1.01          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1.07          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1.91          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The intrinsic value of stock option awards that vested duringthe fiscal year represents the value of the Company’s closing stock price on the last trading day of the fiscal year in excessof the exercise price multiplied by the number of options that vested. Total intrinsic value of options that vested and were exercisableduring the fiscal years ended July 31, 2020, 2019, and 2018 was $0, $159 and $743, respectively. The intrinsic value of optionsoutstanding at July 31, 2020, 2019, and 2018 was $79, $955 and $1,723, respectively. The intrinsic value of the options exercisedin fiscal 2020, 2019 and 2018 was $0, $117 and $6,014, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the fiscal year ended July 31, 2019 certain directorsand officers of the Company exercised 203,511 stock options in non-cash transactions. The officers and directors received 23,376net shares of common stock. The Company did not receive any proceeds from this exercise. The net shares issued represent the differencebetween the fair market value of the options on the date of exercise less the strike price cost to exercise the options.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 89 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            27            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Listed below are the assumptions used to determine the fairvalue of options granted during fiscal years 2020, 2019 and 2018:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Grant    Year            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Options    Granted            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Exercise    Price Range            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Term             <br/>             (years)            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Vesting    Period (years)            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             FMV    of options Granted/Per Share            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Expected    Life (years)            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Expected    Volatility %            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Interest    Rate %            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Vested    Shares at 7/31/2020            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           2020          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           773,032          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           $2.20 - $3.32          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           5          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           2 - 3          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           $0.86 - $1.34          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           3.25 – 3.5          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           53.77 – 66.24          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           0.27 – 1.2          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           —          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           715,321          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           $2.80 - $3.21          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           2 - 3          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           $1.06 – $1.23          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           3.25 - 3.5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           48.06 - 50.56          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           2.47- 2.96          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           359,411          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           415,580          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           $4.42 - $8.36          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           2 - 3          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           $1.53 - $2.76          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           3.25 - 3.5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           42.59 - 46.14          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           2.07- 2.79          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">           247,150          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes information for stock optionsoutstanding at July 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; border-bottom: Black 1.5pt solid">           Range of Exercise prices          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Shares          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted-Average           <br/>           Remaining Contractual           <br/>           Life in Years          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted-Average           <br/>           Exercise Price          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%">           $2.20 - $3.32          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           1,389,245          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 11%; text-align: center">           2.5          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2.58          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           $4.35 - $4.66          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           696,705          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: center">           1.5          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           4.46          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1.5pt">           $5.52 - $8.36          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           550,546          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">           2.0          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           $          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           7.26          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: right; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2,636,496          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="text-align: right; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes information for stock optionsexercisable at July 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; border-bottom: Black 1.5pt solid">           Range of Exercise prices          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Shares          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted-Average           <br/>           Remaining Contractual           <br/>           Life in Years          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted-Average           <br/>           Exercise Price          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%">           $2.20 - $3.32          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           359,411          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 11%; text-align: center">           3.4          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2.80          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           $4.35 - $4.66          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           558,372          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: center">           1.5          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           4.47          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1.5pt">           $5.52 - $8.36          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           539,379          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">           2.0          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           $          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           7.28          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: right; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1,457,162          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Performance Stock Units        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        To better align the long-term interest of executives with growingU.S. practices, beginning in fiscal 2018, the Company granted long-term incentive awards in the form of time based stock optionsand performance-based restricted stock units (“Performance Stock Units” or “PSUs”). The PSUs earned willbe determined over a three-year performance period. The primary performance metrics will be revenue and Adjusted EBITDA growth.Payouts based on revenue and adjusted EBITDA goals will be modified based on Total Shareholder Return (“TSR”) performancerelative to Enzo’s peer group.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the fiscal years ended July 31, 2020, 2019 and2018, the Company awarded PSUs to its executive officers. These awards provide for the grant of shares of our common stock at theend of a three–year period based on the achievement of average revenue growth and adjusted EBITDA growth over that period.During the fiscal year 2020, one former executive forfeited a total of 14,500 PSUs. As of July 31, 2020, the Company did not accrueany compensation expense for these PSU’s as the achievement of the growth goals is currently not probable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes PSU’s granted and outstandingthrough July 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Grant Date            </b>           </font>          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Total Grant          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Forfeitures          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Outstanding          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Fair Market Value            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             At Grant Date (000s)            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; font: 10pt Times New Roman, Times, Serif">           7/31/2018          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           32,000          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (4,000          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           28,000          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           124          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           1/3/2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           80,500          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,500          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           70,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           196          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           2/25/2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           98,600          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           98,600          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           217          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <!-- Field: Page; Sequence: 90 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            28            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Restricted Stock Awards        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The fair value of a restricted stock award is determined basedon the closing stock price on the award date. As of July 31, 2020, there were 817 shares of unvested restricted stock which havea weighted average award price of $3.34 per share. As of July 31, 2020, there was approximately $3 of unrecognized compensationcost related to these unvested shares of restricted stock to be recognized over a weighted average remaining period of approximatelysix months.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There were no awards made during the fiscal years ended July31, 2020, 2019 or 2018. During the fiscal year ended July 31, 2020, a total of 811 restricted stock awards vested. The fair valueof the awards that vested during the years ended July 31, 2020, 2019 and 2018 was $2, $4 and $24, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 13 - Employee benefit plans        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has a qualified Salary Reduction Profit SharingPlan (the “Plan”) for eligible U.S. employees under Section 401(k) of the Internal Revenue Code. The Plan providesfor voluntary employee contributions through salary reduction and voluntary employer contributions at the discretion of the Company.For the years ended July 31, 2020, 2019, and 2018, the Company authorized employer matched contributions of 50% of the employees’contribution up to 10% of the employees’ compensation, payable in Enzo Biochem, Inc. common stock. The share-based 401(k)employer matched contribution was approximately $839, $832, and $782 in fiscal years 2020, 2019, and 2018, respectively. As ofJuly 31, 2020, 2019 and 2018 the Company accrued a total of $481, $475 and $493 in 401(k) matching contributions within the Accruedliabilities account.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s Swiss operations provide a pension plannamed the Enzo Life Sciences (ELS) AG Vertrag - Nr. 2/401144, (the “Swiss Plan”) under the Swiss government’ssocial security system for Swiss employees. The current required minimum saving contribution is 13% for employees over age 25 andminimum annual investment return is 1.00%. Employees are required to contribute based on a formula and the Company’s Swissoperations make contributions of at least 40% of the employee contribution. The status of the Swiss Plan, which is substantiallyfunded as of December 31, 2019, the latest plan year end, is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           As of December 31,          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2018          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2017          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Total Assets          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,181          </td>          <td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,064          </td>          <td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,849          </td>          <td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Accumulated Benefit Obligation          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,401          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,308          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,094          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Funded status          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           91          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           90          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           88          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Fiscal Year ended July 31,          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2017          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Employer contributions          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           165          </td>          <td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           208          </td>          <td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           205          </td>          <td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The contract for the Swiss Plan automatically renews on itsannual anniversary unless notice of termination is provided three months prior. The current contract will automatically renew onDecember 31, 2020. Currently the Company has no plans to change the current funding or plan design. No events have occurred thatwould impact the Swiss Plan status.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 14 - Royalty and other income        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company had a license agreement with Qiagen that began in2005, whereby the Company earned quarterly running royalties on the net sales of Qiagen products subject to a license until theunderlying patent expired in April 2018. During the years ended July 31, 2020, 2019 and 2018, the Company recorded royalty incomeunder the agreement of approximately $0, $0 and $712 respectively, which is included in the Life Sciences products segment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 15 - Commitments        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Leases        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        An entity owned by certain executive officers/directors of theCompany owns the building that the Company leases as its main facility for clinical laboratory operations and certain researchoperations. In addition to the minimum annual rentals of space, the lease is subject to annual increases, based on the consumerprice index. Annual increases are limited to 3% per year. Rent expense for this lease, inclusive of real estate taxes, approximated$1,833, $1,849, and $1,798 during fiscal years 2020, 2019 and 2018, respectively.       </p>       <!-- Field: Page; Sequence: 91 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            29            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Employment Agreements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has employment agreements with certain officersthat are cancellable at any time but provide for severance pay in the event an officer is terminated by the Company without cause,as defined in the agreements. Unless cancelled earlier or with notice as defined, the agreements automatically renew for two years.The current agreements expire January 2021. As of July 31, 2020, aggregate minimum compensation commitments under these agreements,exclusive of termination and change in control provisions, is $480.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Purchase commitments        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of July 31, 2020, the Company had purchase commitments forlab instrumentation in the amount of $3,249.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 16 – Contingencies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has brought cases in the United States DistrictCourt for the District of Delaware (“the Court”), alleging patent infringement against various companies. In 2017,the Court ruled that the asserted claims of the ‘180 and ‘405 Patents are invalid for nonenablement in cases involvingAbbott, Becton Dickinson, Gen-Probe, Hologic, and Roche. That ruling was affirmed by the United States Court of Appeals for theFederal Circuit (“Federal Circuit”) in June 2019. Enzo subsequently filed a petition for certiorari regarding the invalidityruling for the ‘180 and ‘405 Patents in February 2020; the Supreme Court denied Enzo’s petition on March 30,2020. There are currently two cases that were originally brought by the Company in the Court. In those two cases, Enzo allegespatent infringement against Becton Dickinson Defendants and Roche Defendants, respectively. The claims in those cases involve the‘197 Patent. Both cases are stayed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In separate inter partes review proceedings before the U.S.Patent and Trademark Office involving, among others, Becton Dickinson, certain claims of the ‘197 Patent were found unpatentableas anticipated or obvious and cancelled by the Patent Trial and Appeals Board (“Board”). Enzo appealed that decisionto the Federal Circuit. On August 16, 2019, the Federal Circuit affirmed the Board’s decision, finding that each of the challengedclaims is unpatentable. The Company filed a petition for rehearing and rehearing en banc on October 30, 2019, which the FederalCircuit denied on December 4, 2019. The Company filed a petition for certiorari with the Supreme Court on March 3, 2020, whichis pending.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In April 2019, the Company entered into an agreement with Hologicand Grifols, resolving litigation resulting from four cases originally brought by the Company in the Court.  As a result,Enzo dismissed (1) a stayed patent litigation regarding the ’180 and ’197 Patent against Hologic in the Court; (2)the Consolidated Appeals against Gen-Probe and Hologic resulting from two cases filed in the Court, and (3) the Company’sappeal in the litigation involving the ’581 Patent that involved both Hologic and Grifols. As a result of the agreement withHologic, Hologic withdrew from Enzo’s Federal Circuit appeal of the Board’s adverse rulings in the        <i>         inter partes        </i>        review proceedings regarding the ’197 Patent filed by Hologic and joined by Becton Dickinson mentioned above.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On February 5, 2020, Harbert Discovery Fund, LP and HarbertDiscovery Co-Investment Fund I, LP (“Plaintiffs”) brought an action in the United States District Court for the SouthernDistrict of New York against the Company and five of its present or former Directors, Dr. Elazar Rabbani, Barry W. Weiner, Dr.Bruce A. Hanna, Dov Perlysky and Rebecca Fischer (“defendants”). On March 26, 2020, Plaintiffs filed an amended complaintagainst the same defendants. Count I asserted the Company violated Section 14(a) of the Securities and Exchange Act of 1934 andRule 14a-9 thereunder by disseminating proxy materials that made two purportedly false statements: (a) a “January 28, 2020Enzo press release [that purportedly] falsely stated that the Annual Meeting would be ‘delayed’ by action of the Boardto February 25, 2020 when, in fact, the Annual Meeting would convene as planned on January 31, 2020”, and (b) a “January31 Enzo Proxy [that purportedly] falsely stated that the Proposed By-Law Amendment [to Article II, Section 9] would be approvedif it received…a majority of the votes….rather than the required Supermajority Vote as provided for in the Charter.”Count II asserted a claim against the individual defendants under Section 209a) of the Exchange Act premised on Enzo’spurported violation of Section 14(a) and Rule 14a-9. Count III asserted the individual defendants breached their fiduciary duty,based on the same conduct and by seeking to entrench themselves. Count IV purported to assert a derivative claim for a declarationthat any amendment to Article II Section 2 requires the approval of 80% of Enzo’s shareholders. On July 16, 2020, the daybefore the defendant’s motion to dismiss was due, plaintiffs asked the Court to dismiss their claims without prejudice.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 92 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            30            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Defendants asked plaintiffs to dismiss the claims with prejudice,but they refused. On July 17, 2020, the Court dismissed the claims without prejudice. If plaintiffs reassert the claims, defendantsintend to vigorously defend against them.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There can be no assurance that the Company will be successfulin any of these litigations. Even if the Company is not successful, management does not believe that there will be a significantadverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputesthat arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolutionof these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or resultsof operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As described in Note 3, third-party payers, including governmentprograms, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary,against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their ownerror), and we may be required to refund payments already received. During the third fiscal quarter of 2019, a significant third-partypayer informed us outside of their typical business practice that they believe it overpaid the Company during certain periods offiscal 2018. The Company disputed these claims and formally sent legal appeal letters to the payer. During the fiscal 2020 period,we recorded $0.8 million in legal and related expenses as a result of reduced reimbursements this payer made to us. In April 2020,we and the payer entered into a settlement agreement and release whereby the parties agreed that the $0.8 million previously withheldby the payer shall fully and completely satisfy the dispute.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following legal settlements are included in the statementof operations under Legal settlements, net within the Life Science segment for the 2019 periods:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company, along with its subsidiaries Enzo Life Sciences,Inc. entered into a Settlement Agreement as of February 5, 2019 (the “Agreement) with Roche Diagnostics GmbH and Roche MolecularSystems, Inc. (together, “Roche”) with respect to an action between the Company and Roche before the U.S. DistrictCourt, Southern District of New York, Case No 04-CV4046. Roche agreed to pay the Company $21 million in settlement pursuant tothe Agreement. The Company received $19.4 million net of attorney contingency payments. This settlement does not affect the Company’scivil action for patent infringement against Roche in the U.S. District Court for the State of Delaware, Enzo Life Sciences Inc.v. Roche Molecular Systems Inc., et al., civil action No. 12 cv-00106, which remains pending on appeal.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company, along with its subsidiaries Enzo Life Sciences,Inc. entered into a settlement and license agreement as of April 16, 2019 (the “Agreement”) with Hologic, Inc. (“Hologic”),Grifols, S.A., and Grifols Diagnostic Solutions Inc. (together, “Grifols”) to settle all outstanding patent disputesamong the parties.  The terms of the agreement include one-time payments totaling $14 million to the Company in exchange forfully paid-up, worldwide licenses to Hologic and Grifols. The Company received $9.5 million net of attorney contingency payments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 17 - Segment reporting        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has three reportable segments: Products, ClinicalServices and Therapeutics. The Company’s Products segment develops, manufactures, and markets products to research and pharmaceuticalcustomers. The Clinical Services segment provides diagnostic services to the health care community. The Company’s Therapeuticssegment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performancebased on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other”consist of corporate general and administrative costs which are not allocable to the three reportable segments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Legal and related expenses incurred to defend the Company’sintellectual property, which may result in settlements recognized in another segment and other general corporate matters are considereda component of the Other segment. Legal and related expenses specific to other segments’ activities are allocated to thosesegments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Legal settlements, net, represent activities for which royaltieswould have been received in the Company’s Products segment. Management of the Company assesses assets on a consolidated basisonly and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policiesof the reportable segments are the same as those described in the summary of significant accounting policies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 93 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            31            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following financial information represents the operatingresults of the reportable segments of the Company:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Year ended July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Clinical           <br/>           Laboratory Services          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Life           <br/>           Sciences Products          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Therapeutics          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Other          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Consolidated          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 11pt">           Revenues – Services and Products          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,964          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           26,561          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           74,525          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 11pt">           Grant income          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,496          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,496          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 11pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           49,460          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           26,561          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           76,021          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Operating costs and expenses::          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Cost of revenues          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           38,855          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           13,396          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           52,251          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Research and development          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,509          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,190          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           749          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,448          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Selling, general and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           23,533          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10,485          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,942          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           42,960          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Legal and related expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           211          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,516          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,729          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Total operating costs and expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           64,108          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           26,073          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           749          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           15,458          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           106,388          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Operating (loss) income          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (14,648          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           488          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (749          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (15,458          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (30,367          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Other income (expense)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Interest          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (36          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           56          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           434          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           454          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Other          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           45          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           13          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           430          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           488          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Foreign exchange gain          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           905          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           905          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           (Loss) income before taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (14,639          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,462          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (749          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (14,594          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,520          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Depreciation and amortization included above          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,553          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           964          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           263          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,780          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Share-based compensation included  above:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Selling, general and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           57          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           74          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           756          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           887          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Cost of sales          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           46          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           46          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           103          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           74          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           756          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           933          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Capital expenditures          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,811          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           322          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           37          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,170          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 94 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            32            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following financial information represents the operatingresults of the reportable segments of the Company:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Year ended July 31, 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Clinical           <br/>           Laboratory Services          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Life           <br/>           Sciences Products          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Therapeutics          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Other          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Consolidated          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 11pt">           Revenues          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           51,115          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           30,055          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           81,170          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">           Operating costs, expenses and legal settlements, net:          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Cost of revenues          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           44,226          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           13,696          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           57,922          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Research and development          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           31          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,257          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           887          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,175          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Selling, general and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           24,230          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           11,860          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,175          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           44,265          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Legal and related expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           159          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           27          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,814          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Legal settlements, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,925          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (28,925          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Total operating costs, expenses and legal settlements, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           68,646          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,085          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           887          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           10,989          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           79,437          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Operating income (loss)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (17,531          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           31,140          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (887          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,989          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,733          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Other income (expense)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Interest          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (64          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           67          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,053          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,056          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Other          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           364          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           382          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Foreign exchange loss          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (682          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (682          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Income (loss) before taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (17,579          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           30,527          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (887          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (9,572          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,489          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Depreciation and amortization included above          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,625          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,221          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           190          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,036          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Share-based compensation included  above:          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Selling, general and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           147          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           95          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           697          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           939          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           147          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           95          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           697          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           939          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Capital expenditures          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,374          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           605          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,147          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           8,126          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Page; Sequence: 95 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            33            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following financial information represents the operatingresults of the reportable segments of the Company:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Year ended July 31, 2018        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Clinical           <br/>           Laboratory Services          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Life           <br/>           Sciences Products          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Therapeutics          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Other          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Consolidated          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Revenues          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           71,077          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           29,936          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           101,013          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Operating costs and expenses:          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Cost of revenues          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           46,008          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           14,377          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           60,385          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Research and development          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,305          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           905          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,210          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Selling, general and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           24,656          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           11,617          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,182          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           44,455          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Legal and related expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           67          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           58          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,002          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,127          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Total operating costs and expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           70,731          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           28,357          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           905          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           13,184          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           113,177          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Operating income (loss)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           346          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,579          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (905          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (13,184          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (12,164          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Other income (expense)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Interest          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (91          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           50          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           894          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           853          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">           Other          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           29          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           11          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           128          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           168          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Foreign exchange loss          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (275          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (275          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Income (loss) before taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           284          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,365          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (905          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (12,162          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (11,418          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Depreciation and amortization included above          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,667          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,387          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           76          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,130          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">           Share-based compensation included in above:          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -11pt; padding-left: 11pt">           Selling, general and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           125          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           79          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           609          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           813          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           125          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           79          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           609          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           813          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -11pt; padding-left: 11pt">           Capital expenditures          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,685          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           203          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,888          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Page; Sequence: 96 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            34            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Geographic financial information is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Net Services, Products and Grant and royalty revenues from unaffiliated customers, Year ended July 31,:          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">           United States          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           64,040          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           68,081          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           87,296          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Switzerland          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           608          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           820          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           829          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           United Kingdom          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,189          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,642          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,494          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Other international countries          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           10,184          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           10,627          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           11,394          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           76,021          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           81,170          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           101,013          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Long-lived assets, at July 31,          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">           United States          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           41,946          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           22,057          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Switzerland          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           352          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           376          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           United Kingdom          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           23          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           64          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Other international countries          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           67          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           96          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           42,388          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           22,593          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s reportable segments are determined basedon the services they perform, the products they sell, and the royalties and license fee income they earn, not on the geographicarea in which they operate. The Company’s Clinical Laboratory Services segment operates 100% in the United States with allrevenue derived there. The Life Sciences Products segment earns product revenue both in the United States and foreign countriesand royalty and license fee income in the United States. The following is a summary of the Life Sciences Products segment productand royalty revenues attributable to customers located in the United States and foreign countries for the years ended July 31,:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">           United States          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           14,580          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           16,966          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           16,220          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">           Foreign countries          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           11,981          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           13,089          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           13,716          </td>          <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           26,561          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           30,055          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           29,936          </td>          <td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 97 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            35            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ENZO BIOCHEM, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         July 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Dollars in thousands except share data)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 18 - Summary of Selected Quarterly Financial Data (unaudited)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table contains statement of operations informationfor each quarter of the years ended July 31, 2020 and 2019. The Company believes that the following information reflects all normalrecurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results forany quarter are not necessarily indicative of results for any future period. Unaudited quarterly financial data for fiscal 2020and 2019 is summarized as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="14" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Quarter Ended          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif">           Fiscal 2020          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           October 31,           <br/>           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           January 31,           <br/>           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           April 30,           <br/>           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           July 31,           <br/>           2020          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Total revenues          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           20,207          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           19,384          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           16,903          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           19,527          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Gross profit          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,686          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,809          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,425          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7,850          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Loss before income taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (7,648          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (7,687          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (9,860          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (3,325          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Net loss          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (7,648          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (7,687          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (9,860          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (3,325          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Basic and diluted loss per common share          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.16          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.16          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.21          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.07          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="14" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           Quarter Ended          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif">           Fiscal 2019          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           October 31,           <br/>           2018          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           January 31,           <br/>           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           April 30,           <br/>           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           July 31,           <br/>           2019          </td>          <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Total revenues          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           21,260          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           19,327          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           19,662          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">           20,921          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Gross profit          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7,021          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,579          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,302          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           6,346          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Income (loss) before income taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (5,978          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,408          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           22,265          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (5,390          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Net income (loss)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (5,978          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,408          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           22,265          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (5,390          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Basic and diluted loss per common share          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.13          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.18          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.47          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (0.11          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 98 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            36            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="fin_009">         </a>         ENZO BIOCHEM, INC         <br/>         SCHEDULE II         <br/>         VALUATION AND QUALIFYING ACCOUNTS         <br/>         As of and for the Years ended July 31, 2020, 2019 and 2018         <br/>         (in thousands)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           July 31,          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; border-bottom: Black 1.5pt solid">           Description          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Balance at           <br/>           Beginning           <br/>           of Year          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Charged           <br/>           (credited) to costs           <br/>           and expenses          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Charged           <br/>           to other           <br/>           accounts          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Deductions          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Balance at           <br/>           end of Year          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 9%; text-align: center">           2020          </td>          <td style="width: 1%">          </td>          <td style="width: 40%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Allowance for doubtful accounts receivable          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 7%; text-align: right">           166          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 7%; text-align: right">           28          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 7%; text-align: right">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 7%; text-align: right">           —          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 7%; text-align: right">           194          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: center">           2019          </td>          <td>          </td>          <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Allowance for doubtful accounts receivable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           145          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           42          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           21          </td>          <td style="text-align: left">           (1)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           166          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: center">           2018          </td>          <td>          </td>          <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">           Allowance for doubtful accounts receivable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           147          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2          </td>          <td style="text-align: left">           (1)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           145          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: center">           2020          </td>          <td>          </td>          <td style="text-align: left">           Deferred tax valuation allowance          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           23,527          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6,550          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           30,077          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: center">           2019          </td>          <td>          </td>          <td style="text-align: left">           Deferred tax valuation allowance          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           24,471          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (944          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           23,527          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: center">           2018          </td>          <td>          </td>          <td style="text-align: left">           Deferred tax valuation allowance          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           32,581          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (8,110          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           —          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           24,471          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 3%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="width: 97%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Write-off of uncollectible accounts receivable.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        S-1       </p>       <!-- Field: Rule-Page -->       <div style="width: 100%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>